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ABSTRACT 
	  
 
There is a continuing need for improvements in the cryopreservation of clinically 
relevant cells, tissues and organs as advances in transplantation science and 
regenerative medicine rise alongside an aging populace that intensifies demand. 
Antifreeze (glyco)proteins (AF(G)Ps) and antifreeze proteins (AFPs) are classes 
of proteins found in cold acclimatized species. Ice recrystallization is a highly 
damaging process that occurs upon the thawing of frozen specimens with 
AF(G)Ps and AFPs limiting this effect in a process termed ice recrystallization 
inhibition (IRI). However AF(G)Ps and AFPs largely fail to improve in vitro and ex 
vivo cryopreservation due to their secondary property of dynamic ice shaping. 
The biocompatible and synthetically accessible polymer poly(vinyl alcohol) (PVA) 
has been shown to process a strong IRI activity. The IRI property of PVA along 
with numerous other polymers and polyols is investigated to highlight the 
uniqueness of PVA (Chapter 2). PVA is then explored as a cryoprotectant with 
red blood cells (Chapter 3), immortalized mammalian cell lines (Chapter 4) and 
primary cells (Chapter 5) with a significant advantageous effect observed with 
each cell type in terms of the number of cells recovered post thaw. However, this 
is despite the use of proportionately low concentrations of PVA compared to 
traditional membrane permeable cryoprotectants. The application of PVA as a 
cryoadjuvant could therefore improve the cryopreservation of cells, tissues and 
organs resulting in widespread clinical benefits. 
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CHAPTER 1.  
 
1. INTRODUCTION. 
 
1.1. IMPACT OF ICE IN THE MODERN WORLD.   
 
Ice has and continues to play a pivotal role in the natural world. Historically ice 
has influenced the course of evolution as organisms attempt to occupy and 
inhabit every conceivable niche on earth with profound genetic consequences on 
divergence and speciation.1 Paleoclimatology has in particular emphasized the 
impact of ice ages and the consequential genetic legacies that have been left 
behind as these climatic oscillations incite extinction events and apply a strong 
natural selection criterion.2 Recent ice ages have also been attributed to 
influencing human migration patterns by analysis of mitochondrial DNA 
chronology.3 The reason for these dramatic shifts is that simply the formation of 
ice in biological systems tends to be highly destructive. Though many physical 
and behavioral adaptations have been abundantly recorded for centuries, these 
alone are not sufficient to explain how numerous species prosper in 
environments that even in the present day mankind struggles to subsist in.4 
However this not only applies to extremes of cold but also extremes of heat5, 
pressure6, pH7 and altitude8 whereby oxygen and nitrogen availability is limited. 
The majority of extremophiles are microorganisms and thus have minimal 
capacity for physical or behavior adaptations and therefore unable to regulate 
 	  	   2	  
their temperature despite an excellent capacity to develop antimicrobial 
resistance mechanisms and utilize a wide variety of metabolites. Much interest 
has therefore been shown in identifying, isolating and manipulating the molecular 
mechanisms that permit their survival9, with advances in genomic sequencing 
enhancing the rate and reducing the cost at which an organism can be 
sequenced.10,11 Genomic sequencing has enabled prolific improvements in the 
molecular biology toolkit by providing thermostable enzymes including DNA 
polymerases and DNA ligases. Improvements have and continue to be exploited 
in related disciplines such as catalysis and biotechnology.  
 
In contrast to other extremophiles there has been a comparatively limited amount 
of success in utilizing the molecular mechanisms of cold acclimatized species. 
However the scope for manipulating such adaptations is enormous especially in 
cryobiology and by association transplantation science and regenerative 
medicine. These fields currently have an over-reliance on organic solvents that 
are decidedly cytotoxic.12-14 There is also a demand from many engineering and 
materials science disciplines particularly in the area of transportation such as 
aviation15,16 but also in energy generation17-20 and communications21. Therefore 
there is great potential for improvement and interest is intensifying due to the 
discovery of antifreeze (glyco)proteins (AF(G)Ps)22 and antifreeze proteins 
(AFPs)23 from multicellular organisms. Understanding the mechanisms and the 
properties of these molecules in particular their interactions with ice is an ongoing 
pursuit with studies targeting the molecules directly but also in utilizing 
synthetically more accessible derivatives and polymeric mimics.24 
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1.2. NATURAL MOLECULAR ADAPTATIONS. 
 
1.2.1. Antifreeze (glyco)proteins (AF(G)Ps). 
 
The discovery of Antifreeze (glyco)proteins (AF(G)Ps) occurred a little over 40 
years ago shortly after the unusually high freeze tolerance of several antarctic25 
and arctic26 fish species was identified and attributed to select abnormal body 
fluid characteristics.27 The landmark paper of DeVries and Wohlschlag in 1969 
was the first to describe the presence and influence of a mixture of glycoproteins 
(later termed AF(G)Ps) isolated from the serum of three antarctic fish species 
including the two very different species Trematomus borchgrevinki and 
Dissostichus mawsoni of the nototheniidae family.28 Plus how these proteins 
accounted for approximately 30 % of the observable freezing point depression 
and postulated how AF(G)Ps enabled their survival in seawater at subzero (-2 
°C) temperatures.29 It was also noted that the contribution of AF(G)Ps to the 
freezing point depression was greater than expected for the given number of 
particles in solution (colligative effect). Colligative freezing point depression is 
defined by Blagden’s law that states that in an ideal solution the freezing point 
depression of that solution is defined by the product of the molality, cryoscopic 
constant (H2O = 1.853 °C.kg/mol) and van’t hoff factors of any additional 
solutes.30,31 As a consequence and to account for the abnormally high freezing 
point depression there must be the existence of an active (non-colligative) 
property. Further work quickly acknowledged the presence of several AF(G)Ps of 
different molecular weights (MW) in the blood sera and an elemental analysis 
further clarified their composition.32 The composition of AF(G)Ps was proposed to 
be a tripeptide repeat consisting of one threonine and two alanine residues with 
an O-linked disaccharide moiety conjugated to each threonine residue. The 
disaccharide moiety of which was later confirmed as the complex disaccharide β-
 	  	   4	  
D-galactosyl(1→3)-α-N-acetyl-D-galactosamine giving rise to a complete primary  
AF(G)P structure (Figure 1.1.).33 The substitution of a minority of alanine residues 
for proline was also apparent in some low molecular weight (MW) AF(G)Ps from 
these early observations.34 No known naturally occurring β-D-galactosyl(1→3)-α-
N-acetyl-D-galactosamine substitutions were identified and this remains the case 
up to the present day emphasizing the importance of this specific disaccharide 
moiety, that is not frequent elsewhere in nature. However this disaccharide is 
present on a T-antigen associated with >85 % of human carcinomas.35 The 
isolation and identification of AF(G)Ps from an arctic fish species occurred soon 
after.36,37 A significant freezing point depression had been previously noted 
though in the blood sera of another arctic fish species (Eleginus gracilis) prior to 
this.38 AF(G)Ps have since also been discovered in several insect species.39,40  
 
 
 
 
 
 
Figure 1.1. Structural representation of a typical AF(G)P. AF(G)P 
compromising of an AAT tripeptide backbone with an O-linked β-D-
galactosyl(1→3)-α-N-acetyl-D-galactosamine disaccharide moiety, with AF(G)Ps 
isolated with between 4 and 55 repeat units. 
 
The presence of AF(G)Ps in both arctic and antarctic fish species raised interest 
in exploring their evolutionary origins41 with a general consensus that AF(G)Ps in 
arctic and antarctic specimens arose by convergent evolution42 and how this was 
driven by ancient climatic changes.43 A vast number of AF(G)Ps have now been 
identified and subcategorised according to their MW into 8 different groups. 
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Larger AF(G)Ps with MW values between 20 kDa and 34 kDa are categorised 
into AF(G)P groups 1-4 and small AF(G)Ps under 20 kDa into groups 5-8 with the 
smallest identified AF(G)P (AF(G)P8) just 2.4 kDa corresponding to tripeptide 
repeat units of between 4 and 55 in number.22,44,45 
 
As the prevalence of AF(G)Ps grew as did interest in their native expression and 
in their responsiveness to different thermal stimuli with seasonal changes in 
AF(G)P expression attributed to hormonal changes as hypophysectomised 
specimens lost the ability to modulate expression with changing surface water 
temperature.46 AF(G)P expression has also been studied in depth in a controlled 
environment showing how the concentration of all AF(G)Ps decreases over a 16 
week period with specimens incubated at the comparatively high temperature of 
+4 °C.47 AF(G)Ps have also been confirmed to be distributed in numerous body 
fluids with the highest concentration detected in blood plasma but with notable 
amounts in peritoneal, pericardial and extradural fluids also.48  
 
Understanding the interaction of AF(G)Ps with water and ice and how this is 
related to AF(G)P structure, which may elucidate clues as to their mechanistic 
functionality (Section 1.3.), soon became a popular avenue of interest. Numerous 
techniques have been utilised to investigate the primary, secondary and tertiary 
structure of AF(G)Ps.49 The primary structure of AF(G)Ps has been elaborated in 
brief prior and consists principally of a tripeptide (AAT) backbone with nearly all 
AF(G)Ps having a C-terminal sequence ending in two alanine residues. A notable 
exception however has been identified though in an AF(G)P isolated from 
Eleginus gracilis with a penultimate arginine residue.50 Arginine residues have in 
addition to this been identified to rarely substitute for threonine residues within 
the peptide backbone.51 Proline residues have also been observed in low MW 
AF(G)Ps substituting for alanine residues with a consequence on secondary 
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structure elements.52 One of the first investigatory studies using circular 
dichroism (CD) pertained that AF(G)Ps contain minimal α-helical and β-sheet 
content.32 Raman spectroscopy and proton NMR (90 MHz) studies from around 
the same period tended to support this also.53,54 Advancements in both proton 
NMR (300 MHz)55 and carbon NMR (68 MHz)56 have driven a better 
understanding of the solution conformation of AF(G)P supporting a random coil 
configuration. However even more recent experiments using a combination of 
infra red (IR) spectroscopy and proton NMR (500 MHz) that focused on a short 
chain (14 residue) proline containing AF(G)P8 showed local ordering that aided 
to induce a type II polyproline helical conformation. Using the same parameters a 
mixture of AF(G)Ps 1-5 elicited no local ordering, supporting a random coil 
conformer, with no long range ordering present in either AF(G)P8 or AF(G)P 1-5 
subsets.57,58 Molecular dynamics (MD) simulations further supported the 
formation of a type II polyproline helical conformer in the same proline containing 
AF(G)P8 but stressed that several other confirmations are attainable with 
energetically equal minima.59 Carbon NMR (100 MHz) and fourier transform infra 
red spectroscopy (FTIR) experiments further support the highly flexible structure 
of AF(G)Ps.60 Therefore AF(G)Ps do not share many secondary structure 
elements typical of most proteins. As a consequence there is no well defined 
three dimensional model or precise tertiary structure.61 The structure of AF(G)Ps 
is no doubt influenced heavily by the presence of the disaccharide moieties, the 
majority of modifications of which are known to completely negate antifreeze 
activity.32,62 The comparatively high density of carbohydrates makes conventional 
structural biology approaches more difficult also.63 
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1.2.2. Antifreeze Proteins (AFPs). 
 
Soon after the discovery of AF(G)Ps, serum proteins with similar properties 
including an ability to induce a non-colligative freezing point depression were 
identified from the arctic fish species Pseudeopluronectes americanus64 but 
lacked any carbohydrate content. These proteins were termed as antifreeze 
proteins (AFPs) and are more akin to traditional globular proteins. From this point 
to the present day many AFPs have been identified in a vast array of organisms. 
Along with numerous fish species, AFPs have been isolated from insects65,66, 
plants67-71, fungi72, yeast73 and bacterium72. However unlike with AF(G)Ps that 
have a uniform primary structure bar for a few select proline and arginine 
substitutions, AFPs comprising a wide variety of primary and by virtue secondary 
and tertiary structures have been categorized. In fish species alone four 
significantly different variants of AFP (type I-IV)74-77 have been classified with 
instances of some species expressing more than one type.78 AFPs present within 
insects are also structurally diverse.79-81 AFP diversity is emphasized in a recent 
review by Haridas and Naik that highlights 11 distinct AFP variants.82 As AFPs 
lack the structural complexities caused by the carbohydrate content of AF(G)Ps 
and have MWs from as low as 2.7 kDa many AFP structures have been solved 
by both NMR and x-ray crystallography (Figure 1.2.). Structural biology has 
therefore elucidated the diversity in AFP structures giving a much more 
complicated view of their functionality (and the functionality of AF(G)Ps 
additionally). Therefore AFP structures containing predominantly an α-helical, β-
sheet, random coil arrangement or even a combination of all three have been 
reported. 
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Figure 1.2. Structural representations of various AFPs highlighting 
secondary structure motifs and structural diversity. (A) AFP type I74, (B) AFP 
type II75, (C) AFP type III76, (D) AFP (Hypogastrura harveyi (Snow Flea))81, (E) 
AFP (Choristoneura fumiferana (Spruce budworm))80 and (F) AFP (Tenebrio 
molitor  (Yellow mealworm beetle))83. 
 
The lack of available material from source due to the logistical problems in 
attaining specimens in addition to refining AFPs and AF(G)Ps of a suitable purity 
has always been a bottleneck. However in the present day many groups are able 
to express various AFPs from recombinant systems.84,85 and perform site-direct 
mutagenesis experiments which has helped to improve mechanistic 
understanding.85 AF(G)Ps however have yet to be expressed in traditional 
unicellular recombinant systems due to the complexities of glycosylation which is 
a posttranslational modification typically seen in higher eukaryotes. However an 
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insect AF(G)P from Ixodus scapularis has been successfully incorporated into 
Drosophlia melanogaster that then displayed an improved freeze tolerance.40 
Therefore the application of AFPs and AF(G)Ps could be promising as 
expression systems improve further, though the use of non-native proteins could 
raise immunogenicity problems.86 In spite of these improvements there is an 
overwhelming issue concerning the application of AFPs and AF(G)Ps in 
cryopreservation in that they have been shown to a have significant cytotoxic 
effect in in vitro models.87 More importantly AFPs and AF(G)Ps failed in vitro and 
ex vivo to improve the cryopreservation of biological materials on several 
occassions.88,89 The details and reasoning of which are highlighted in Section 1.5. 
and emphasize the need for mimics that eliminate any detrimental effects or 
properties. 
 
1.2.3. Non-protein based strategies of cold acclimatization. 
 
A final area of interest is in non-protein based strategies that have been observed 
frequently in terrestrial organisms but predominately in insects and 
amphibians.90,91 These approaches were first described even before the 
discovery of AF(G)Ps or AFPs in the late 1950s.92,93 These strategies have 
focused on both freeze avoidance and freeze tolerance whilst AFPs and AF(G)Ps 
only enable the former and not latter94 though behavioral adaptations have also 
been recorded in these organisms to aid thermoregulation.95 These freeze 
tolerance and freeze avoidance mechanisms have allowed several organisms to 
survive in harsher environments even at temperatures as low as -60 °C.96 Non-
protein based strategies tend to work by the perturbance of metabolic pathways 
in response to cold stimuli induced by seasonal changes to produce very high 
concentrations of a single small organic molecule be it either glycerol, sorbitol, 
glucose, trehalose or one of several other polyols in conjunction with anti ice 
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nucleating factors (Figure 1.3.).97 This is a very energy intensive process and 
such polyols can constitute up to 10 % of dry weight and therefore this process is 
only undertaken annually with the onset of winter.98 
 
 
 
 
 
 
 
 
 
Figure 1.3. Representative non-protein based low MW weight 
cryoprotectants (non-exhaustive list).94 (A) Glucose, (B) Sorbitol, (C) 
Trehalose, (D) Ethylene Glycol and (E) Glycerol. 
 
In addition to this such organisms often suppress metabolic functions (undergo 
diapause) and promote extensive dehydration thereby increasing solute 
concentration in any remaining water content and causing a lowering of the 
supercooling point98 though this has not been observed in all cases.99 The rate of 
ice formation (if any) is then very gradual and occurs over a period of hours or 
even days, though most ice formation is extracellular even extensive intracellular 
ice formation that is typically more injurious has been reported to be reasonably 
well tolerated.100 As a consequence organisms have been frequently reported to 
pertain an ice content of 65 % of total body water.101 Though values as high as 
82 % have been documented.102 More recently however the isolation of a 
xylomannan103 from the Alaskan insect Upis ceramboides akin to AFPs and 
AF(G)Ps is the first non-protein compound to be isolated from nature with similar 
properties and therefore hypothesized to have an analogous cryoprotective 
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effect104 with other antifreeze xylomannans recently verified in 8 other species 
including the plant Solanum dulcamara and frog Rana lessonae.105 The 
identification of a diverse number of solutions that nature has evolved inspires a 
great number of potential applications for clinical benefit. The precise 
understanding of the mechanisms and activities of AFPs and AF(G)Ps in 
particular as these are present at low concentrations could elucidate improved 
strategies for the cryopreservation of cells, tissues and organs.106 
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1.3. MOLECULAR INTERACTIONS OF AFPS AND 
AF(G)PS WITH ICE. 
 
The properties that enable AFPs and AF(G)Ps to confer antifreeze activity in vivo 
has been of interest in order to attain whether or not such properties can be 
translated in vitro for use in cryopreservation.107 As AF(G)Ps were discovered it 
was quickly documented that they were able to depress the freezing point of a 
solution by an amount far greater than expected for their given concentration 
(colligative effect). Therefore another process must be taking place in order to 
explain this pronounced lowering of the freezing point transition or non-colligative 
effect that accounted for approximately 30 % of the freezing point depression 
seen in these organisms.29,32 Currently three distinctive properties have been 
attributed to AFPs and AF(G)Ps that describe and explain their antifreeze 
properties and remain measures for quantifying the effectiveness of AFP and 
AF(G)P mimics.24 
 
1.3.1. Ice Recrystallization Inhibition (IRI). 
 
One property of AFPs and AF(G)Ps is the ability to prevent or impede the kinetic 
growth or ripening of ice crystals during thawing in a process termed ice 
recrystallization inhibition (IRI). Importantly this does not alter the freezing point 
or alter probability of nucleation (the formation of ice crystals). The process of ice 
recrystallization is where by larger ice crystals grow at the expense of small 
adjacent ice crystals in order to minimize the total surface energy in a process 
similar to ostwald ripening.108-110 AF(G)Ps and AFPs are able to reduce this 
process in a concentration dependant manner such it almost becomes 
indistinguishable over a reasonable time period.111 A physical measure with 
suitable reproducibility of IRI activity was first described by Knight et al. who 
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developed the now commonplace standard for measuring IRI activity the “splat” 
assay.112 The development of the “splat” assay was driven by the inadequacies of 
prior methods that involved the freezing and annealing of supercooled solutions. 
Previous techniques used a small volume of a supercooled solution between two 
thin glass slides in which grain (ice crystal) size determination was driven by both 
the spontaneous rate of nucleation in addition to growth, with the unpredictability 
of nucleation limiting satisfactory replication. The “splat” assay (Section 2.5.3.) 
overcomes this by impacting a small droplet (≈10 µL) from a height of 
approximately 2 m on to a pre-cooled surface (> -50 °C) forming a polycrystalline 
wafer (thereby removing the rate of nucleation as a variable) comprising of very 
small ice crystals (< 10 µm ∅) of a thickness typically less than 50 µm. That is 
then annealed at a constant temperature between -6 °C and -8 °C for a desired 
period of time (normally 30 minutes) before quantifying grain size. The value 
reported is frequently the mean value of the largest dimension of the ten largest 
ice crystals within a significant field of view (Figure 1.4.) and termed the mean 
largest grain size (MLGS). An isotonic control is often used as a positive control 
(100 %) by which IRI activity is compared. Domain recognition tools have also 
been developed that aim to improve and hasten image analysis.113 Several 
modifications have been developed since that use solutions consisting of a high 
proportion of solutes (up to 30 % (w/v)) such as sucrose or hydroxyethyl starch 
(HES) in addition to the analyte of interest.114,115 Another method that uses 
capillary tubes for the simultaneous measurement of multiple samples has also 
been reported.116 The splat assay has been widely used to report relative IRI 
values for many AFPs, AF(G)Ps and their mimics.117-120 IRI is the property of 
AFPs and AF(G)Ps that is understood to be of the most benefit in 
cryopreservation by attenuating damage arising from ice crystal growth. 
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Figure 1.4. Example micrographs taken from “splat” IRI measurements. (A) 
Positive control (PBS) exemplifying ice recrystallization over a 30 minute period 
at -6 °C and (B) ice recrystallization in the presence of a IRI active compound 
under the same experimental conditions (scale bar = 400 µm). 
 
1.3.2. Thermal Hysteresis (TH). 
 
The second property that AFPs and AF(G)Ps exhibit is thermal hysteresis (TH). 
Thermal hysteresis is where by the freezing point of a solution is lowered but the 
melting point of the same solution is unchanged. This as a result creates a gap 
between the freezing and melting points. An important observation is that any ice 
crystals held isothermally within this gap will neither shrink nor grow henceforth 
leading to the term thermal hysteresis (TH) and was among the first 
characteristics of AF(G)Ps identified.107 The size of the TH gap varies with 
different AFPs, AF(G)Ps and mimics giving different values but the highest TH 
gaps observed tend not to be greater than 1.5 °C with the majority lower than 0.5 
°C.61,72,121 However a few exceptional “hyper-active” AFPs have been isolated 
that generate a TH gap in excess of 2 °C.122-124 TH is typically measured at 
precise temperature intervals using a nanolitre osmometer to accurately monitor 
changes in ice crystal size indicating the upper and lower TH gap boundaries.125 
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TH activity has been strongly associated with the final property of AFPs and 
AF(G)Ps the ability to alter ice crystal morphology.  
 
1.3.3. Dynamic Ice Shaping (DIS). 
 
The third and final property that AFPs and AF(G)Ps exhibit on the freezing and 
thawing process is dynamic ice shaping (DIS). DIS is a phenomenon that results 
in the alteration of the ice crystal growth habitat resulting in its extreme the 
formation of ice crystals with a hexagonal bipyramidal “needle-like” morphology 
(Figure 1.5.A). The onset of DIS has been studied in great depth with the 
following mechanistic understanding. A starting point is to consider the 1977 
article by Raymond et al. who first described an absorption inhibition model for 
the binding and interaction of AF(G)Ps to ice and links absorption to TH activity 
and discusses how absorption leads to DIS.126 Later an article by Knight et al. 
who observed that an (α-helical) AFP interacted and bound to a single specific 
plane of ice only termed the (6) prism faces (A-axis). Binding to the prism faces 
leaves only the opposing perpendicular (2) basal planes (C-axis) unbound and 
able to expand (Figure 1.5.B)127 giving rise to a step-pinning model that supports 
these observations (Figure 1.5.C.).24,128 This adsorption inhibition process can 
further explain the freezing point depression leading to TH as growth on the 
prism faces forms a surface with a highly convex curvature (Figure 1.5.C) that is 
energetically unfavourable (Kelvin effect).22 NMR studies have further supported 
the adsorption inhibition model showing the complementary fit of AF(G)Ps to the 
ice crystal lattice.129 Houston et al. explored the adsorption inhibition process 
further and showed how the modification of an oligopeptide derived from a type I 
α-helical AFP resulted in a reduction in DIS activity inciting a milder change in ice 
crystal morphology indicating that binding to the ice crystal lattice is not a on/off 
behaviour.130 Ice shaping events with a range of AFPs, AF(G)Ps and mimics 
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have since been shown77,131,132 in a concentration dependant manner and it is this 
property that is thought to create a prohibitive effect for the application of native 
AFPs and AF(G)Ps as cryopreservatives. The formation of hexagonal 
bipyramidal “needle-like” structures has been shown to increase mechanical 
damage, a property that AFP and AF(G)P mimics attempt to suppress, whilst 
retaining the beneficial effect of IRI. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Mechanisms and consequences of DIS. (A) Representative 
micrographs of ice crystal morphologies (and sizes) arising from left to right no 
ice shaping, strong DIS effect and a mild DIS effect (adapted from Peltier et al., 
2010).131 (B) Illustration of the prism and basal planes showing how AF(G)P 
binding to the prism plane enables growth in the basal plane only and thereby 
adopting a hexagonal bipyramidal structure. (C) Depiction of the step pinning 
model showing AFP/AF(G)P (red) binding to the ice crystal lattice and the 
formation of a curved surface (Kelvin effect) forming between each binding site. 
(adapted from Gibson, M.I., 2010).24  
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1.4. SYNTHETIC MIMICS OF AFPS AND AF(G)PS. 
 
Given the complexities of isolating AFPs and AF(G)Ps from primary sources and 
recombinant systems in addition to problems typically associated with the 
application of non-host proteins many synthetic mimics principally close 
derivatives of AF(G)Ps have been developed.133 Synthetic strategies have many 
benefits in that synthetic mimics allow the impact of single tailored made 
modifications on the aforementioned properties of IRI, TH and DIS to be 
assessed. These alterations have created an improved understanding on how 
AF(G)Ps interact and manipulate ice. AFP variants through site-specific 
mutagenesis with reduced activities have elucidated the importance of key 
residues but tend to be too large to be synthesized by solid phase peptide 
synthesis (SPPS) limiting throughput. Progressive improvements have begun to 
lead to the rational design of synthetic mimics that are more synthetically 
accessible, scalable with greater biochemical stability and that are less likely to 
cause immunogenicity concerns. These mimics tend to be biosynthetically 
inaccessible to natural expression systems but with further refinement could 
perhaps be produced artificially on a significantly sufficient scale. 
 
The work of Ben et al. has arguably contributed the most substantial progress 
over the last decade in this regard beginning in 1999 with the synthesis of a 
AF(G)P mimic that consisted of a tripeptide backbone with three repeat units 
using SPPS.134,135 Following on a single β-D-galactose per tripeptide unit was 
conjugated by a C-linkage that is less likely to be susceptible to biochemical 
degradation (Figure 1.6.A).136 Soon after more complex longer chain C-linked 
derivatives were synthesised.137,138 However it was not until 2005 that several C-
linked AF(G)P derivatives (Figure 1.6.B) were tested and reported to have IRI 
activity in a concentration dependant manner with no TH activity successfully 
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separating these two properties. A critical observation was that IRI activity was 
strongly influenced by the linkage length that separated the galactoside moiety 
from the peptide backbone. A longer linkage length (Figure 1.6.B (n=2,3)) 
corresponded to a dramatic reduction in IRI activity whilst the shortest linker the 
most representative of AF(G)Ps had a much higher IRI activity. (Figure 1.6.B 
(n=1)).120 This IRI activity was then found to be comparable to freshly isolated 
AFGP887,113 with the effect of AFGP8 aggregation induced at higher 
concentrations and corresponding effect on TH activity also explored.139 Later in 
2008 Czechura et al. showed that substituting galactose for either glucose, 
mannose and talose monosaccharide moieties negated IRI activity emphasizing 
the importance of retaining a galactose moiety in synthetic preparations which 
further supports the prevalence of the naturally occurring β-D-galactosyl(1→3)-α-
N-acetyl-D-galactosamine disaccharide moiety.140 The variation in IRI activity 
between each of these monosaccharides in addition to several disaccharides 
was then attributed to differences in their hydration index which was reflected by 
their (weak) IRI activities as stand alone entities.141  
 
Following on, a more extensive investigation into linkage length using derivatives 
of Figure 1.6.A and Figure 1.6.B highlighted a preferred separation distance 
corresponding to differences in solution conformation as ascertained by CD and 
MD. CD studies failed to illustrate any significant differences in secondary 
structure composition but using a model compound of an IRI active mimic in MD 
simulations a unique orientation resulting in a hydrophobic pocket that interacts 
favourably with the quasi liquid layer (QLL) of the ice crystal lattice was 
identified.142 The development of a triazole containing C-linked AF(G)P caused a 
dramatic reduction in IRI activity regardless of the linkage length employed 
(Figure 1.6.C) so that the chemical composition (bulkiness) of the linker is as 
important as the separation distance.143 A similar loss of IRI activity was 
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additionally identified in fluorinated mimics and in mimics with increasing 
carbohydrate hydrophobicity.144 The differences in the IRI activities of several 
monosaccharides and disaccharides as cryoprotectants (at high concentrations) 
has since been investigated with human embryonic liver cells (WRL-68)145 and 
umbilical cord blood146. A beneficial cryoprotective effect was also shown 
decisively with active C-linked AF(G)P mimics and WRL-68 cells.147  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. AF(G)P analogues developed by Ben and co-workers. (A) 
Original C-linked serine derivative136, (B) C-linked galactosyl serine derivative120, 
(C) C-linked triazole serine derivative (inactive)143, (D) n-octyl-β-D-
galactopyranoside148 and (E) N-octyl-D-gluconamide.148 
 
In 2012 Wilkinson et al. reported a complete synthesis of AF(G)P with 2, 4, 8, 12, 
16 and 32 repeat units (1.2 kDa – 19.5 kDa) with 8 repeat units or greater giving 
significantly high IRI activity similar to AF(G)P8 where as the shorter 2 and 4 
repeat unit polypeptides had no significant activity even at concentrations 100x 
higher. Notable TH values were also reported in each compound that displayed 
significant IRI activity.149 However the largest 19.5 kDa AF(G)P prepared also 
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represents the largest AF(G)P synthesised to date and indeed one of the largest 
native glycoproteins of any kind. Soon after it was reported that n-octyl-β-D-
galactopyranoside possessed a strong IRI activity where as n-octyl-β-D-
glucopyranoside did not with this relationship reversed when examining N-octyl-
D-aldoamides, though in each instance it was the presence of the large 
hydrophobic alkyl chain that proved critical (Figure 1.6.D and Figure 1.6.E.).148 
Finally Corcilius et al. synthesised a range of peptides and glycopeptides with 
type II polyproline helical topology though only two derivatives displayed 
significant IRI activity.150 
 
Several other research groups have also synthesised AF(G)P mimics including 
Miller et al. who synthesised O-linked triazole containing mimics using microwave 
assisted SPPS.151 Within the same group Peltier et al. investigated the effect of 
substitutions in the peptide backbone (with select proline for alanine 
replacements) and saccharide moiety (β-galactose and α-N-acetyl-
galactosamine) compared to AF(G)P8 with respect to DIS and TH activity. Whilst 
galactose containing analogues had no DIS activity except at the highest 
concentration tested of 80 mg/mL, those containing α-N-acetyl-galactosamine did 
have a profound influence on DIS with either peptide backbone configuration in a 
concentration dependant manner forming hexagonal rods at 20 mg/mL. At higher 
concentrations (80 mg/mL) morphology changed to the widely observed 
hexagonal bipyramidal structure (Figure 1.5.A), where as this structure was 
observed with native AF(G)P8 (β-D-galactosyl(1→3)-α-N-acetyl-D-galactosamine 
disaccharide) at a much lower concentration of 20 mg/mL.131 These studies show 
how alterations in the conjugated saccharide can have profound influence on ice 
crystal morphology with the formation of hexagonal bipyramidal structures. 
Hexagonal bipyramidal structures have been deemed to be detrimental to cells 
as “needle-like” morphologies incite greater mechanical damage during 
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cryopreservation negating any beneficial IRI activity. Using proton NMR they 
were able to determine the importance of the appropriate solution conformation, 
how the N-acetyl-amine group and α-linkage were key features of any interacting 
conformation that modified the ice crystal growth habitat. Eliminating DIS effects 
whilst maintaining IRI activity would be highly desirable. Ben et al. showed with 
similar monosaccharide containing analogues (Figure 1.6.B) that did display an 
IRI activity a lack of TH activity successfully separating these properties.120 
Tachibana et al. showed that the removal of the N-acetylamine group from N-
acetylgalactosamine resulted in a loss of both TH and DIS activity highlighting 
how these two properties are linked.152 In the same study Tachibana et al. who 
successfully produced a variety of AF(G)P mimics alongside an earlier reported 
synthesis (one of only three) of AF(G)P (8 repeat units)153 also showed the 
importance of the N-acetyl-amine motif and α-configuration of the O-linked 
glycosidic linkage and further concluded that a type II polyproline helical like 
conformation is required for antifreeze activity.154 
 
Many others have also investigated synthetic methodologies for the production of 
AF(G)P mimics including Garner et al. who used a native chemical ligation-
desulphurization strategy to produce α-N-acetyl-galactosamine peptides 
containing up to six repeat units.155 Heggemann et al. have also reported the use 
of a microwave enhanced synthetic strategy to produce a range of short chain 
AF(G)P mimics with various backbone substitutions including serine and glycine 
that are not seen in any native AF(G)Ps in addition to proline containing 
polypeptides. These mimics closely resemble those seen elsewhere in literature 
(i.e. O-linked α-N-acetyl-galactosamine peptides without backbone modifications) 
that displayed potent IRI activity. The work of Heggemann et al further supports 
how the α-N-acetyl-galactosamine moiety is critical for activity as discussed prior 
with a fully acetylated galactoside containing mimic (lowering its hydration index) 
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possessing a significantly reduced IRI activity. Three mimics that contained 
altered peptide backbone structures had minimal IRI activity at the highest 
concentration studied of 4 mg/mL. 4 mg/mL is low by comparison to some other 
studies but up to three and one hundred times greater than the concentrations of 
other mimics in the same study that possessed potent activity. The lack of activity 
was despite the presence of the critical α-N-acetyl-galactosamine 
monosaccharide moiety. The only exception to this (Figure 1.7.A) is a proline 
containing analogue that in contrast to others is able to adopt a regular periodic 
(type II polyproline helix) secondary structure where as those with substituted 
glycine and serine residues plus irregularly placed proline residues are not and 
henceforth accounts for the difference in IRI activity.156 Periodicity highlights the 
importance of AF(G)P mimics being able to adopt consistent and regular 
conformations that are inhibited by residues that promote flexibility such as 
glycine or greater steric hindrance such as (unconjugated) serine residues. 
Periodicity is an important conjecture in the rational design of AF(G)P mimics. 
The same group soon after reported the synthesis of small AF(G)P molecules 
and that these synthetically derived AF(G)Ps had comparable properties to 
naturally derived AF(G)P8. These short chain mimics further clarified the 
importance of chain length with increasing chain length purporting to a higher 
activity with CD data supplementing the likelihood of a type II polyproline helical 
conformation.157 However oligoproline peptides with triazole conjugated α-N-
acetyl-galactosamine and β-D-galactosyl(1→3)-α-N-acetyl-D-galactosamine 
moieties (Figure 1.7.C) did not illicit strong IRI activity despite the formation of 
type II polyproline helical secondary structure elements as noted by CD.158 This 
lack of activity is presumed to be due to the presence of the large triazole 
functional group as a spacer agreeing with findings (Figure 1.6.C) by Capicciotti 
et al.143 Finally the work of Nishimura et al. has to be reviewed with regards to 
improving the synthetic pathways of attaining relevant glycopeptide mimics159,160 
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and in understanding AF(G)P function.152 However interestingly a 2009 
publication that details the production of cyclic AF(G)P mimics consisting of 2,3 
and 4 repeat units (Figure 1.7.B) that do not possess the typical secondary 
structure elements due to this cyclization with a characteristic shift in CD spectra 
do have equivalent TH and DIS characteristics (IRI was not measured). The 
synthesis of cyclic AF(G)Ps represent the first instance of AF(G)P like 
glycopeptides with antifreeze properties that do not have the otherwise 
necessary type II polyproline helical conformation seen elsewhere.161 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7. Other AF(G)P mimics. (A) Antifreeze active proline containing 
AF(G)P mimic with a N-acetyl-galactosamine monosaccharide moiety, activity is 
only conserved with periodic proline substitutions.156 (B) Example of an antifreeze 
active cyclic (2 repeat units) AF(G)P mimic that does not form a typical type II 
polyproline helical conformation161 and (C) an antifreeze inactive AF(G)P mimic 
that does form a type II polyproline helical conformation but the presence of the 
comparatively bulky triazole spacer inhibits antifreeze activity.158 
 
A high number of the previously discussed AF(G)P mimics have identified a 
relatively strict criterion for antifreeze activity, though in some instances IRI 
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activity has been successfully separated from TH and DIS activity. However 
despite the production of many AF(G)Ps, several non-protein like molecules have 
been identified that have minimal resemblance to any of the mimics discussed 
(Figure 1.6. and Figure 1.7.) but strong antifreeze properties. The first of these is 
the synthetically simple and commercially available polymer poly(vinyl alcohol) 
(PVA) (Figure 1.8.A) that has been shown to have a strong IRI activity even over 
prolonged periods of time.117 PVA has also been demonstrated to have a strong 
concentration and MW dependence with regards to IRI potency.118,162 However 
IRI activity is reduced and eventually lost with decreasing MW and with the 
gradual acetylation of the polymer backbone163 highlighting the importance of 
hydration which is consistent with other AF(G)P mimics and their corresponding 
IRI activities.141 This is further emphasized with observations that neither 
poly(ethylene glycol) (PEG) (Figure 1.8.B) which is isomeric to PVA, poly(vinyl 
pyrrolidone) (PVP) (Figure 1.8.C) or poly(acrylic acid) (PAA) (Figure 1.8.D) have 
IRI activity consistent with their lack of hydroxyl groups.164 Furthermore DIS has 
been shown with unusually high concentrations (10 mg/mL) of a large MW PVA 
(27 kDa)165 and only a mild TH effect even at 50 mg/mL and a MW of 13 kDa.166 
Further characterization of PVA and its interactions with ice in addition to different 
arrangements of PVA such as branched or star polymers is also of interest as 
well as analyzing PVA and these variants by CD for the formation of secondary 
structure like motifs akin to glycopeptide mimics. With the use of MD to help 
gauge further its interactions with ice. Exploring a range of periodic and block 
copolymers comprising in part PVA would also be attractive.167 The use of 
polymeric macromolecules has many advantages. Firstly the controlled synthesis 
of PVA on a large scale is regularly employed on a financially viable basis which 
is advantageous with respect to other AF(G)P mimics that are synthetically 
intensive with a comparatively small return. Furthermore PVA has excellent 
biocompatibility168, biodegradability169 and already has FDA approval as a 
foodstuff therefore the translation to a clinically employed preparation would have 
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reduced risk compared to glycopeptide mimics that may have unknown biological 
interactions often associated with non-host proteins.86,170,171 However the 
administration of an AFP III (referenced as ice structuring protein (ISP) III) 
preparation orally to 42 healthy volunteers failed to identify any adverse 
effects.172 As a consequence of this AFP III is now used commercially in ice 
cream preparations in numerous products within the Unilever PLC portfolio as 
reducing ice recrystallization improves quality, longevity and eases logistics. 
 
 
 
 
 
Figure 1.8. Select polymeric compounds assessed for antifreeze 
activities.118,164 (A) antifreeze active poly(vinyl alcohol) (PVA) and antifreeze 
inactive polymers (B) poly(ethylene glycol) (PEG), (C) poly(vinyl pyrrolidone) 
(PVP) and (D) poly(acrylic acid) (PAA). 
 
A final and recently recognized ice interaction phenomena has been reported by 
Deville et al. who observed that zirconium acetate complexes (Figure 1.9.A) had 
a strong ice structuring tendency reporting similarities to many other AF(G)P 
mimics and polymers. However zirconium acetate has a low MW (327 g/mol) and 
a financially non-restrictive availability and Deville et al later elucidated on a 
possible mechanism corresponding with these observations.173 Mizrahy et al. 
have very recently reported however that neither zirconium acetate or zirconium 
acetate hydroxide (Figure 1.9.B) possesses notable TH activity but yet still 
demonstrate DIS which is contradictory to other observations that TH and DIS 
are intrinsically linked but given the vast structural differences from AF(G)Ps and 
AFPs an alterative mechanism could be at play.174,175 However the use of 
zirconium acetate complexes would likely be undesirable with biological materials 
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due to the higher molar concentrations that would be required and thus may be 
better suited as an antifreeze from a materials science perspective as opposed to 
usage is clinical applications. 
 
 
 
 
Figure 1.9. Antifreeze active Zirconium compounds. (A) Zirconium acetate 
and (B) Zirconium acetate hydroxide. 
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1.5. CURRENT STORAGE STRATEGIES OF 
BIOLOGICAL MATERIALS. 
 
The field of cryobiology and preservation science has diversified extensively over 
the last 60 years with the preservation of a wide range of biomaterials now 
undertaken. Concurrent advances in the areas of haematology, reproduction 
medicine and transplantation science have accelerated the demand for 
technologies that improve the storage of these materials ex vivo to prolong their 
clinical viability. In parallel, improvements in biocatalysis, biotechnology and a 
range of molecular biology techniques have also incentivized the development of 
novel methodologies that extend the longevity of therapeutics and biochemical 
reagents. Preservation science can be broadly categorized into fours areas. 
Hypothermic storage (above 0 °C), non-vitrifying (ice present) cryopreservation, 
vitrifying (ice absent) cryopreservation and lyophilisation (freeze drying).  
 
1.5.1. Haematology. 
 
The demand for blood products is enormous and can emphasized by the number 
of units (1 unit ≈ 470 mL) required daily. The vast majority of blood products 
required clinically are red blood cells (RBCs) also referred to as erythrocytes, 
though there is also a significant demand for blood plasma and platelets. For 
example approximately 44,000 units in the USA and 6,000 units in the UK are 
needed every day with equivalent per capita quantities required across the 
developed world. Long-term, the demand for blood products is increasing as the 
mean population age continues to rise.176,177 The majority of transfusions at 
present are for chronic illnesses as opposed to acute emergencies meaning 
overall (UK) demand is reasonably predictable and consistent as shown in table 
1.1.178  
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Table 1.1. Breakdown of the clinical use of donated blood units in the UK.179 
 
However donations are not provided uniformly across the year with numerous 
instances highlighting a significant drop in donations at times of adverse weather 
and during large sporting or cultural events. Fluctuations are exemplified in 
Figure 1.10 and summarized in Table 1.2 that detailing centralized UK blood 
stocks over a 14 week period highlighting instances where demand outstrips 
supply and how different blood groups (ABO/Rh) are more at risk at attaining 
dangerously low supply levels depending on their different compatibilities.   
 
 
 
 
 
 
 
 
 
 
Figure 1.10. UK blood stocks over a 14-week period. Highlighting the 
inconsistency of donations with over a 14,000 (unit) difference between the 
highest and lowest quantities recorded.179 
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Table 1.2. Detailed breakdown of UK blood stocks over a 14 week period. 
Highlighting the relative demands of each blood group (ABO/Rh) in particular the 
high demand for O- blood (universal donor*) and comparatively low demand for 
AB+ (universal recipient¥) blood. 
 
A fundamental issue is that RBCs only have a functional life span between 100 
and 120 days in vivo. However ex vivo, RBCs can only be routinely stored for 
between 35 and 42 days hypothermically before being deemed clinically 
unviable.180 Hypothermic storage is defined as the preservation of biological 
material at temperatures significantly lower than normal physiological 
temperatures but above the freezing point of the storage solution (usually around 
4 °C). Many storage solutions have been developed with a variety of solutes that 
prevent coagulation such as ethylenediaminetetraacetic acid (EDTA), citrate and 
heparin as well as solutes to help maintain a compatible osmotic pressure.181-183 
Several issues have been identified in the hypothermic storage of RBCs ex vivo 
including a reduction in ATP and 2,3-DPG concentration.184 A reduction in 2,3-
DPG a key regulator of oxygen affinity in haemoglobin causes a reduction in 
oxygen release though this change is reversible with 2,3-DPG levels recovering 
approximately 3 days after transfusion, however this may still have clinical 
repercussions in certain scenarios.185 A reduction in ATP is linked with an overall 
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reduction in RBC metabolic activity, many other metabolites are also suppressed 
as lower temperatures inhibit biochemical processes with a 97 % reduction 
observed at storage temperatures of between 1 °C and 6 °C.186 Another issue in 
storing RBCs hypothermically ex vivo is alterations in cell deformability caused in 
part by changes such as those mentioned above that can alter membrane 
composition but additionally changes in physiochemical properties that alter 
membrane plasticity. Hypothermic storage increases the likelihood of membrane 
lesions and irreparable injuries and has been associated with changes to 
aggregability, adhesiveness, volume, flexibility and internal viscosity in addition to 
other rheological properties.187,188 Many additives have been studied to maintain 
RBC survival ex vivo and maximize posttranfusion viability including the addition 
of saline, adenine, glucose and mannitol (SAGM) to help retain favourable 
metabolic activity.189 Plus inorganic phosphates that act as both a pH buffer as 
other additives tend to incite acidity and as a substrate for 2,3-DPG production. 
However cumulatively these additives accelerate decay limiting storage to a legal 
maximum of 42 days defined by a minimum 24 hour posttransfusional (in vivo) 
survival rate of 75 %. In vitro, unviable samples are defined as haemolysis 
exceeding 0.8 % (EU) or 1.0 % (USA).190,191 However even at this level of viability 
the immune system may be temporarily compromised as non-viable RBCs are 
identified and removed from the body, a clinical detriment. Continuing research is 
focused upon not only extending the maximum storage limits but also improving 
the quality of hypothermically stored RBCs, which would improve logistics and 
avoid secondary transfusions and disorders associated from the transfusion of 
non-viable cells, though no dramatic improvements or changes have been 
implemented over the previous 20 years. 
 
Another technique that aims to retain the long-term viability of RBCs is 
cryopreservation that can be defined in this context as the storage of RBCs at 
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low or ultra low temperatures such that RBCs are not freely in suspension but 
frozen. The cryopreservation of RBCs is advantageous in that it has no upper 
limit on storage duration and cellular energetics are minimized. However even 
though such storage conditions are not inherently damaging both the freezing 
and thawing process can inflict significant damage by a variety of mechanisms, 
the prevalence and impact of which is dependant upon the rates of freezing and 
thawing amongst an array of other factors.192 The freezing rate of RBCs can have 
a significant impact on viability. Slow freezing promotes the formation of 
extracellular ice that as a consequence creates an osmotic gradient that favours 
the efflux of water from the cell, which is influenced by other additives that alter 
osmolarity. The rate at which water exchange occurs is highly dependant on the 
rate of ice formation that is in turn dependant upon the cooling rate. If the rate of 
efflux is sustainable such that RBCs can control the rate of water loss then the 
cell will slowly become dehydrated.193 However if the rate of dehydration is too 
high then membrane lesions and excessive cell shrinkage may occur and in 
conjunction, the levels of some solutes may reach localized concentrations that 
may have a consequential cytotoxicity.194 The exact effect of solute cytotoxicity 
however remains a contested topic and it is believed that membrane lesions may 
alter permeability allowing the entry of previous impermeable molecules shifting 
osmolarity detrimentally.195-197 The presence of extracellular ice can also 
depending upon the density (haematocrit) of RBCs have a significant impact with 
regards to inciting significant mechanical damage.198,199 A rapid cooling rate 
which there by limits the duration with which RBCs are exposed to the potentially 
damaging effects experienced at slow cooling rates is offset by an increased 
probability in the development of intracellular ice. Intracellular ice formation 
occurs during rapid cooling as the efflux of water in addition to changes in 
membrane permeability associated with low temperatures allow an undesirable 
retention of water within the cytoplasm. Intracellular ice formation can occur by 3 
different mechanisms.200 The formation of intracellular ice is hypothesized to 
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incite greater mechanical damage and to be avoided where possible.201 Once 
frozen RBCs are often kept at temperatures below -150 °C indefinitely until 
required though an array of storage conditions have been employed that have no 
significantly detrimental effects.180,202,203 The thawing of RBCs is a process that is 
just as critical as freezing. However it is more difficult to precisely thaw cells in a 
controlled manner, as implementing a high thaw rate requires the use of 
temperatures that exceed tolerable levels. The problems associated with 
controlled thawing are more prevalent with RBCs as they are stored and 
transfused in large volumes (470 mL) meaning that they cannot be thawed 
homogeneously. Heterogeneous thawing would result in exposing a substantially 
high proportion of RBCs to undesirably high temperatures. As a consequence 
RBCs must be thawed at a comparatively slow rate. Slow thawing results in 
allowing ice recrystallization that is highly detrimental and a significant cause of 
cryoinjury. Aside from a financial and practical perspective, ice recrystallization 
damage is one of the main reasons as to why RBCs are not routinely 
cryopreserved. 
 
The cryopreservation of RBCs requires a complex array of cryoprotective agents 
(CPAs) and at substantially higher concentrations than those used in 
hypothermic storage solutions in order to best mitigate against the damaging 
effects listed previously. CPAs can be broadly categorized into membrane 
permeable and membrane impermeable additives.180,204,205 Membrane permeable 
additives including glycerol and DMSO are often necessary at exceptionally high 
concentrations.202 Standard RBC cryopreservation uses glycerol at high 
concentrations up to 40 wt% with significant discrepancies between the 
techniques employed in Western Europe and North America. The removal of 
glycerol prior to transfusion is a necessity as glycerol can induce 
posttransfusional intravascular haemolysis.206 Early efforts in the 1950s to 
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translate glycerol cryopreservation into a clinical setting were dampened by the 
inability to remove glycerol (deglycerolisation) sterilely as bacterial contamination 
of blood products was and is, if now only a minor issue a continual concern.207 
However the frequency of bacterial contamination occurring in platelet 
transfusions is far higher.208 The development of continuous flow centrifugation in 
the 1960s allowed the clinical use of glycerol as a cryoprotectant with two 
different methodologies now fully developed. European blood banks tend to use 
a comparatively low glycerol (15 – 20 wt%) concentration and rapid cooling (<100 
°C per minute) technique storing at a temperature between -165 °C and -196 °C 
and thawing at between 42 °C – 45 °C.209 Conversely North American blood 
banks use a higher glycerol (40 wt%) concentration and slow cooling (1 °C per 
minute) technique storing at -80 °C and thawing at 37 °C.210 The addition and 
removal of glycerol though must be highly controlled in order to limit osmotic 
damage and prevent patient exposure to glycerol and thus requires specialized 
equipment and training increasing expense and processing time, which is often 
incompatible with clinical requirements demanding immediacy. The viability of 
RBCs after deglycerolisation is limited to 24 hours and thus poses another 
significant limitation, meaning that the cryopreservation of RBCs is typically 
limited to rare blood types for autologous transfusion and military applications 
where by logistics can limit the availability of donations.211,212 Therefore current 
research is predominantly focused on the improving the speed of postthaw 
processing and extending the shelf life of RBCs after deglycerolisation.206  
 
Other cryopreservation techniques focus on the application of membrane 
impermeable (and henceforth extracellular) CPAs which include poly(vinyl 
pyrrolidone) (PVP), hydroxyethyl starch (HES), and dextran. However PVP and 
HES can led to posttransfusional intravascular haemolysis at concentrations 
between 15 – 25 wt%.213-215 Several of these were used clinically as acute 
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plasma expanders albeit at concentrations lower than those used to attain a 
cryoprotective effect that offset hypovolemia in instances of severe trauma,216 
though HES has been shown to interfere with coagulation which may have 
clinical repercussions.217 Instances of Pruritus have also been associated with 
prolonged exposure at high doses.218 Furthermore recent studies conducted by 
Boldt et al are under intense scrutiny for fraudulent claims regarding studies and 
trials into the efficacy and safety of HES that strongly supported the use of HES 
in intravascular fluid replacement therapy.219 These factors have contributed to 
the recent and immediate withdrawal within the EU (14/06/13) and limited 
application in the US (24/06/13) of HES in intravascular fluid replacement 
therapy.220 HES is the most widely studied extracellular CPA and can be 
synthesised relatively easily on a large scale at various molecular weights and is 
readily metabolized and excreted (fragments smaller than 40 kDa)221 from the 
body.222,223 The cryoprotective mechanism of HES and other extracellular CPAs 
differs from glycerol. HES serves to alter viscosity224 and is known to strongly 
interact with water and as changes in viscosity occur it increases the rate of 
water efflux promoting faster dehydration enabling more rapid cooling and 
lowering the likelihood of intracellular ice formation upon cooling and thawing.204 
Patients whom were transfused with RBCs cryopreserved with HES had an 
elevated incidence of haemglobinuria indicative of possible renal toxicity when 
HES was not removed prior to transfusion.225 The absence of clinical data 
evaluating patients subjected to multiple HES cryopreserved RBC transfusions in 
addition to the reasons aforementioned have limited the clinical application of 
HES and in general extracellular CPAs in RBC cryopreservation. 
 
Vitrification is the freezing of an aqueous solution at ultrahigh cooling rates such 
that ice formation is circumvented and instead an “ice-free” amorphous glass 
solid is attained.226 The obvious benefits of vitrification include the complete 
elimination of ice formation and the corresponding damage associated with it. 
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The cooling rates required to attain a vitrified state are often very high. For 
example pure water can attain a vitrified state at -138 °C but ice crystal formation 
often occurs at temperature much higher than this. In order to avoid ice formation 
cooling at 106 °C/min is necessary therefore being impractical for all but the 
smallest volumes and certainly not feasible for the cryopreservation of RBCs 
clinically.227 Devitrification and consequential ice crystal formation can occur upon 
thawing or suboptimal storage conditions.228 The addition of PVP, HES and 
dextran have been shown to lower the freezing rates required to attain a vitrified 
state and improve overall recovery rates.180 Monosaccharides and disaccharides 
also have a similar effect.229 However subsequent haemolysis after transfusion 
was undesirably high plus the concentrations of these CPAs needed is 
excessively high and cytotoxic.22 The addition of membrane impermeable 
monosaccharides and disaccharides has shown to alleviate some of the 
toxicological consequences of using high concentrations of short chain diols as 
RBC cryoprotectants.230,231 Nonetheless an implementable cryopreservation 
strategy of RBCs using vitrification has yet to be successfully applied but remains 
an active area of investigation. 
 
A final area of research into the storage of RBCs is lyophilisation. Lyophilisation 
or freeze drying is the sublimation of ice under vacuum removing a vast majority 
of the water content.232 The lyophilisation of RBCs would be beneficial as it would 
harbour significant logistical benefits as the overall weight of the lyophilized 
product prior to rehydration is minimized and it has been suggested that 
lyophilised RBCs could be stored at room temperature possibly indefinitely if kept 
sterile.233 The addition of PVP, PEG and dextran was able to improve overall 
recovery during freezing after lyophilisation, cryostorage and rehydration and 
even though lyophilised RBCs initially showed acceptable recovery a high 
frequency of membrane lesions were later identified limiting their application. 
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Even though desiccation (i.e. the removal of water) has been frequently observed 
in nature it has yet to be successfully replicated by others by lyophilisation or 
otherwise with RBCs.234  
 
Ice recrystallization upon thawing as aforementioned is a key mechanism of 
cryoinjury192 during cryopreservation and to a lesser extent during thawing of 
vitrified samples as a consequence of devitrification.228,235 However none of the 
previously identified methodologies aim principally at eliminating ice 
recrystallization, though thawing cells rapidly can reduce ice recrystallization, this 
is problematic with RBCs due to the large volume and number of cells required 
for transfusions. IRI may therefore provide a means of limiting damage arising 
from extracellular ice crystal growth and improve the cryopreservation of RBCs 
by increasing the number of cells recovered subsequent to freezing. Efforts at 
improving the cryopreservation of RBCs by inhibiting ice recrystallization has 
been attempted previously.88 The work of Carpenter and Hansen demonstrated 
the use of a type I recombinant AFP isolated from winter flounder 
(Pseudopleuronectes americanus) in decreasing the level of haemolysis in RBCs 
supplemented with 30 wt% HES (MW 450 kDa, 0.7 degree of substitution). A 
decrease in haemolysis was observed at concentrations as low as 8 µg/mL, 
though maximum protection was conferred at 62 µg/mL. Increasing the 
concentration of AFP, which resulted in a more profound IRI activity, actually 
elicited a reduction in cryoprotection. At the maximum concentration tested of 
1.54 mg/mL the level of haemolysis was higher than when RBCs were 
cryopreserved in the complete absence of AFP, which the authors attributed to 
the presence of hexagonal bipyramidal “needle-like” ice crystal structures caused 
by DIS. Reductions in haemolysis were the most apparent when slow thawing 
(20 °C, air) conditions were used that greatly promote ice recrystallization, though 
the addition of AFP could not reduce haemolysis to levels observed when an 
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optimal fast thawing (45 °C, water) technique was applied that minimized ice 
recrystallization. Continuing studies by Carpenter et al expanded on these 
findings by comparing type I, II and III AFPs and their ability to improve the 
cryopreservation of RBCs. Using a similar freezing and thawing regime each AFP 
was found to convey a cryoprotective effect in a similar concentration dependant 
manner, though the loss of cryoprotection at higher concentrations was far less 
apparent with AFP II and AFP III but speculated that on a molar basis the loss 
could be comparable. Continuing on several mutant variants of AFP III were 
generated using site-directed mutagenesis. One mutant (P29A) which had a 
reduced (50 %) thermal hysteresis activity that the authors attribute as a measure 
of beneficial “antifreeze” activity in addition to observations by cryomicroscopy of 
substantially greater ice crystal growth did confer a significantly reduced level of 
cryoprotection.236 These findings highlight that the inhibition of ice 
recrystallization can confer beneficial cryoprotection but that the exact 
mechanism by which cryoprotection is conveyed in vitro remains elusive as 
simply increasing IRI activity does not yield improved cryopreservation. This 
highlights a balance between the properties of IRI and DIS and its importance in 
identifying a candidate IRI active compound with beneficial cryoprotection to 
RBCs. 
 
1.5.2. Reproductive medicine. 
 
Substantial differences exist between the storage strategies used with RBCs 
(Section 1.5.1) and in reproductive medicine, which is fundamentally due to the 
differences in the their biology in which these cells are donated and required, 
subcategorized broadly into spermatozoa, oocytes and embryos. Also RBCs are 
anuclear and required in substantially larger volumes where as in reproductive 
medicine the volumes and number of gametes and embryos is minute by 
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comparison.237 One of the first successful cryopreservation strategies of any 
biological tissue was demonstrated by Polge et al. in 1949 who were able to 
cryopreserve (frog and fowl) spermatozoa using a high concentration of the 
vitrifying organic solvent glycerol and attained a statistically significant amount of 
functional spermatozoa upon revival but were unable to produce any viable 
offspring.238 Since then a variety of techniques that principally utilize glycerol but 
also DMSO239 and raffinose240 as cryoprotectants have been applied to a range 
of spermatozoa, oocytes and embryos and revolutionized selective breeding 
capabilities and improved assisted reproduction (artificial insemination) especially 
with cattle with the first successfully conceived calf occurring in 1951 and is in the 
present, commonplace.241 The application of such protocols soon drew notable 
success with human spermatozoa despite morphological and size dissimilarities 
as well as differences in membrane composition.242 The storage of spermatozoa 
is also of increasing importance in the conservation of mammalian species but 
significant optimization is often required in order to attain the highest yields.243 
The cryopreservation of certain species such as members of the rodent, 
marsupial and porcine families still remains difficult not only in their ability to 
successfully undergo cryopreservation but also in their sensitivities to the 
concentrations of glycerol required for successful cryopreservation.244 However 
unlike any other biological materials the (acceptable) survival rate of motile and 
viable spermatozoa is typically only between 50 % - 60 % at best, which is clearly 
unacceptable for most other cell types but still of practical use.245,246 This is in part 
due to the high osmosensitivity of spermatozoa.247,248 Few studies have 
investigated the application of AFPs and AF(G)Ps to aid the cryopreservation of 
spermatozoa. In particular the work of Payne, et al. reported that both AFP I and 
AF(G)Ps 1-8 decreased the motility of ram spermatozoa prior to freezing 
indicative of a cytotoxic effect even at a concentrations of 0.1 µg/mL that offset 
their beneficial effects during thawing except with the use of AFP I at the highest 
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concentration tested, 10 µg/mL.249 However in contrast to this Koshimoto et al. 
showed that whilst ice recrystallization is a detrimental consequence of slow 
thawing and lowered the recovery of mouse spermatozoa the addition AFP I, 
AFP III or AF(G)P at concentrations up to 100 µg/mL did not induce cytotoxicity. 
However the impact of each of these as additives during the cryopreservation 
process was highly disadvantageous with each additive, with each increase in 
concentration tested lowering recovery progressively in comparison to the 
complete absence of AFP I, AFP III or AF(G)P. Reductions in recovery were 
hypothesized to be as a result of DIS.250 A similar effect had been reported 
elsewhere with chimpanzee spermatozoa using AFP III.251 A comparable 
experiment again investigating AFP I, AFP III and AF(G)P but using bull 
spermatozoa by Prathalingam et al. in contrast showed a mild benefit by the 
addition of either cryoprotectants irrespective of the concentration used (0.1 
µg/mL – 100 µg/mL).252 A positive effect upon AFP I and AFP III addition was 
also reported by Beirão et al. albeit with fish spermatozoa that are substantially 
different to their mammalian counterparts.253 
 
The cryopreservation of unfertilized mammalian oocytes is a unique problem as 
oocytes are large cells often stored individually with a low membrane 
permeability to water and thus this increases the probability of intracellular ice 
formation (due to greater water retention) and ice crystal growth during thawing 
both of which are highly destructive processes.254 Though live births from 
cryopreserved oocytes were reported over 35 years ago in mice255 and then 
following on from rabbits256, cows257, horses258 and even humans,259 though 
success rates still remain very low with between 1 % and 5 % of cryopreserved 
human oocytes resulting in a live birth.260,261 Two different approaches have been 
used to prolong the storage of human oocytes (neither of which contain additives 
with IRI activity). A slow freezing strategy (2 °C/min) that uses a high 
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concentration of propan-1,2-diol (membrane permeable) and sucrose (membrane 
impermeable) with a 10 minute pause at -7 °C to ensure ice nucleation before 
cooling down to a temperature greater than -150 °C. A rapid thawing strategy is 
then used when required with the controlled and gradual removal of both propan-
1,2-diol and sucrose subsequent.262 The second technique uses a combination of 
DMSO and PEG to achieve a vitrification state by rapid cooling, though the high 
concentration of DMSO means that significant exposure to DMSO at 
physiological temperatures (37 °C) can lower fertilization rates.263,264  
 
A study by O’Neil et al. that undertook human oocyte cryopreservation with and 
without the addition of 1 mg/mL AF(G)P showed that the addition of AF(G)P at 
room temperature as opposed to 4 °C reduced fertilization rates compared to the 
absence of AF(G)P. However when AF(G)P was added at 4 °C an improvement 
in recovery and the resulting downstream measures (fertilization and blastocyst 
formation) was attained.265 An earlier study by Arav et al. agrees with the benefits 
(though with swine as opposed to human oocytes) of AFP I, AFP II, AFP III and 
AF(G)P addition (at a high concentration of 20 mg/mL) by assessing morphology 
post freezing but did not investigate whether or not these oocytes were then able 
to undergo fertilization successfully.266 A recent article by Jo et al. also showed 
that the addition of 0.5 µg/mL AFP III also led to an improvement in the post thaw 
survival and development of mouse oocytes.267 
 
The final area of reproductive medicine to consider is the cryopreservation of 
fertilized (pre-implantation) embryos with discrepancies in the preferred 
cryopreservation method depending upon the stage of blastocyst development at 
which cryopreservation is performed. Again two approaches similar to those 
undertaken with oocyte cryopreservation focusing on either slow cooling or 
vitrification are the standard methodologies utilized. A slow cooling strategy with 
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an early stage embryo (8-cell maximum) uses propan-1,2-diol and sucrose as 
before as the CPAs preferred.268 Embryos isolated at a later stage of 
development however, utilize glycerol instead of propan-1,2-diol. However the 
first successful cryopreservation of (mouse) embryos was attained using a slow 
thawing strategy but with DMSO as the CPA of choice and resulted in the 
production of a significant proportion of viable offspring.269 DMSO based 
cryopreservation has been replicated in several other species since including 
humans aided by concurrent improvements in in vitro manipulation.270 Vitrification 
approaches using several different additives at high concentrations have also 
been successfully implemented.271,272 A few studies have investigated the use of 
AFPs in improving the viabilities of cryopreserved embryos. An example of which 
is an article by Baguisi et al. who investigated the addition of AFP I or AFP III to 
ovine embryos and showed no significant impact on recovery or pregnancy rates 
when these were stored hypothermically (i.e. no ice formation) over a period of 4 
days.273 Robles et al. showed that AFP I had a similar benefit improving the 
storage of fish embryos, though these have an inherently different developmental 
biology.274 Overall however few reports have investigated the use of AFPs and 
AF(G)Ps as cryoprotective agents presumably due to the lack of readily available 
materials and the ethical concerns arising from such experiments. 
 
1.5.3. Transplantation medicine. 
 
Transplantation medicine is the final area in which cryobiology continues to have 
a positive impact but is vastly different in comparison to haematology and 
reproductive medicine. Firstly the diversity of cell biologies within the umbrella of 
transplantation medicine means that no one strategy or solution will likely be 
applicable. A successful strategy will in part depend on whether or not the 
transplanted material is simply a single cell type, a tissue containing a few cell 
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varieties or an entire organ with increasing complexities understandably 
applicable with each, in terms of volume, structure and biology. Especially as the 
procurement of such materials is often non-ideal.275,276 Furthermore transplanted 
material often has to retain a proliferative capacity in order to have a long-term 
clinical benefit (where as RBCs do not). Overall however as the demand for 
transplantable material is increasing year on year especially with the 
development of new transplant procedures that further diversify the types of cells 
and tissues that require transit and storage ex vivo in addition to an aging 
populace the importance of minimizing wastage is pivotal.277,278 
 
The storage of hepatocytes that constitute the primary cell type within the liver is 
one most pressing concerns at present with over 100,000 liver transplants 
successfully conducted between 2009-2012 in the USA and over 16,500 on 
current waiting lists according to the organ procurement and transplantation 
network.279 Understanding the idealized cryopreservation technique for 
hepatocytes and other hepatic cell types would no doubt translate to clinical 
benefits and hasten post-operative recovery.280 Furthermore the use of 
hepatocytes from more readily available (non-human) sources has great 
importance in the field of pharmacokinetics and pharmacodynamics in assessing 
novel xenobiotics and in quantifying potential drug-drug interactions.281,282 Current 
long-term storage strategies are reliant on the cryopreservation of fresh 
hepatocytes as opposed to hypothermic strategies which are only effective in the 
short term.283,284 The cryopreservation medium of choice for hepatocytes for 
transplantation is often University of Wisconsin (UW) solution (an isotonic 
solution principally consisting of lactobionate and raffinose as osmotic stabilizers 
and dexamethasone as a membrane stabilizer) supplemented with between 10 
% (v/v) and 20.5 % (v/v) DMSO depending on the specific cooling rates and cell 
densities used285-287 and is usually undertaken as soon as possible after 
isolation.288 Critically all cryopreservation medium has to be devoid of animal 
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material in order to minimize the risk of zoonosis (animal to human disease 
transfer) and immunogenicity issues such as fetal calf serum that is 
commonplace in in vitro cell culture preparations. Hepatocytes are then 
cryopreserved slowly (1 °C/min – 2 °C/min) as opposed to rapid freezing 
(vitrification) to minimize osmotic shock and the probability of intracellular ice 
formation. The final storage temperature has also been shown to be of 
importance with the optimal temperature being -150 °C or lower with a reduction 
in viability with prolonged storage at temperatures greater than this.289 The 
thawing of hepatocytes is undertaken rapidly (37 °C, water) in order to minimize 
the damaging effects of ice recrystallization.290 However once thawed 
hepatocytes are then cooled back to 4 °C to lessen the cytotoxic impact of DMSO 
observed at 37 °C, with the removal of DMSO of critical importance to avoid the 
adverse effects of DMSO infusion to patients. Despite DMSO removal at the low 
temperature of 4 °C, the maintenance of hepatic function after cryopreservation 
remains a challenging problem.291,292 Several studies have investigated the use of 
several additives in improving the cryopreservation process. Rubinsky et al. 
showed that the supplementation of 1 mg/mL AF(G)P (predominately AF(G)P8) 
to a glycerol (as opposed to DMSO) based cryopreservative mixture had a 
benefit on whole rat liver cryopreservation (2 °C/min) albeit preparations were 
only cooled down to a maximum of -3 °C  for 6 hours though this was still 
sufficient time for prolific ice formation.293 Miyamoto et al. investigated the use of 
a range of oligosaccharides which have mild IRI activity162 with benefits shown in 
a concentration dependant manner with both rat and human hepatocytes in terms 
of viability and attachment rate ,which is of importance in plating in vitro and in 
the adherence to the hepatic sinusoidal endothelium after engraftment in vivo.294 
However these improvements were not attributed to a reduction in ice 
recrystallization.295 Finally Soltys et al. showed that a combination of 2,3-
butandiol (serving as a mimic for DMSO) and AFP I had little impact on the 
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cryopreservation of hepatocytes or sinusoidal (another cell type within the liver) 
cells.296  
 
Another primary cell type that has importance in the field of transplantation are 
islet cells, especially given the rate at which the incidence of type II diabetes 
(diabetes mellitus) is increasing in the developed world. The demand for islet 
cells for transplantation is therefore likely to see substantial increases 
alongside.297,298  Islet transplantation has been shown to eliminate dependence 
on insulin supplementation in type I diabetic patients in a landmark study by 
Shapiro et al. and thus is a real therapeutic possibility if sufficient material is 
available299 and has been replicated in other transplant centers since.300 Cell 
lines derived from pancreatic islets are also gaining more prominence as models 
for diabetic activity and metabolic homeostasis.301 Current strategies to islet 
cryopreservation follow a similar methodology to that used with hepatocytes in 
the application of a slow cooling rate, with cells supplemented with high 
concentrations of DMSO (investigations using HES have also been described).302 
When required cells are thawed rapidly prior to the removal of DMSO.303,304 
Various other (faster) freezing rates have been investigated but a slow freezing 
rate predominates in current protocols.305 A vitrification approach has additionally 
been reviewed but acknowledges that further progress is required if this is to 
compete with established methodologies.306 The use of IRI additives to improve 
the cryopreservation of islet cells has been documented by Matsumato et al. who 
demonstrated the effect of a synthetic AF(G)P analogue152 on RBC and islet 
cryopreservation. The effect on RBCs was of a similar beneficial value to those 
seen elsewhere with native AFP I, AFP II and AFP III.88,236 The synthetic AF(G)P 
analogue showed an initial benefit in terms of cell recovery, which was then lost 
at higher concentrations due to DIS. This effect also occurred when applied to 
the cryopreservation of islet cells using standard procedures, supplemented with 
0.5 mg/mL of the AF(G)P analogue providing beneficial effects but at a higher 
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concentration of 1 mg/mL this benefit was negated due to DIS.307 Another area of 
interest in this regard includes the cryopreservation of cardiac tissue and 
cardiomyocytes308 that again uses similar protocols to islets and hepatocytes for 
use in transplantation.309 However the addition of AF(G)P at 0.5 mg/mL in this 
instance proved to be detrimental and lowered significantly, cardiac output89 
which was attributed again to the effects of DIS.310  
 
Stem cells whether it be haematopoietic, mesenchymal or embryonic stem cells 
have a great potential to revolutionize medicine in the 21st century, particularly in 
the field of regenerative medicine.311-313 The cryopreservation of stem cells 
therefore is of exceptional interest. Current cryopreservation strategies tend to 
focus on the use of DMSO as aforementioned.314-317 However strategies that aim 
to reduce the current reliance upon DMSO have been developed, with the use of 
other CPAs such as trehalose, sucrose and HES substituting for a substantial 
part of the DMSO content used in traditional methodologies.318,319 Plus the use of 
vitrifying strategies enabling DMSO free preparations to be successfully 
cryopreserved.320 No strategies have been reported however that focuses on 
enhancing the cryopreservation of stem cells by attenuating ice recrystallization. 
The cryopreservation of scarcely available and poorly understood biomaterials 
could be argued as one of the key challenges in advancing transplantation, 
therefore even minute benefits many translate into substantial clinical gains.  
 
1.5.4. Pharmaceuticals and biotechnology.  
 
A final area of interest to briefly touch upon is the storage of pharmaceuticals and 
other biological preparations, the preservation of proteins, drugs, vaccines and 
genetic constructs such as plasmids in addition to numerous microorganisms 
(viruses, bacteria, protozoa, fungi and algae). The relative instability at 
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physiological temperatures of these often warrants the need for 
cryopreservation321 or lyophilisation322 strategies, to limit their degradation or 
unwarranted proliferation. Of particularly importance is the storage of transgenic 
(protein) products for therapeutic use or proteins that having been extensively 
mutated for structural studies and thus may have a less stable tertiary structure. 
The continuous propagation of microorganisms is also undesirable especially 
those that may be pathogenic or highly virulent. However these processes must 
be carefully undertaken, as the removal of water by ice crystallization or 
sublimination will produce high but localized salt concentrations (originating from 
the buffers required at physiological temperatures) or create pH shifts, which can 
cause denaturation or aggregation in proteins that cannot be reversed upon 
reconstitution. Such issues are especially apparent with membrane bound 
proteins. Numerous excipients have been shown to improve the storage of 
proteins over the long term including sugars (e.g. trehalose), polyols (e.g. 
glycerol), polymers (e.g. PVP), amino acids, organic salts and inorganic 
salts.323,324 As with most other storage strategies, the concentration and storage 
temperatures of the preparations is influential on the relative recovery rates.325  
 
One of the most commonly utilized protectants for protein (enzyme) storage is 
the osmolyte, trehalose (Figure 1.3.C) that has no reactivity with proteins but has 
advantageous effects on protein stabilization allowing suitable catalytic activity 
upon reconstitution and has been demonstrated with a variety of proteins.326-328 
Other studies have shown the effectiveness of a trehalose glycopolymer 
conjugation in the aiding lyophilisation.329,330 However there are no reports of the 
use of AFPs or AF(G)Ps in aiding the cryopreservation or lyophilisation of protein 
preparations presumably due to the difficulties in separating such mixtures. The 
cryopreservation of microorganisms and genetic constructs however tends to rely 
upon the use of high concentrations of glycerol or DMSO principally though a 
range of penetrating and non-penetrating CPAs have been used depending upon 
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the organism or preparation of interest.205,321 Lyophilisation strategies have also 
been successfully implemented.331,332 The use of AFPs and AF(G)Ps in this 
capacity is limited but an interesting study that may be of use elsewhere was 
conducted by McKown et al. who successfully incorporated an AFP I gene 
(Psudeopluronectes americus) into yeast that then displayed improved survival 
rates subsequent to cryopreservation due to AFP expression.333 Overall there 
has been little progress on improving the cryopreservation or lyophilisation 
protocols currently used within the pharmaceutical sciences and in molecular 
biology. The use of more elaborate molecular biology tools and an increasing 
shift away from small molecule xenobiotics towards therapeutic biologics 
emphasizes the importance of understanding the interactions of ice with AFPs 
and AF(G)Ps. This will become more important with time and is an area that 
requires extensive monitoring in the future. 
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CHAPTER 2.  
 
2. ICE RECRYSTALLIZATION INHIBITION 
ACTIVITIES OF CARBOHYRATES, SMALL 
MOLECULES AND POLYMERS. 
 
2.1. CHAPTER SUMMARY.  
 
The importance of identifying novel IRI compounds as potential cryopreservatives 
has been extensively iterated (Chapter 1). The IRI activity of a range of 
monosaccharides, disaccharides, oligosaccharides, low molecular weight (MW) 
polyols and natural and synthetic polymers was assessed with poly(vinyl alcohol) 
(PVA) having potent IRI activity. All of the compounds examined except PVA 
displayed a comparable decrease in the mean largest grain size (MLGS) of ice 
with increasing [OH]\L with no observable multivalent effect. PVA had an 
anomalously high IRI activity attributed to a hydrophobic and surfactant 
character, though few hydrophobic molecules and surfactants have IRI activity. 
Furthermore the impact of freezing rates on ice crystal growth and the 
concentration of the cryoprotectant DMSO on ice crystal formation was assessed 
by cryomicroscopy. A slower freezing rate enabled greater ice crystal growth and 
significant amounts of DMSO incited vitrification under conditions that mimic 
rapid cryopreservation protocols. Differential scanning calorimetry (DSC) further 
supported this and emphasized the minimal impact of PVA at concentrations with 
IRI activity. This work forms the basis of the publication. Deller, R. et al. Ice 
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recrystallization inhibition by polyols: comparison of molecular and 
macromolecular inhibitors and role of hydrophobic units. Biomater Sci 1, 478–485 
(2013). 
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2.2. INTRODUCTION. 
 
Nature has continually battled to limit the detrimental effects of ice across the 
natural world, developing a variety of mechanisms to combat both its presence 
and growth allowing a diverse number of organisms to inhabit every landscape 
and ocean on earth.1 The life science revolution over the last century has led to 
the notion of cryopreservation, the low temperature storage of clinically relevant 
cells, tissues and organs leading to advances in transfusion and transplantation 
science.2 The importance of cryopreservation is escalating alongside the ever-
increasing rates of transplantation caused by an aging population and in parallel 
the continuing advances in the emerging field of regenerative medicine.3-6 
However despite recent advances many unanswered questions remain about the 
properties and interactions of ice especially within biological systems.7 One of the 
main exceptions is that it is well documented that the presence and growth of ice 
in biological systems is highly destructive and to be avoided where possible.8,9 
Few strategies are available at present for manipulating the presence and growth 
of ice, fewer still in a clinical context.10 The evolution of antifreeze proteins 
(AFPs) and antifreeze (glyco)proteins (AF(G)Ps) has since their discovery over 
40 years ago in the circulatory systems of arctic and antarctic fish species proven 
to be one of the principal molecular mechanisms by which organisms can thrive 
in sub-zero environments.11,12 However the isolation of AFPs and AF(G)Ps from 
primary sources has proven difficult on a large and financially viable scale 
(Chapter 1).13 The synthesis of AFPs and AF(G)Ps using both recombinant and 
synthetic strategies is another challenging limitation that does not need 
reiterating here.14 
 
Soon after their discovery it was hypothesized that AFPs and AF(G)Ps could 
have clinical application as cryoprotectants for isolated cells, tissues and organs 
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both in vitro and ex vivo.15 The rationale for hypothesizing that AFPs and 
AF(G)Ps could be applied as cryopreservatives can be put into perspective by 
considering their ice interacting properties, which are three-fold. The first property 
is ice recrystallization inhibition (IRI) that is the kinetic inhibition (slowing) of ice 
crystal growth. AF(G)Ps  and AFPs successfully arrest ice crystal growth such 
that almost no appreciable increase in ice crystal size occurs.16,17 Ice crystal 
growth is a result of a form of ostwald ripening that aims to limit the total surface 
energy and therefore large ice crystals will grow at the expense of small ones via 
the transfer of water molecules in the liquid phase of adjacent and interfacing ice 
crystals.18,19 The inhibition of H2O transfer is believed to be due to the interaction 
or binding of AF(G)Ps and AFPs along a particular plane of the ice crystal 
lattice.20 The second property is dynamic ice shaping (DIS). As AF(G)Ps 
preferentially bind a single (prism) plane of the developing ice crystal lattice any 
ice crystal growth (albeit significantly reduced) will occur only in the opposing 
unbound (basal) plane. As such the adsorption-inhibition mechanism will incite 
explosive ice crystal growth in the single unbounded plane changing the overall 
morphology dramatically. In the extreme DIS can generate “needle like” 
hexagonal bipyramidal ice crystal structures.21 The final property is thermal 
hysteresis (TH). TH is whereby the freezing point of a solution decreases to an 
extent greater than colligative effects alone without any corresponding change in 
melting point, creating a thermal hysteresis gap between these two temperatures. 
Thus ice crystals held isothermally within this thermal hysteresis gap will neither 
shrink nor grow as they are neither freezing or melting.22 The intensity of each 
property is highly influenced by concentration. The mechanisms behind all these 
observed behaviours is not fully understood but growing evidence is supporting 
the importance of the quasi-liquid layer (QLL) and how AF(G)Ps modulate the 
interactions of ice with the surrounding bulk water.23 Understanding these 
properties in more depth may allow the development of molecules that 
manipulate or separate these properties and improve current cryopreservation 
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techniques24 or from an engineering perspective prevent ice accumulation that 
can result in structural failures.25-28 
 
The aforementioned limitations in accumulating native AFPs and AF(G)Ps 
however has lead to extensive investigations using simpler structural mimics that 
are synthetically more accessible.29 Figure 2.1. highlights some key modifications 
undertaken in order to replicate native AF(G)P behaviour but additionally improve 
and simplify synthesis as well as addressing some of the negative concerns 
regarding the use of non-native proteins such as biochemical stability and 
immunogenicity.30 However in many cases the beneficial ice recrystallization 
inhibition (IRI) property of AF(G)Ps has been negatively affected but successfully 
separated from TH and DIS activities.14,31-38  
 
Modifications include the use of short chain AF(G)P (principally AF(G)P8) mimics 
as AF(G)Ps have been identified with a range of chain lengths from between 4 
(2.6 kDa) and 55 (33 kDa) tripeptide (AAT) repeat units and classified according 
to their MW into 8 distinct groups with AF(G)P1 containing the largest and 
AF(G)P8 the smallest.16 However the efficiency of even the current state of the 
art SPPS39,40 techniques limits the production of polypeptides to approximately 70 
residues (e.g. even with 99% efficiency for each coupling step the final yield of a 
70 residue polypeptide would be lower than 50%) restricting overall length. The 
susceptibility of the glycosidic bond to hydrolysis also limits downstream 
modifications.  
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Figure 2.1. Strategies for the rationale design of AF(G)P mimics. (A) Native 
AF(G)P structure with targeted alterations in composition and structure 
undertaken in many studies aiming to reduced synthetic complexity and improve 
scalability whilst retaining or improving control over IRI, DIS and TH activity with 
examples from literature showing a (B) monosaccharide substitution, (C) 
carbonyl linkage and (D) linkage extension. 
 
A second obvious area of interest that has been readily exploited is the 
substitution of the relatively complex β-D-galactosyl(1→3)-α-N-acetyl-D-
galactosamine disaccharide moiety to a simpler and more accessible 
(mono)saccharide moiety. For example Liu et al. developed a set of (C-linked 
and serine substituted) analogues of AF(G)P8 with glucose, mannose and talose 
carbohydrate moieties but these had poor IRI activity.36 A (C-linked and serine 
substituted) AF(G)P8 analogue with galactose though had a reasonably strong 
concentration dependant IRI activity and was tolerated by WRL-68 cells (in vitro) 
at a concentration of 5 mg/mL even after a period of 20 hours36,41. The work of 
Peltier et al. illustrated the differences between an AF(G)P8 analogue containing 
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either a glucose or N-acetyl-galactosamine monosaccharide moiety. They 
revealed a lack of DIS activity with the glucose moiety but a profound effect 
remained with the N-acetyl-galactosamine moiety, though the resulting ice crystal 
morphology was different to that induced by native AF(G)P8.42 Finally the work of 
Matsumoto et al. that utilized a N-acetyl-galactosamine monosaccharide moiety 
on larger (32 to 48 residues) peptide backbone was able to improve the recovery 
of red blood cells (RBCs) and islet cells was attributed to its IRI activity.43 
Therefore even subtle changes in glycosylation can have large and detrimental 
effects on IRI, DIS and TH activity but retain antifreeze activity that translates into 
a beneficial cryopreservative effect. Understanding and rationalizing what 
differences these saccharide moieties have is an important task as well as their 
activities independent of the peptide backbone as stand alone entities.  
 
Alterations to the peptide backbone-saccharide conjugation principally carbonyl 
(C-linked) ligations using serine as opposed to threonine as aforementioned have 
been undertaken for synthetic ease.33,38 The synthesis of thio (S-linked) 
glycopeptides is also possible but it is understood that thio linkages have not yet 
been incorporated into AF(G)P analogues.44 Synthetic modifications have 
produced mimics that may be more biochemically stable compared to the native 
O-linked glycosylated AF(G)Ps that are more susceptible to degradation by 
naturally occurring protein degradation pathways.45 An extension of which is the 
introduction of spacers altering the distance and flexibility of the saccharide 
moiety from the peptide backbone and its consequential effect on IRI activity. The 
early work of Liu and Ben showed that increasing the distance between the 
peptide backbone and a (non-native) monosaccharide moiety resulted in a 
dramatic reduction in IRI activity rationalizing the need to maintain a distance 
between these features comparable to native AF(G)Ps.32 Finally subtle changes 
in the composition of the peptide backbone have been identified and isolated in 
some naturally occurring AF(G)P family members. The most significant of which 
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is the substitution of alanine for proline46 and threonine for arginine47 in low MW 
AF(G)Ps with the widely investigated AF(G)P8 a notable example.48 
 
None of these AF(G)P derivatives have IRI activity that is truly comparable to 
native AF(G)P, though some do lack any detectable TH activity successfully 
separating these properties. The removal of DIS activity (linked to TH) is 
particularly desirable as this has been shown to be detrimental in 
cryopreservation.49,50 A range of synthetic polymers that loosely resemble 
AF(G)P structure have been evaluated and several studies have identified that 
the simple, scalable and biocompatible polymer, poly(vinyl alcohol) (PVA) has a 
potent IRI activity.51,52 It has been shown that the activity of PVA is strongly 
affected by the degree of hydrolysis, with stepwise reductions in hydrolysis by 
controlled acetylation lowering IRI activity. With hydrolysis less than 80% having 
adverse effects on IRI potency. Chain length has also been shown to be 
important with a higher chain length corresponding with a stronger IRI activity, 
though improvements in IRI activity are offset by a reduction in aqueous solubility 
lowering the final obtainable concentration.53 Efforts at improving the 
understanding of AF(G)Ps and ice as well as the investigation of small non-
peptide molecules as IRI active molecules is therefore key and an ongoing aim 
going forward. The work of Tam et al. first investigated a small selection of 
carbohydrates (monosaccharides and disaccharides) as IRI active compounds in 
an attempt to define how subtle differences in structure that affect hydration 
number may relate to their potential as IRI active compounds.54 Hydration 
number is defined as the number of H2O molecules strongly associated to each 
carbohydrate molecule and differences in hydration number have been 
postulated to be as a consequence of differences in carbohydrate 
stereochemistry.55,56 The hydration number of many monosaccharides, their 
respective methyl derivatives and disaccharides have been defined accurately in 
literature.57 Several other descriptors including the anomeric effect, hydrophobic 
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index and hydrophilic volume amongst others are also important in resolving how 
carbohydrate structure can affect H2O interactions and together characterize the 
hydration layer.58,59 The hydration layer is the region of H2O molecules affected 
by the presence and interaction of a molecule in an aqueous system.60 Therefore 
extending the preliminary findings of Tam et al. and investigating how a diverse 
variety of carbohydrates and low MW polyols affect IRI activity was undertaken 
as several studies have already highlighted the importance of the interaction 
between ice and bulk water via the quasi liquid layer (QLL).61,62 How 
carbohydrates modulate this process may allow the rationale design or 
identification of potent IRI active molecules.	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2.3. RESULTS AND DISCUSSION. 	  
2.3.1. IRI activity of monosaccharides, disaccharides and 
oligosaccharides. 
 
The standard method to determine IRI activity was proposed by Knight et al. who 
developed the “splat” test (Section 2.5.3.).63 In brief the splat test involves the 
release of a small (10 µL) droplet from approximately 2 m on to a pre-cooled 
aluminum plate (> -50 °C) causing an instantaneous phase change resulting in 
the formation of a single layer of ice crystals as a result of this impact. The 
consequent annealing of this layer at -6 °C (other studies have used annealing 
temperatures as low as -8 °C) promotes ice crystal growth. The rate of ice crystal 
growth is therefore in turn determined by the composition and IRI activity of the 
sample. Annealing for a period of 30 minutes allows for accurate and quantifiable 
differences to be measured. The mean largest grain size (MLGS) is the value 
commonly reported, which is the mean value of the largest single dimension of 
the ten largest ice crystals across a reasonably sized viewing field (1.33 mm2). 
This value is usually then expressed as a percentage of a non-IRI active 
(isotonic) control such as PBS. It is necessary to emphasize that the volume of 
each inhibited ice crystal would be significantly lower (as a % value). The splat 
assay can therefore be used to accurately measure IRI activity and provide an 
initial screen for identifying novel cryopreservatives as IRI activity as been 
implicated as being a mechanism that may reduce cryodamage during freezing 
and thawing processes (Chapter 1). To begin with a range of naturally occurring 
monosaccharides (including aldopentoses and aldohexoses) and a methyl-β-D-
galactopyranoside derivative (Figure 2.2.) were assessed for IRI activity over an 
extensive concentration range (Figure 2.3.).  
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Figure 2.2. Structures of various monosaccharides investigated for IRI 
activity. (A) Aldopentoses, (B) Aldohexoses and (C) Other monosaccharides. 
 
The immediate benefits of using monosaccharides are that they are readily 
available from a variety of natural sources, biocompatible and highly soluble in 
aqueous solutions. Deliberately high concentrations (up to 50 mg/mL) of 
monosaccharides were eventually used in order to help emphasize and resolve 
their weak IRI activity. However high concentrations can lead to a significant 
colligative freezing point depression which should not be ignored when high 
concentrations of cryopreservatives are used.64 Estimations of freezing point 
depression can be easily calculated for concentrations that constitute a near ideal 
solution.65 For example the composition of PBS (Section 2.5.1.) leads to a 
colligative freezing point depression approximating 0.58 ºC and a 50 mg/mL 
solution of glucose in PBS (the highest concentration tested) tends to a freezing 
point depression of 1.1 ºC. Carbohydrates (unlike AF(G)Ps) have no reported 
non-colligative effects on freezing point depression (TH activity), which is 
important given the perceived benefits of separating IRI from DIS and TH. Even 
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though the solubility of glucose and other monosaccharides permits solutions as 
high as 400 mg/mL this would cause a drastic lowering of the freezing point (≈-
4.74 ºC) that would affect the rate of ice crystal growth regardless of any IRI 
activity. Furthermore the precipitation upon cooling/freezing would tend to non-
representative and erroneous IRI results. In addition to this, these high 
concentrations of solute would reduce the molar fraction of H2O and possibly 
cause vitrification as opposed to ice crystal formation, given the high rate of 
cooling samples are subjected to during the “splat” assay. 
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Figure 2.3. IRI activity of (11) monosaccharides. IRI activity of 
monosaccharides listed in Figure 2.2. Each measurement represents the MLGS 
(%) of 10 crystals with error bars representing ± standard deviation; (A) MLGS 
(%) vs. Concentration (mg/mL); (B) MLGS (%) vs. Concentration (mmol); (C) 
MLGS (%) vs. Concentration (wt %); (D) MLGS (%) vs. Concentration ([OH]/L). 
Error bars represent ± standard deviation. 
 
In order to best resolve any differences between each molecule, the IRI data set 
is displayed in terms of MLGS (%) against concentration in mg/mL (Figure 2.3.A), 
mmol (Figure 2.3.B), wt % (Figure 2.3.C) and [OH]\L (Figure 2.3.D). Figure 2.3. 
shows that no monosaccharide possessed a high level of IRI activity over this 
concentration range (Figure 2.27.). A weak correlation can be seen in each 
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representation with the MLGS (%) decreasing (i.e. increasing IRI activity) with 
rising monosaccharide concentration. The highest concentration tested with the 
greatest but still only moderate IRI activity would induce significant changes in 
osmolarity. This could be detrimental to many biological tissues for example 
spermatozoa66,67 and RBCs.68 Therefore the use of disaccharides that in general 
retain reasonable solubility and biocompatibility whilst reducing changes in 
osmotic pressure when compared on a mass basis were assessed for IRI activity 
(Figure 2.4. and Figure 2.5.). As with the assessment of monosaccharides a 
diverse range of subtle structural differences that give a varied hydration number 
were investigated (Figure 2.27.). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.4. Structures of various disaccharides investigated for IRI activity. 
(Clockwise from top left); Cellobiose (Glucose β(1→4) Glucose), Lactose 
(Galactose β(1→4) Glucose), Maltose (Glucose α(1→4) Glucose), Melibiose 
(Galactose α(1→6) Glucose), Turanose (Glucose α(1→3) Fructose), Trehalose 
(Glucose α(1→1) Glucose) and Sucrose (Glucose β(1→2) Fructose).  
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Figure 2.5. IRI activity of (7) disaccharides. IRI activity of disaccharides listed 
in Figure 2.4. Each measurement represents the MLGS (%) of 10 crystals with 
error bars representing ± standard deviation; (A) MLGS (%) vs. Concentration 
(mg/mL); (B) MLGS (%) vs. Concentration (mmol); (C) MLGS (%) vs. 
Concentration (wt %); (D) MLGS (%) vs. Concentration ([OH]/L). Error bars 
represent ± standard deviation. 
 
The range of disaccharides tested shows a similar level of IRI activity to 
monosaccharides when compared on a mass basis (mg/mL) that again increases 
weakly with increasing concentration (Figures 2.3.A and 2.5.A). However to 
further refine any differences between any of the individual disaccharides it is 
possible to relate the MLGS (%) of each disaccharide to its hydration number and 
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hydration index. Hydration number is defined as the number of H2O molecules 
strongly associated with a single carbohydrate molecule (Figure 2.6.) and 
hydration index as the hydration number divided by the partial molar volume 
(Figure 2.7.) as defined and previously investigated by Tam et al.54,57 The 
concentration at which MLGS (%) was measured was deliberately chosen as 50 
mg/mL in order to maximise any potential differences in IRI activity and minimise 
the influence of the inherent variability associated with IRI measurements.63 
Incidentally as each disaccharide tested was of equal MW and possessed the 
same number of hydroxyl functional groups (8) both the molar (mmol) and 
hydroxyl ([OH]\L) concentrations were consistent at 146 mmol and 1.17 [OH]\L. 
The range of monosaccharides tested display significant discrepancies (due to 
their differing MWs) with respect to these values and thus has not been 
compared in this regard here. The findings of Tam et al. highlighted a good 
correlation between hydration number (Adj-R2 = 0.758) and hydration index (Adj-
R2 = 0.791) with MLGS (%).54 In contrast to this as shown in Figures 2.6. and 2.7. 
that use a greater number of disaccharides (7 as opposed to 4) a weaker 
correlation is derived (Adj-R2 = 0.441 (hydration number) and Adj-R2 = 0.287 
(hydration index)) that essentially shows a non linear relationship. Improvements 
to defining more accurate MLGS (%) values may help69 but critically a larger data 
set would be required in order to confidently define any correlation and generate 
a model to predict the MLGS (%) of a carbohydrate from its respective hydration 
index (that accounts for differences in the number of saccharide units). This 
would still only be for a single (and high) concentration that at best would likely 
have only moderate IRI activity given the observations recorded to date. 
Furthermore observations with this albeit rather limited data set do not reflect the 
advantages of using the hydration index as opposed to hydration number as a 
more accurate predictor of IRI activity that the authors ascribe to (i.e. the strength 
and significance of the correlation). The main benefit of the hydration index is the 
ability to normalise the relative unit number of monosaccharides and 
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disaccharides (plus other oligosaccharides) by dividing through with the partial 
molar volume giving a more extensive data set and compares different 
compounds on a molar as opposed to mass basis. 
 
 
 
 
 
 
 
 
Figure 2.6. IRI activity of (7) disaccharides against hydration number. Using 
a concentration 50 mg/mL (146 mmol/1.17 [OH]\L) comparing (A) MLGS (%) 
against hydration number and (B) table illustrating hydration number values and 
MLGS (%) for each disaccharide assessed. 
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Figure 2.7. IRI activity of (7) disaccharides against hydration index. Using a 
concentration 50 mg/mL (146 mmol/1.17 [OH]\L) comparing (A) MLGS (%) 
against hydration index and (B) table illustrating hydration index values and 
MLGS (%) for each disaccharide assessed. 
 
One final set of saccharides were assessed for IRI activity. A small collection (4) 
of oligosaccharides (Figure 2.8.) are illustrated under the same criteria as both 
the monosaccharides and disaccharides prior (Figure 2.2. and Figure 2.4.) and 
again (Figure 2.9.) follow a similar concentration dependant relationship (Figure 
2.28.).  
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Figure 2.8. Structures of various oligosaccharides investigated for IRI 
activity. (Clockwise from top left); Raffinose (Galactose α(1→4) Glucose β(1→2) 
Fructose), Maltotriose (Glucose α(1→4) Glucose α(1→4) Glucose), Stachyose 
(Galactose α(1→6) Galactose α(1→6) Glucose β(1→2) Fructose) and 
Maltoheptose (Glucose α(1→4) Glucose (6x)).  
 
To best highlight these similarities to other saccharides, each data set was 
combined into a single figure comparing MLGS (%) against concentration (mmol) 
(Figure 2.10.A) showing that on a molar basis that oligosaccharides outperform 
disaccharides that in turn outperform monosaccharides. However as these 
compounds all have a varied valency (i.e. number of hydroxyl groups) and there 
may be a beneficial multivalent effect in a similar manner to that observed with 
for example carbohydrate recognition proteins and thus a molar comparison may 
be unrepresentative and misleading.70,71 To probe the relative activity of each set 
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an alternative measure ([OH]\L) was used (Figure 2.10.B). Using the [OH]/L 
measure it can be concluded that no significant differences are apparent between 
monosaccharides, disaccharides and oligosaccharides. However the impact of 
[OH/L] is profoundly different when comparing the saccharide moieties and IRI 
activities of synthetic mimics. This means that the IRI activity of two maltotriose 
(Glucose α(1→4) Glucose α(1→4) Glucose) molecules is roughly equivalent to 
three maltose (Glucose α(1→4) Glucose) molecules or six glucose molecules. 
Simply increasing concentration does influence (albeit weak given the wide 
concentration range) IRI activity but with no benefits from multivalency. Therefore 
the use of oligosaccharides as IRI additives would be preferred in a biological 
context in terms of limiting changes in osmotic pressure and are less susceptible 
to metabolic degradation and is the main rationale for their inclusion in 
hypothermic storage solutions.72,73  
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Figure 2.9. IRI activity of (4) oligosaccharides. IRI activity of oligosaccharides 
listed in Figure 2.8. Each measurement represents the MLGS (%) of 10 crystals 
with error bars representing ± standard deviation; (A) MLGS (%) vs. 
Concentration (mg/mL); (B) MLGS (%) vs. Concentration (mmol); (C) MLGS (%) 
vs. Concentration (wt %); (D) MLGS (%) vs. Concentration ([OH]/L). Error bars 
represent ± standard deviation. 
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Figure 2.10. Comparative IRI activity of monosaccharides, disaccharides 
and oligosaccharides. (A) MLGS (%) vs. concentration (mmol) and (B) MLGS 
(%) vs. concentration ([OH]/L]). Each measurement represents the MLGS (%) of 
10 crystals with error bars representing ± standard deviation. 
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2.3.2. IRI activity of low MW polyols. 
 
Given the importance of hydration and the interactions that hydroxyl groups may 
have with ice and water a vast array of low MW polyols were investigated for IRI 
activity. Low MW polyols including an extensive range of aliphatic, nitro and 
benzyl compounds (Figure 2.11.). IRI activity was investigated to examine if any 
of these polyols had activity similar to saccharides of a comparable MW. The only 
stipulation being that they contain at least one hydroxyl group regardless of their 
cytotoxicity that would limit their application in vitro, ex vivo and in vivo as the 
main rationale is to attempt to identify and analyse structural motifs conducive to 
IRI activity. Several of the low MW molecules were deliberately chosen as such 
to analyse the impact (if any) of minor differences in their corresponding structure 
such as hydroxyl group positioning (nitro derivatives) and hydroxylation (ectoine 
and hydroxyectoine). These differences have profound effects on their 
physiochemical properties, such as solubility and phase transition temperatures. 
No significant differences in IRI activity could however be derived due to 
differences  in either hydroxyl group placement or extent of hydroxylation.  
 
Figure 2.12. shows a similar concentration dependant relationship to the 
saccharides examined previously (Figure 2.10.) and thus it can be concluded that 
a reduction in MLGS (%) can be initiated simply by increasing the concentrations 
of a polyol in an aqueous system as all the low MW polyols tested fit within the 
range of the previously tested saccharides on a [OH]\L basis (appendicized in full 
in Figure 2.28.). No notable differences were apparent between the aliphatic, 
benzyl and nitro derivatives and other polyols. However these conditions are 
unattractive due to the physiologically high concentrations required to have 
significant impact that may incite unwarranted changes in osmotic pressure and 
would have profound effects chemically and biochemically.  
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Figure 2.11. Structures of various small non-carbohydrate derived polyols 
investigated for IRI activity. (A) Aliphatic derivatives, (B) Nitro derivatives, (C) 
Benzyl derivatives and (D) Other Polyols. 
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Figure 2.12. IRI activity of (16) small molecule polyols. Each measurement 
represents the MLGS (%) of 10 crystals with error bars representing ± standard 
deviation; (A) MLGS (%) vs. Concentration (mg/mL); (B) MLGS (%) vs. 
Concentration (mmol); (C) MLGS (%) vs. Concentration (wt %); (D) MLGS (%) 
vs. Concentration ([OH]/L). Error bars represent ± standard deviation. 
 
Extreme changes in osmotic pressure would necessitate their careful addition 
and removal (assuming their moderate IRI activity translates into cryoprotection), 
which is further complicated by their varied membrane permeability to different 
cell types and other pharmacodynamic and pharmacokinetic properties. These 
are all undesirable qualities, as cryopreservation usually demands the immediate 
storage of biological tissues after isolation in order to maintain maximal viability 
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and clinical scenarios are often unpredictable and demand rapid availability and 
therefore cryopreserved samples would require swift or no post-thaw 
processing.24 Therefore alternative IRI active compounds would be desirable 
though as aforementioned simply isolating or synthesizing the compounds 
utilised by nature is not possible due to a myriad of reasons. The molecular 
mechanisms of cold acclimatisation regularly observed in biological systems are 
not typically small molecules but are predominantly macromolecules13,74. 
However a limited number of small molecules most notably glycerol and 
trehalose have been identified in the natural world to behave as desiccants in a 
few select freeze protective insect species as well as in a number of bacterium in 
response to low temperatures.75,76 Desiccation in this context aims to minimize 
water content and in cold acclimatised organisms limiting the formation and 
presence of ice entirely (freeze prevention) thus allowing these species to remain 
dormant (diapause) and inactive for prolonged periods of time77 and differs from 
other (freeze tolerance) mechanisms. More specifically these macromolecules 
are either AFPs which are typical globular proteins forming four distinctive 
families (in fish species for instance)78 or AF(G)Ps that are proteins with a repeat 
and (semi)regular tripeptide (AAT) structure consistently glycosylated with a 
single disaccharide moiety per tripeptide.11 Closely related mimics of AF(G)Ps 
have yielded mixed results in terms of comparable IRI activity.32,33,42 Convergent 
evolution that is whereby two different species independently by geographical 
separation or otherwise develop similar or near-identical mechanisms to a 
common problem (i.e. freeze tolerance) has been observed with the development 
of AF(G)Ps in arctic and antarctic fish species.79,80 Therefore it is unsurprising 
that a biosynthetically simpler but similar mimic or glycoprotein with comparable 
IRI activity has not been successfully identified, otherwise it is possible that 
separate structures would of arisen in nature rather than on the convergence of a 
single structure. The conservation of AF(G)P structure can be exemplified by the 
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diversity of AFPs with for instance AFP type I proteins have a high α-helical 
content where as AFP type II proteins have mainly β-sheet and random coil 
secondary structure motifs, yet they both have similar properties.81 Exploring 
macromolecules that are synthetically inaccessible to nature and have modest 
similarity but take into account what is currently understood about the interaction 
of AF(G)Ps and AFPs with water/ice is the next step. The rationale of which leads 
towards the exploration and examination of synthetically derived (glyco)polymers 
as IRI active compounds and potential AFP and AF(G)P mimics. 
 
2.3.3. IRI activity of synthetic and natural polymeric 
macromolecules.  
 
Previous studies by Inada et al., Budke et al. and Gibson et al. have investigated 
the IRI activity of several synthetic polymers and macromolecules.51,52,82 These 
are appealing as even at a high mass concentration their molar concentration is 
not sufficient to significantly alter osmolarity detrimentally. Additionally from a 
synthetic perspective polymers are not inhibited in terms of chain length to same 
extent as SPPS derived mimics have been and can be fine tuned or modified by 
several established chemistries.83,84 However polydispersity especially at low 
degrees of polymerisation can be problematic in ensuring batch-to-batch 
replication. The physiochemical properties of polymers vary widely and as such 
their application may be limited by for example their aqueous solubility and photo 
and thermal stability. A variety of (glyco)polymers with a range of complexities 
have been investigated in literature but the relatively simple polymer poly(vinyl 
alcohol) (PVA) has repeatedly showed a potent IRI activity. The IRI potency of 
many other (glyco)polymers is significantly reduced in comparison except at high 
concentrations (40 mg/mL) where high MW (105 kDa) Poly(methyl-6-O-
methacryloyl-α-D-glucopyranoside) (PMAMGlc) had significant IRI activity, 
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though activity was reduced with a PMAMGlc of MW 56.5 kDa and lost 
completely at lower MW values (18 kDa and 37 kDa) that are akin to the MW of 
even the largest AF(G)Ps.82 It is understood that PVA is the synthetic derivative 
with the most comparable IRI activity to native AF(G)Ps.29,85 To probe this activity 
further a selection of PVA molecules (Section 2.5.2.) amongst a collection of 
other high MW polymers were investigated for IRI activity (Figure 2.13.). One of 
the other polymers examined was poly (ethylene glycol) (PEG) as it is isomeric to 
PVA but only contains a single terminal hydroxyl group and has excellent 
aqueous solubility and commercial availability. Examining PEG allows the 
importance of hydroxylation (hydration) to be further clarified. Both hydroxyethyl 
starch (HES) (140 kDa) and dextran (40 kDa) were chosen as these naturally 
derived branched chain polysaccharides have been shown to have cryoprotective 
properties when applied to biological materials at high concentrations86,87 though 
not without adverse clinical side effects.88  
 
PVA from 3 commercially available preparations were chosen and purified with 
MWs of 9 kDa (80 % hydrolysis), 31 kDa (98-99 % hydrolysis) and 85 kDa (99 
%+ hydrolysis). The aqueous solubility of 85 kDa PVA however was extremely 
low and precluded its analysis and was not examined. Literature findings suggest 
PVA molecules of reasonable size may gelate easily at low temperatures 
preventing their application successfully.89 The IRI activity of PVA (9 kDa and 31 
kDa), PEG (8 kDa and 100 kDa), HES and dextran at 10 mg/mL in PBS is 
illustrated in Figure 2.14. It is immediately apparent that both 9 kDa and 31 kDa 
PVA possess a strong IRI activity with a MLGS (%) of 33.7 % ± 1.8 % and 16.8 
% ± 24.4 % respectively with 8 kDa and 100 kDa PEG having values much larger 
at 90.4 % ± 5.7 % and 73.6 % ± 6.9 %.  Furthermore the cryoprotectants HES 
and dextran have low IRI activity with values of 87.9 % ± 6.0 % and 90.1 % ± 5.9 
%, implying their cryoprotective properties are independent of any IRI effect. 
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Micrographs of polynucleated ice crystals subsequent to annealing at -6 ºC for 30 
minutes assist to visualize the clear difference between inhibited (5 mg/mL 9 kDa 
PVA) and uninhibited ice crystal growth and are the basis from which MLGS (%) 
values are derived (Figure 2.15.). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.13. Structures of various high molecular weight polymers 
assessed for IRI activity. (Clockwise from top left); Poly(vinyl alcohol) (PVA), 
Poly(ethylene glycol) (PEG), Hydroxyethyl Starch and Dextran (α(1→6) glucose 
and α(1→6) and α(1→3) glucose units). 
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Figure 2.14. IRI activity of different polymers of various molecular weights 
and polydispersities. Each polymer was tested at a concentration of 10 mg/mL. 
All measurements represent the MLGS (%) of 10 crystals with error bars 
representing ± standard deviation. 
 
 
Figure 2.15. Micrographs of polynucleated ice crystal wafers. Illustrating ice 
recrystallization (growth) of various solutions annealed at -6 °C for 30 minutes; 
From left to right; PBS, 10 mg/mL 8 kDa PEG and 10 mg/mL 9 kDa PVA. Scale 
bar = 400 µm. 
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The low % MLGS of PVA is astonishing and PVA possesses a significantly 
greater IRI activity than any other polymers, (mono-, di- and oligo-) saccharides 
and low MW molecules tested. The %MLGS is also lower than the majority of 
those reported elsewhere with no immediate explanation (i.e. hydration index) for 
this anomalously high IRI activity (Figure 2.16.). Two other compounds that have 
similar properties but vastly different structures from AFPs and AF(G)Ps include 
a (lipo)xylomannan polysaccharide from the freeze tolerant Alaskan beetle Upis 
ceramboides identified by Walters et al. that additionally has strong TH activity. 
The IRI activity of (lipo)xylomannan is significant as it is the first compound to be 
isolated from nature that has no protein component.90,91 Studies by Deville et al. 
have also shown that preparations of zirconium acetate influence ice crystal 
structure though its properties with respect to ice recrystallization remain 
unknown but nonetheless continues to be an intriguing prospect (Section 
1.4.).92,93 
 
Expanding the concentration range further the IRI activity of 9 kDa PVA and 31 
kDa PVA between 0.0125 mg/mL and 1.5 mg/mL was assessed with significant 
activity observed at concentrations as low as 0.2 mg/mL (0.0048 [OH]/L) 9 kDa 
PVA (84.3 % ± 6.4 %) and 0.05 mg/mL (0.0012 [OH]/L) 31 kDa PVA (53.3 % ± 
11.3 %) (Figure 2.17.) highlighting the potency of PVA as an IRI active compound 
and its potential to mitigate cryodamage caused by ice recrystallization. 
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Figure 2.16. Selection of low MW compounds tested for IRI activity 
compared to 31 kDa PVA, 40 kDa Dextran and 140 kDa HES. Measurement of 
MLGS (%) vs. concentration ([OH]/L) highlighting the anomalously high IRI 
activity of PVA. Each measurement represents the (%) MLGS of 10 crystals with 
error bars representing ± standard deviation.  
 
 
 
 
 
 
 
 
 
Figure 2.17. IRI activity of a range of concentrations of 9 kDa and 31 kDa 
PVA. Measurement of MLGS (%) vs. Concentration ([OH]/L). Each measurement 
represents the MLGS (%) of 10 crystals in triplicate with error bars representing ± 
standard deviation.  
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2.3.4. IRI activity of PVA over an extended time frame. 
 
The definition of IRI is the kinetic inhibition (slowing) of ice crystal growth, but a 
low rate of ice crystal growth will persist regardless, therefore it is important to 
assess IRI activity over a longer period as larger volume samples (e.g. organs) 
would be subjected to sufficiently long thawing times that would under normal 
circumstances promote extensive ice recrystallization. As a result some ice 
crystals may reach sizes that cause cryodamage at concentrations that only have 
a partial and inadequate inhibitory effect. Figure 2.18. shows the IRI activity 
(MLGS (µm)) of 9 kDa PVA and 31 kDa PVA over a 120-minute period at 20-
minute intervals at 0.2 mg/mL, 2 mg/mL and for 9 kDa PVA 20 mg/mL also (31 
kDa PVA was not soluble at this concentration). These measurements were 
calculated using MLGS (µm) as opposed to MLGS (%) in order to not give the 
impression of shrinking ice crystals (i.e. decreasing MLGS (%)) and to gain 
values for the overall ice crystal size, which is a more important measure over a 
prolonged period. It must noted that over a prolonged period at concentrations 
where IRI activity starts to decrease (e.g. 0.2 mg/mL 31 kDa PVA and 2 mg/mL 9 
kDa PVA) that a few significantly large ice crystals (as a consequence of ostwald 
ripening) appeared and persisted skewing the size distribution and giving a large 
standard deviation (Figure 2.19). Importantly even the presence of a few large ice 
crystals such as these may prove detrimental to cells, a consideration to 
undertake with all IRI compounds both natural and synthetic. Pleasingly though 
the presence of moderately low concentrations of both 9 kDa and 31 kDa PVA 
appear to dramatically arrest significant ice recrystallization within this extended 
time frame, with MLGS values of 90.1 µm ± 19.9 µm (44.9 % ± 9.9 %) and 36.4 
µm ± 3.2 µm (18.2 % ± 1.6 %) for 2 mg/mL solutions of 9 kDa and 31 kDa PVA 
respectively compared to a value of 200.5 µm ± 20.5 µm for PBS after 120 
minutes. 
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Figure 2.18. IRI activity of 9 kDa PVA and 31 kDa PVA at various 
concentrations over a 120-minute period. MLGS (µm) of (A) 9 kDa PVA and 
(B) 31 kDa PVA at 20-minute intervals relative to PBS. Each measurement 
represents the MLGS (µm) of 10 crystals with error bars representing ± standard 
deviation. 
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Figure 2.19. Micrographs of polynucleated ice crystal wafers after 120 
minutes. Illustration of ice recrystallization (growth) of various solutions annealed 
at -6 °C for 120 minutes; From left to right; PBS, 2 mg/mL 9 kDa PVA (note the 
presence of a few persistently large ice crystals) and 2 mg/mL 31 kDa PVA. 
 
2.3.5. Investigation of the hydrophobic and surfactant 
characteristics of PVA underlying its anomalously high IRI 
activity. 
 
Considering all the data thus far, PVA clearly has an anomalously high activity 
and requires further investigation to identify any properties that may rationalise its 
IRI potency. The work of Capicciotti et al. has identified the potent IRI activity of 
two low MW carbohydrate derivatives, the non-ionic surfactant n-octyl-β-D-
galactopyranoside and related IRI to its critical micelle concentration (CMC) in 
addition to the high potency of the hydrogelator n-octyl-D-gluconamide. Though 
they also showed that the ability to form micelles or promote gelation did not 
necessarily correlate with an appreciable IRI activity but did hypothesize the 
importance of hydration as n-octyl-β-D-glucopyranoside lacked an appreciable 
IRI activity.94 Such findings correlated with galactose, n-methyl-β-D-
galactopyranoside and n-methyl-α-D-galactopyranoside having higher hydration 
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number values than glucose, n-methyl-β-D-glucopyranoside and n-methyl-α-D-
glucopyranoside respectively.57 Balcerzak et al. expanded on the work of 
Capicciotti et al. and showed the importance of hydrophobicity in IRI activity.95 
This work focuses on the use of small MW lysine based surfactants, which have 
been previously investigated as anti-ice nucleating agents as potent IRI active 
compounds.96,97 These findings highlighted that the presence of a hydrophobic 
long chain alkyl group (decyl) at the C-terminus of a lysine residue permitted 
potent IRI activity. Alkyl chains longer than decyl resulted in a loss of IRI activity 
but shorter chain alkyl groups tended to a reduction in IRI activity correlating with 
shortening chain length, though the shortest chain length (butyl) examined still 
retained moderate IRI activity. Continuing on from this they investigated a range 
of double alkyl-substituted compounds (amino side chain and N-terminus) that 
again had IRI activity with potency varying with chain length and substitution 
applied. A simple comparison between PVA and these compounds is not easily 
possible, though it is important to assess whether or not PVA has any 
hydrophobic characteristics as suggested by these findings. However as 
aforementioned the ability to form micelles should not be considered a definite 
indicator of IRI activity but the formation of micelles is indicative of 
amphiphilicity.98,99 To probe whether or not PVA can form micelles indicative of 
amphiphilicity and therefore hydrophobicity, a dye inclusion assay with 
fluorescent 1,2-diphenyl-1,3,5-hextriene (DPH) was performed (Section 2.5.5).100 
Dye inclusion assays are often used to determine the self-assembly of block 
copolymers in water.101 The organic dye DPH is only sparingly soluble in water 
and only fluoresces in a hydrophobic environment and therefore fluorescence will 
be detected as a consequence of aggregation. For that reason a range of 
concentrations of 9 kDa PVA and for comparison 8 kDa PEG, 40 kDa dextran, 
glucose, sucrose and trehalose were evaluated for micelle formation and define 
(if any) a corresponding critical micelle concentration (CMC) (Figure 2.20). 
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Figure 2.20. Assessment of critical micelle concentration (mg/mL) using 
fluorescence spectroscopy. Investigation of several different polymers and 
small molecules and the fluorophore DPH that fluoresces significantly (+1000) 
only in hydrophobic environments, indicative of aggregation. (A) All compounds 
assessed at concentrations between 0-20 mg/mL; (B) 9 kDa PVA and 8 kDa 
PEG assessed at a wider concentration range between 0-40 mg/mL. 
 
Only 9 kDa PVA (the least IRI activity PVA identified) shows any significant 
fluorescence and only at concentrations above 10 mg/mL (CMC) where as all 
other materials tested were negative including 8 kDa PEG even up to a 
concentration of 40 mg/mL. The detection of fluorescence implies that 9 kDa PVA 
is capable of forming micelles. However experiments undertaken by colleagues 
demonstrated an absence of micelles (typically on the scale of 100Å) at 
comparable concentrations using dynamic light scattering (lower limit of 
approximately 1 nm). The lack of particle detection by dynamic light scattering is 
contradictory to the notion of micelle formation and therefore implies that PVA 
has the capability to form local hydrophobic domains and incorporate DPH 
without the onset of micelle formation. A finding that correlates well with the work 
of Capicciotti et al. as n-octyl-β-D-galactopyranoside, which has a CMC 
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approximating 30 mM defined by MD102 and a range of biophysical methods103 is 
higher than the concentration (11 mM) with potent IRI activity. A similar trend 
observed with 9 kDa PVA that has IRI activity at concentrations (0.2 mg/mL) far 
lower than the perceived CMC here of 10 mg/mL. These findings tend to the 
hypothesis that PVA is able to present a local hydrophobic domain important to 
its anomalously high IRI activity though the abundance of hydroxyl groups will 
understandably play a part in IRI and other water/ice interactions, which is 
contrary to majority of surfactants that self assemble into micelles in aqueous 
solutions.104 The lack of IRI activity in other (glyco)polymers may be due to their 
greater conformational flexibility causing inability to present this characteristic 
hydrophobic domain.82 The step-wise increase in the moderate IRI activity of 
methyl-glucopyranoside, ethyl-glucopyranoside and octyl-glucopyranoside 
compared to glucose and arabinose (same valency as allyl-glucose derivatives) 
is attributed to presence of a hydrophobic domain, though this IRI activity is still 
significantly below that of PVA. The CMC of octyl-glucopyranoside is 25 mM and 
at concentrations higher than this the allyl chain (hydrophobic domain) is 
sequestered into the micelle core and not available to interact in the surrounding 
hydration layer.105 The CMC of octyl-glucopyranoside advocates that the dye 
inclusion assay is able to detect the presence of hydrophobic domains but not 
able to separate hydrophobicity from IRI activity.85 The very high IRI activity of 
PVA though does excitingly suggest that PVA maybe able to improve 
cryopreservation by modulating ice crystal growth at biocompatible 
concentrations to reduce or alleviate ice recrystallization cryodamage (Chapters 
3, 4 and 5). However to best understand the effect that PVA may have it is 
necessary to assess how ice crystal growth in the presence and absence of PVA 
is affected by various fast and slow freezing rates.106,107 
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2.3.6. The effect of freezing rates and DMSO content on ice 
crystal formation and growth. 
 
The freezing and thawing of cells, tissues and organs is a complex process 
(Chapter 1) and does not need reexamining here. Understanding nucleation (ice 
crystal formation) and ice crystal growth during the freezing process in an 
absence of cryoprotective additives is important as current cryopreservation 
strategies utilize an expansive array of freezing rates,24 therefore understanding 
these properties may allow the rational design and implementation of novel 
cryopreservatives including PVA.  
 
To probe any differences in ice crystal size and overall morphology, an 
assortment of cooling rates were used to freeze PBS (no cryoprotective effect) 
precisely from +2 °C to -78 °C at rates ranging from 0.5 °C/min to 150 °C/min by 
cryomicroscopy (Section 2.5.6.). Figure 2.21. illustrates micrographs of PBS 
taken at -78 °C with a clear indication that decreasing the freezing rate increases 
ice crystal size, with dramatically large differences between the slowest and 
fastest rates examined. How ice crystal size changes with freezing rate has 
obvious relevance to ice crystal growth during freezing and thawing, particularly 
slow thawing. To further investigate ice formation during freezing, 
cryomicroscopy was used to examine how solutions containing differing 
concentrations of the organic solvent, DMSO behave when cooled at a constant 
cooling rate of 40 °C/min down to -78 °C. Figure 2.22. illustrates a micrograph at 
-78 °C of a PBS solution containing 10 % (v/v) DMSO (Figure 2.22.A) which has 
clear ice crystal formation under these conditions and is akin to the 
concentrations used to cryopreserve immortalized mammalian cell lines as well 
as numerous primary cell types.108 However these solutions are often far more 
complex and comprise high concentrations of FBS (> 5% (v/v)) in an isotonic cell 
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medium in addition to DMSO and thus may behave differently. In contrast to this 
a PBS solution with 50% (v/v) DMSO (Figure 2.22.B) inhibits ice formation under 
identical conditions, even when cooled further down to -150 °C (the lowest 
temperature attainable) no ice crystals were detected (Figure 2.22.C). The 
freezing point depressions of water/DMSO mixtures have been widely 
documented109 as well as MD simulations attempting to model this 
phenomena.110 These freezing point depressions may be responsible for an 
absence of immediate ice formation at -80 °C but would be anticipated at -150 
°C, this is suggestive therefore of a vitrified (ice crystal free) state. The presence 
of nucleators is also known to affect the probability of ice crystal formation and 
alter freezing points.111 To put the effect of nucleators into the context of 
cryopreservation a review by Morris & Acton highlights the impact of ice 
nucleation112 while Vigier & Vassoille describe ice nucleation and crystallization in 
water and glycerol (another commonly used organic cryoprotectant) mixtures as 
a consequence of devitrification upon thawing.113 Cryomicroscopy while enabling 
an accurate qualitative indication of ice crystal formation (nucleation) a more 
powerful tool for assessing phase transitions (i.e. nucleation/freezing or 
vitrification) is differential scanning calorimetry (DSC).114   
 
 
 	  	   108	  
 	  	  	  	  	  	  
 
 
Figure 2.21. Micrographs illustrating ice crystal growth during freezing at 
various cooling rates. Highlighting increasing ice crystal size with decreasing 
freezing rate. (Scale bar = 200 µm) All samples (200x magnification) were cooled 
to -78 °C at the indicated rate, and images taken once that temperature had been 
reached.  
 
 
 
 
 
 
 
 
Figure 2.22. Micrographs of DMSO solutions cooled to -80 ºC at 40 ºC/min. 
(A) 10 % (v/v) solution of DMSO showing ice crystal formation; (B) 50 % (v/v) 
DMSO and (C) 50 % (v/v) DMSO cooled further to -150 ºC. Each showing an 
absence of ice crystal formation (100x magnification). 
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2.3.7. Investigation of freezing and thawing by Differential 
Scanning Calorimetry. 
 
DSC is a thermoanalytical technique that precisely measures the differences in 
energy required between a reference and sample of interest to maintain a 
preprogrammed shift in temperature and is distinct from the similar technique of 
thermogravimetric analysis (TGA), though both techniques are used widely in 
materials science. TGA simply measures the mass loss of a sample with respect 
to increases in temperature and can be used to describe and define a range of 
physical and chemical phenomena including vaporization, desolvation and 
decomposition.115 DSC however can be used to detect exothermic and 
endothermic events (presented as peaks) and therefore phase transitions. The 
onset, asymmetry and broadness of these peaks are commonly used to assess 
purity. Impurities tend to shift and broaden phase transitions and can be used to 
consequently detect and approximate for example freezing point depressions.116 
A liquid to solid phase transition is typically observed by a large exothermic event 
and these are distinct from glass transition events that evidential in this context of 
vitrification.117 Vitrification is a consequence of a rapid decrease in temperature 
causing a liquid to undergo a glass transition, which is the instantaneous switch 
from the liquid phase to an amorphous solid with abrupt changes in several 
material properties including viscosity and heat capacity.118 These changes can 
also be implemented by high pressure and a high solute concentration and 
therefore circumvent ice formation.119 The potential benefits for cryopreservation 
are enormous and were first identified by Polge et al. over 60 years ago with the 
use of high concentrations of glycerol to cryopreserve spermatozoa.120 Despite 
early promise numerous problems have been encountered including 
devitrification.121 Devitrification caused by inadequate storage conditions or as a 
consequence of the thawing process results in ice crystal formation, which then 
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inflicts sufficient cryodamage due to recrystallization.119 The cooling rates 
required to typically incite vitrification are very high and therefore difficult to 
achieve with all but the smallest volumes even after the addition of large amounts 
of solute that reduce the absolute temperature and the cooling rates required.122 
Additionally the concentration of cryoprotectant often DMSO or glycerol 
necessary can be cytotoxic and difficult to eliminate postthaw.123 In recent years 
though progress have been made, difficulties remain in overcoming the 
aforementioned challenges.124,125 Using DSC it is therefore possible to investigate 
the processes of freezing and vitrification as separate events and assess how 
increases in DMSO concentration promotes either ice crystal formation or 
vitrification when cooled rapidly to -78 ºC at 40 ºC/min which mimics the 
conditions used in cryomicroscopy.  
 
Figure 2.23. illustrates the DSC traces (Figure 2.23.A) attained for a range (0.5 % 
(v/v) – 15 % (v/v)) of DMSO solutions highlighting freezing transitions due to the 
presence of exotherms (+ve peaks), though these do not correlate strongly (Adj-
R2 = 0.3857) in a linear fashion indicative of the spontaneous nature of nucleation 
(Figure 2.23.C). Such findings are consistent with those demonstrated by 
cryomicroscopy. Concentrations of DMSO at 20, 30, 40 and 50 % (v/v) however 
did not elicit any exothermic peaks suggestive of no ice crystal formation (Figure 
2.23.B). Understanding the effect of solute concentration upon thawing is equally 
of importance and thus each sample once cooled to -78 ºC was warmed slowly at 
2.5 ºC/min until a final temperature of +2 ºC. Melting is observed as a 
consequence of a large endothermic event during thawing and Figure 2.24.A 
shows the effect of DMSO concentration on the onset (1 ºC thermal lag) and 
duration of melting with higher concentrations having broader and less 
pronounced peaks at lower temperatures. Interestingly both 20 % (v/v) and 30 % 
(v/v) DMSO while showing no ice crystal formation during freezing appear to 
have endothermic events indicative of melting which may be as a consequence 
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of devitrification leading to subsequent ice formation. Figure 2.24.B highlights that 
melting correlates strongly (Adj-R2 = 0.973) with concentration which agrees well 
with existing literature.126 From these findings it can be postulated that solute 
concentration affects the duration and onset of melting which is significant 
because this will have a consequence on the onset and duration at which ice 
recrystallization can occur especially at 10 % (v/v) DMSO that is the 
concentration most prevalent in cryobiology.24 
 
Figure 2.23. DSC traces upon cooling various concentrations (% (v/v)) of 
DMSO. (A) DSC traces (heat flow (mW)) assessing the freezing point of DMSO 
solutions between 0.5 % (v/v) and 15 % (v/v) (indicated by large exothermic 
peaks) down to a temperature of -78 ºC at 40 ºC/min; (B) Solutions greater than 
or equal to 20 % (v/v) DMSO that failed to freeze under identical conditions; (C) 
Temperature (°C) at PeakMax vs DMSO (v/v). 
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Figure 2.24. DSC traces upon thawing various concentrations (% (v/v)) of 
DMSO. DSC traces (heat flow (mW)) of (A) DMSO solutions heated from -78 ºC 
to +5 ºC at a rate of 2.5 ºC/min exemplifying endothermic (thawing) transitions 
and the effect of DMSO concentration and (B) temperature at each peak 
minimum vs. DMSO concentration (% (v/v)) for the DSC traces presented in (A) 
demonstrating a strong linear relationship. 
 
Several studies have investigated the impact and role of PVA and other polymers 
as inhibitors of heterogeneous ice nucleation in conjunction with high 
concentrations of organic solvents to help promote vitrification and evade ice 
formation.127-130 PVA is able to strongly inhibit ice nucleation events and reduce 
the concentrations of DMSO and glycerol required to incite vitrification and is 
available as a commercial preparation (Super cool X1000TM, 21st century 
medicine, CA, USA) for this purpose.131 However our aims are not to prevent ice 
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formation, as the high concentrations of organic solvents required for vitrification 
(even with the addition of PVA) limit their application in cryobiology due to their 
cytotoxicity and in the difficulties in removing these membrane permeable 
solvents. Instead here we focus on the impact of 9 kDa PVA in an aqueous 
system to detect any effects it may have during the freezing and thawing process 
using DSC. Figure 2.25. illustrates the DSC traces attained from a wide range of 
9 kDa PVA concentrations (0.2 mg/mL – 50 mg/mL). In each instance a large 
exothermic event is detected indicative of ice nucleation even at the highest 
concentration tested (50 mg/mL) with the no significant correlation between the 
onset of each exothermic event and PVA concentration. The absence of a 
significant correlation is suggestive of no anti-nucleating activity in these 
preparations. In contrast to this Ogawa et al. demonstrated a positive change in 
nucleation temperature, with a maximum shift of almost 3 ºC using PVA (22 kDa) 
at a concentration of 1 mmol. At concentrations higher than this the nucleation 
temperature began to revert, corresponding with a decrease in the (colligative) 
melting point though the rate at which this reversion occurred was approximately 
4.3 times greater, a constant that varies between different additives.129 This effect 
was not detected in our experiments with 9 kDa PVA but the freezing rate used in 
our experiments (40 ºC/min) were far greater than the (5 ºC/min) used in this 
study which may account for this difference. A 40 ºC/min freezing rate was 
chosen in order to mimic the rapid freezing rate used in several cryopreservation 
protocols. Interestingly the increase in nucleation temperature was found to be 
independent of MW when compared on a mass basis in the same study which 
differs with respect to the IRI activities of PVA which have a strong MW 
dependant activity over a similar MW range.53 Analogous relationships involving 
changes (though depressions as opposed to increases) in nucleation 
temperature in aqueous systems have been documented elsewhere with non-IRI 
active polymers and small MW polyols including PEG and glycerol.132,133 The 
addition of PVA (13 kDa) to a vitrified system consisting of 35 % (v/v) 1,2-
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propandiol that is cooled at 5 ºC/min does cause a significant freeze point 
depression with the addition 3 % (w/w) PVA (the highest tested) producing a 50 
ºC depression, though under the same conditions and concentrations PEG 
induced a 30 ºC shift.134 Therefore under non-vitrifying conditions there is no 
significant effect on ice formation during rapid freezing that is detrimental to the 
potential application of PVA as a cryoprotectant.  
 
 
 
 
 
 
 
 
 
Figure 2.25. DSC traces upon cooling various concentrations (mg/mL) of 9 
kDa PVA. DSC analysis (heat flow (mW)) assessing the freezing point of 9 kDa 
PVA solutions (indicated by large exothermic peaks) down to a temperature of -
78 ºC at 40 ºC/min. No significant freezing point alteration that correlated with 
concentration was observed even with the addition of up to 50 mg/mL 9 kDa 
PVA. 
 
However our focus is principally upon the effect (IRI) of PVA during thawing as 
opposed to freezing and assessing if PVA incites any large-scale changes during 
thawing especially slow thawing. Figure 2.26.A shows the DSC traces of 
aqueous 9 kDa PVA solutions at the same concentration range and with a slow 
thawing rate of 2.5 ºC/min. It is clear that the concentration of PVA does not 
affect the onset or duration of melting (≈ -6 ºC), though it is worth noting the 
apparent thermal lag in this system equating to about 1 ºC. No exothermic events 
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indicative of recrystallization (though the magnitude of these cannot be predicted) 
are apparent135 but these may be simply offset and therefore hidden by the 
endothermic melting process over the same time period. Upon closer inspection 
however an interesting endothermic event is recorded at around -22 ºC (Figure 
2.26.B). The magnitude and integral value is though far smaller meaning less 
energy is required for this event when compared to the melting process, but this 
is lessened and even negated (50 mg/mL) with increasing concentrations of 9 
kDa PVA. This event is not seen either in solutions containing DMSO even at 
comparable mass concentrations (though the molar concentration will be 
significantly higher) nor is it reported elsewhere in literature though not many 
studies have been undertaken with most analysing PVA in conjunction with vast 
amounts of organic solvent which would mask this event anyway.130,134 
Investigating further how this secondary minor peak may alter the freezing or 
thawing process remains a tantalising area for future investigation but under 
scenarios where by PVA would be used as a cryoprotectant is unlikely to have 
detrimental effects. 
 	  	   116	  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.26. DSC traces upon thawing various concentrations (mg/mL) of 9 
kDa PVA. DSC traces (heat flow (mW)) of (A) 9 kDa PVA solutions heated from -
78 ºC to +5 ºC at a rate of 2.5 ºC/min exemplifying two endothermic peaks and 
the effect of PVA concentration and (B) detailed view of the minor endothermic 
event depicted in (A). 
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2.4. CONCLUSION. 	  
The IRI activities of a diverse set of monosaccharides, disaccharides, 
oligosaccharides, low MW molecules, natural and synthetic polymers have been 
defined. IRI studies have highlighted that increasing the concentration of hydroxyl 
groups ([OH]/L) tends to an increased IRI activity. However even at high 
concentrations the level of IRI is moderate at best with no discernable differences 
between these polyols even when considering variations in hydration number and 
hydration index. The polymer PVA is an exception and possesses exceptionally 
high IRI activity even at comparatively low concentrations with 31 kDa PVA 
having greater IRI activity than 9 kDa PVA but inferior aqueous solubility. A 
significant level of IRI activity with both PVA molecules is retained even over 
extended time periods and considerably longer than the durations required to 
successfully thaw small biological samples. Cryomicroscopy and DSC studies 
also showed the impact of freezing rates on ice crystal growth and how the 
presence of the cryoprotectant DMSO can inhibit ice formation and promote 
vitrification though at concentrations that are decidedly cytotoxic. Furthermore the 
presence of 9 kDa PVA at concentrations with significant IRI activity had no 
fundamental impact on the freezing or thawing processes that mimic conditions 
used in some cryopreservation protocols. 	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2.5. MATERIALS AND METHODS. 	  
2.5.1. Preparation of Phosphate Buffered Saline. 
 
A single phosphate buffered saline (PBS) tablet (Sigma-Aldrich Company Ltd, 
Dorset, UK) was placed in 200 mL of ultrahigh purity (18.2 mΩ cm (resistivity) at 
25 °C) H2O(l) and stirred until the tablet dissolved fully. This yielded at solution of 
137 mM (8.01 g/L) NaCl(aq), 2.7 mM (0.20 g/L) KCl(aq), 10 mM  (1.78 g/L) 
Na2HPO4 · 2H2O (aq)  and 2.0 mM (0.27 g/L) KH2PO4(aq) at pH 7.4 (303 mOsm/L). 
The solution could then be stored for a period of 3 months at 23 °C until required. 	  
2.5.2. IRI compounds and the purification of HES, PVA, PEG 
and Dextran. 
 
All monosaccharides, disaccharides, oligosaccharides and small MW polyols 
were of the highest attainable quality and sourced from various suppliers (Sigma-
Aldrich Company ltd, Dorset, UK; Fisher Scientific UK Ltd, Leicestershire, UK; 
Carbosynth Ltd, Berkshire, UK;) and used as supplied without further purification. 
9 kDa PVA (average MW 9,000-10,000, 80 % hydrolyzed), 31 kDa PVA (average 
MW 31,000-50,000, 98-99 % hydrolyzed), 85 kDa PVA (average MW 85,000 -
124,000, 99+ % hydrolyzed), 8 kDa PEG (average MW 8,000), 100 kDa PEG 
(average MW 100,000) and 40 kDa dextran (average MW 40,000 obtained from 
Leuconostoc spp) were of the highest attainable quality available (Sigma-Aldrich 
Company ltd, Dorset, UK). Purified (130 kDa) hydroxyethyl starch (0.4 degree of 
substitution) was isolated from the plasma expander, Volulyte® (Fresenius Kabi 
Ltd, Cheshire, UK) that comprises of 6 % (v/v) HES is an isotonic medium. Each 
polymer and polysaccharide was purified by dialysis as follows using ultrahigh 
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quality water with a resistance of 18.2 MΩ cm (25 °C) obtained from a Millipore 
Milli-Q gradient machine fitted with a 0.22 µm filter and MWCO = 1000 dialysis 
membranes (Spectrum Laboratories Inc, CA, USA) and frequent 4 L H2O(l) 
changes. Each sample was then freeze-dried overnight. Samples could then be 
stored for a period of 1 year at 23 °C and diluted with PBS when required. 
 
2.5.3. Assessment of ice recrystallization inhibition (IRI) activity. 
 
Determination of IRI activity was achieved using a modified “splat” assay.63 
Determination of IRI activity involved the expulsion of a 10 µL droplet of analyte 
in PBS using a Hamilton gastight 1750 syringe (Hamilton Bonaduz AG, GR, 
Switzerland) coupled with a BD microlance 3 21G needle (BD, Oxfordshire, UK) 
from a fixed height of 2 m on to a 22x22 mm no.1 thickness glass cover slip 
(Fisher Scientific UK Ltd, Leicestershire, UK) on a CO2(s) cooled aluminium plate 
(> -50 °C). The resulting impact generated a polynucleated ice crystal wafer with 
numerous ice crystals approximately 10 µm in diameter. This wafer was then 
immediately transferred onto a pre-cooled (-6 °C) cryostage (either a nanolitre 
osmometer (Otago Osmometers Ltd, Dunedin, New Zealand) or Linkam BCS196 
cryostage (Linkam Scientific Instruments Ltd, Guildford, Surrey, UK)) and allowed 
to anneal for 30 minutes (or longer if necessary).  Photographs at all 
magnifications were taken using a Canon EOS 500D SLR digital camera (Canon 
(UK) Ltd, Surrey, UK) after 0 and 30 minutes (or longer in case of Figure 2.18.) 
coupled to an Olympus CX41 microscope equipped with UIS-2 20x/0.45/∞/0-
2/FN22, UIS-2 4x/0.1/∞/-/FN22 and UIS-2 10x/0.2/∞/-/FN22 lenses (Olympus 
Ltd, Essex, UK) through cross polarisers. At least 3 fields of view (1.33 mm2) 
were photographed (exemplified in Figure 2.15.) for each compound at each 
concentration, forming an extensive library. The 10 largest ice crystals from each 
image were then measured (40x magnification = 1.44 pixels per µm; 100x 
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magnification = 3.6 pixels per µm; 200x magnification = 7.2 pixels per µm;) using 
the freely available image analysis software image J (http://imagej.nih.gov/ij/)136 
and the mean (µm) and standard deviation calculated and plotted in Origin 8.5 
(OriginLab Corp, MA, USA) allowing the mean largest grain size (MLGS (µm)) 
with a resolution of up to 0.2 µm (200x magnification) to be defined. Each value 
was then contrasted against a positive PBS control (no IRI), which was taken as 
100 % and the MLGS (%) ± standard deviation reported (Equation 2.1.).  
 
Equation 2.1: Calculation of MLGS (%) from MLGS (µm) of compound and 
MLGS (µm) of PBS. 
 
 	  
2.5.4. Assessment of ice formation in PBS solutions at various 
cooling rates. 
 
The rate of ice crystal formation and growth at various freezing rates with a PBS 
solution was achieved using a Linkam BCS196 cryostage (Linkam Scientific 
Instruments Ltd, Guildford, Surrey, UK) coupled to an Olympus CX41 microscope 
equipped with a UIS-2 20x/0.45/∞/0-2/FN22 lens (Olympus Ltd, Essex, UK) and 
a Canon EOS 500D SLR digital camera (Canon (UK) Ltd, Surrey, UK). A 5 µL 
droplet of PBS was placed between two No.0 thickness 19 mm diameter cover 
slips (Fisher Scientific UK Ltd, Leicestershire, UK) and cooled to +2 °C. The 
sample was then cooled to -78 °C at one of a variety of cooling rates (Figure 
2.21.) and images taken (200x magnification) at the focal plane showing ice 
formation. The same sample was used for each freeze/thaw cycle and heated 
rapidly (150 °C/min) to +10 °C for 2 minutes to ensure all ice was melted 
between cooling cycles.  
  
€ 
MLGS (%) =  100 % MLGS ( µm) compound
MLGS ( µm) PBS
⎛ 
⎝ 
⎜ 
⎞ 
⎠ 
⎟ 
 	  	   121	  
2.5.5. Assessment of Critical Micelle Concentration (CMC). 
 
Several polymers including 9 kDa PVA, 8 kDa PEG and 40 kDa Dextran as well 
as several small carbohydrates including glucose, sucrose and trehalose were 
assessed by fluorescence spectrometry using a Synergy HT multi-mode 
microplate reader (BioTek UK, Bedfordshire, UK) for their potential to form 
micelles/undergo aggregation in aqueous solutions at 25 °C. Aqueous 80 µL 
aliquots of analyte ranging from 0-20 mg/mL were added to a clear flat-bottom 
96-well plate (Bibby-Sterlin Ltd, Staffordshire, UK) and 20 µL of 0.01 mg/mL 1,2-
diphenyl-1,3,5-hextriene (DPH) added prior to vigorous mixing and incubation at 
25 °C for a minimum of 3 minutes in absence of light giving a final concentration 
between 0 – 16 mg/mL (or higher in the case of 9 kDa PVA and 8 kDa PEG). The 
fluorescence of each sample was then measured with excitation at 360/40 nm 
and emission of 460/40 nm (sensitivity 35). The CMC was then defined as the 
lowest concentration (mg/mL) with an appreciable level (1000+) of fluorescence. 
 
2.5.6. Assessment of vitrification by cryomicroscopy. 
 
Ice crystal formation was assessed with PBS solutions containing various 
concentrations of DMSO up to 40 % (v/v) using a Linkam BCS196 cryostage 
(Linkam Scientific Instruments Ltd, Guildford, Surrey, UK) coupled to an Olympus 
CX41 microscope equipped with a UIS-2 20x/0.45/∞/0-2/FN22 lens (Olympus 
Ltd, Essex, UK) and a Canon EOS 500D SLR digital camera (Canon (UK) Ltd, 
Surrey, UK). A 5 µL droplet of PBS was placed between two No.0 thickness 19 
mm diameter cover slips (Fisher Scientific UK Ltd, Leicestershire, UK) and 
cooled to +2 °C. Samples were then cooled at 40 °C/min down to a final 
temperature of -78 °C and ice crystal formation was examined at a range of focal 
planes and the results photographed highlighting the presence or absence of ice 
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crystals (Figure 2.22.). If no ice crystal formation was apparent then samples 
were cooled even further down to -150 °C the lowest attainable temperature with 
this instrumentation.  
 
2.5.7. Preparation of samples for differential scanning 
calorimetry (DSC).  
 
Samples were prepared by weighing standard 40 µL aluminum crucibles (Mettler 
Toledo, Leicestershire, UK) and adding 15 µL of analyte before sealing 
(hermetically) and reweighing in order to quantify the exact mass of sample. 
Each sample was then transferred to a liquid nitrogen cooled DSC 1 STAR® 
system (Mettler Toledo, Leicestershire, UK) differential scanning calorimeter. The 
mass of the aluminum crucible and sample mass was inputted into the 
complimentary STARe thermal analysis software to retain a digital record and aid 
analysis. 
 
2.5.8. Freezing and thawing of DSC samples and evaluation of 
DSC spectra. 
 
Each DSC sample was individually cooled from +5 ºC to -78 ºC at a rate of 40 
ºC/min whilst concurrently monitoring the heat flow (mW) of the system to detect 
any endothermic or exothermic transitions. When samples were cooled to -78 ºC 
each sample was then immediately warmed at a rate of 2 ºC/min from -78 ºC to 
+5 ºC. Raw data from each experiment was exported and plotted in Origin 8.5 
(OriginLab Corp, MA, USA) and individual peaks highlighted for comparison 
using the in built modeling functions for linear curve fitting when required.  
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2.6. APPENDIX. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.27. Comprehensive overview of the IRI activities of all investigated 
monosaccharides and disaccharides. (A) monosaccharides and (B) 
disaccharides. Each measurement represents the MLGS (%) of 10 crystals with 
error bars representing ± standard deviation.           
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Figure 2.28. Comprehensive overview of the IRI activities of all investigated 
oligosaccharides and low MW polyols. (A) oligosaccharides and (B) low MW 
molecules. Each measurement represents the MLGS (%) of 10 crystals with error 
bars representing ± standard deviation.	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CHAPTER 3.  
	  
3. ICE RECRYSTALLIZATION INHIBITORS 
IMPROVE THE CRYOPRESERVATION OF 
RED BLOOD CELLS. 	  
3.1. CHAPTER SUMMARY.   
 
The application of poly(vinyl alcohol) (PVA) that has been previously identified 
(Chapter 2) as a potent ice recrystallization inhibition (IRI) active compound is 
explored as a cryoprotectant for improving the cryopreservation of red blood cells 
(RBCs). RBCs are robust and relatively simple (non-nucleated) compared to 
many other cell types yet there is a strong clinical need for prolonging their 
storage. PVA is applied as separate entity and in conjunction with the non-IRI 
active cryoprotectant hydroxyethyl starch (HES) to both ovine (sheep) and 
human RBCs. The addition of PVA is shown to improve recovery rates of RBCs 
that are subjected to slow and consequently detrimental thawing rates with this 
property attributed to the ability of PVA to attenuate ice crystal growth and forms 
the basis of the recently accepted publication in the interdisciplinary journal 
Nature Communications entitled; Synthetic Polymers Enable Non-Vitreous 
Cellular Cryopreservation by Reducing Ice Crystal Growth During Thawing). 
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3.2. INTRODUCTION. 
 
Human red blood cells (RBCs) can only be stored currently ex vivo for a 
maximum of 42 days hypothermically. Hypothermic storage requires RBCs to be 
kept in complex (saline, adenine, glucose and mannitol (SAGM)) solutions 
between 1 °C and 6 °C. The most popular options in order to retain acceptable 
viability (<1 % haemolysis) and posttransfusion survival (75 % after 24 hours) as 
defined by the American Association of Blood Banks being Adsol, Nutricel and 
Optisol.1-4 A decline in the critical metabolites ATP and 2,3-DPG in addition to 
decreases in K+ concentration and pH have been well documented during this 
period. In addition to metabolite depletion there are significant changes in 
metabolism and energetics. The latter of which is reduced by 97 % when 
compared to that at physiological temperatures5 though these effects are usually 
reversed posttransfusion without consequence.6 The likelihood of a myriad of 
clinical consequences however increases with transfusion volume (mean 
transfusion volume approximately 1.4 L) and in neonatal and pediatric medicine.7 
These complications are predominantly of a non-infectious nature, though even 
these are still considered as rare events.8 Increased haemovigilance and 
screening means that bacterial contamination and viral transmission account for 
a minute proportion of adverse reactions.9 A technique that aims to retain and 
extend the viability of RBCs beyond current limits is cryopreservation, which can 
be defined in this context as the storage of RBCs at low or ultra low temperatures 
such that RBCs are not freely in suspension but frozen. The cryopreservation of 
RBCs is advantageous in that it has no upper limit on storage duration and 
cellular energetics are minimized, limiting degradation and eryptosis. However 
even though such storage conditions are not inherently damaging both the 
freezing and thawing process can inflict significant damage by a variety of 
mechanisms, the prevalence and impact of which is dependant upon the rates of 
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freezing and thawing amongst an array of other factors (e.g. haematocrit).10 The 
freezing rate of RBCs can have a significant impact on viability. Slow freezing 
promotes the formation of extracellular ice that as a consequence creates an 
osmotic gradient that favours the efflux of water from the cell. The rate at which 
this occurs is highly dependant on the rate of ice formation that is in turn 
dependant upon the cooling rate. If the rate of efflux is sustainable such that 
RBCs can control the rate of water loss then the cell will slowly become 
dehydrated.11 However if the rate of dehydration is too high then membrane 
lesions and excessive cell shrinkage may occur and in conjunction with this the 
levels of some solutes may reach localized concentrations that may have a 
consequential cytotoxicity.12 The exact mechanism however remains a contested 
topic and it is believed that membrane lesions may alter permeability allowing the 
entry of previous impermeable molecules shifting osmolarity detrimentally.13-15 
The presence of extracellular ice can also, depending upon the density 
(haematocrit) of RBCs, have a significant impact with regards to mechanical 
damage.16,17 A rapid cooling rate which there by limits the duration with which 
RBCs are exposed to the potentially damaging effects experienced at slow 
cooling rates is offset by an increased probability in the development of 
intracellular ice. Intracellular ice formation occurs during rapid cooling as the 
efflux of water in addition to changes in membrane permeability associated with 
low temperatures allow an undesirable retention of water within the cytoplasm 
and can occur by 3 different mechanisms.18 The formation of intracellular ice is 
hypothesized to incite greater mechanical damage and to be avoided where 
possible.19 Once frozen RBCs are often kept at temperatures below -150 °C 
indefinitely until required though an array of storage conditions have been 
employed that have no significantly detrimental effects.1,20,21 The thawing of 
RBCs is a process that is just as critical as freezing. However it is more difficult to 
precisely thaw cells in a controlled manner, as implementing a high thaw rate 
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requires the use of temperatures that exceed tolerable levels. The controlled of 
RBCs is especially true as they are stored and transfused in large volumes (470 
mL) meaning that they cannot be thawed homogeneously. Heterogeneous 
thawing results in exposing a substantially high proportion of RBCs to 
undesirably high temperatures. As a consequence RBCs must be thawed at a 
comparatively slow rate. Slow thawing results in allowing ice recrystallization 
(Chapter 2) that is highly detrimental and a significant cause of cryoinjury. Aside 
from a financial and practical perspective, ice recrystallization damage is one of 
the main reasons as to why RBCs are not routinely cryopreserved as current 
methodologies fail to address the problems arising from ice recrystallization.22 
Therefore the use of an affordable, biocompatible and IRI active additive that can 
be used at low concentrations and easily removed is highly desirable. The 
presence of PVA would limit ice recrystallization, which could limit cryoinjury and 
thus improve the overall yield of intact RBCs recovered after cryopreservation. 
Our aim is for that reason to apply PVA, which has a demonstrable IRI activity 
(Chapter 2) to RBCs in order to reduce the dependency of detrimental organic 
solvents such as glycerol and determine its potential as a novel cryoprotectant to 
limit an otherwise neglected mechanism of cryodamage. 
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3.3. RESULTS AND DISCUSSION. 
 
3.3.1. Degradation of Ovine RBCs stored at 4 °C and 23 °C.  
 
To demonstrate the challenges of the hypothermic storage of ovine RBCs in 
simple isotonic solutions, 25 mL aliquots were prepared and stored statically at 4 
°C and 23 °C in PBS, with haemolysis assessed by quantifying the relative levels 
of haemoglobin leakage over a prolonged period (Figure 3.1. and Section 3.5.4.). 
In brief haemoglobin leakage was assessed by diluting RBCs 2-fold in PBS then 
at the desired time point taking a 20 µL aliquot, diluting in 200 µL PBS prior to 
centrifugation (1950 x g), transferring 50 µL of the supernatant to 150 µL PBS 
and measuring absorbance in a 96-well plate at 450 nm and referenced against 
100 % haemolysed controls. Ovine RBCs stored at 4 °C had a haemolysed 
content exceeding 5 % after 15 days (6.6 % ±0.7 %), which following 42 days at 
4 °C exceeded 50 % (55.5 % ± 2.2 %). Comparable rates of haemolysis were 
mirrored when RBCs were stored at 23 °C which, after 15 days also exceeded 5 
% (5.4 % ± 0.8 %) and after 35 days exceeded 35 % (39.4 % ± 3 %) with 
essentially no differences in haemolysis rates apparent using either storage 
temperature. These values are clearly unacceptable and greatly exceed legal 
limits, helping to emphasize the inadequacies of hypothermic storage for the 
long-term preservation of RBCs and indeed other types of clinically relevant 
biomaterials that tend to have greater fragility and susceptibility. The rates of 
haemolysis highlight the need for a clinically effective cryopreservation strategy, 
as hypothermic techniques are insufficient beyond the short and mid term. More 
effective strategies are of particular importance when rare blood products are 
collected for future autologous transfusion or in instances whereby logistical 
difficulties inhibit the regular and continuous resupply of blood products such as 
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in the recent conflicts in Iraq and Afghanistan, though issues in maintaining 
cryopreservation temperatures would be expected.23,24  
 
 
Figure 3.1. Hypothermic storage of ovine RBCs.	  Static storage of ovine RBCs 
at 4 °C over a 42 day period and static storage of ovine RBCs at 23 °C over a 35 
day period in simple (PBS) isotonic solutions. Samples were taken at frequent 
intervals and each data point was measured (mean) in triplicate with the error 
bars representing ± standard deviation. 
 
3.3.2. Cytotoxicity of current cryopreservatives to Ovine and 
Human RBCs. 
 
Cryopreservation provides a demonstrable alternative to the predominating 
hypothermic storage techniques and enables almost indefinite storage.20 
However to highlight the demand for novel cryopreservatives it is necessary to 
exemplify the inadequacies of commonly utilized cryopreservatives namely the 
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organic solvents glycerol and DMSO. Glycerol is the principal cryoprotective 
agent (CPA) used in the cryopreservation of RBCs but is required at extremely 
high concentrations (15 % (v/v) – 40 % (v/v)).1,25,26 Glycerol is membrane 
permeable and thus can promote rapid changes in osmotic pressure in vitro 
among a wide variety of cell types and is time-consuming and difficult to eliminate 
postthaw, which is critical as glycerol can incite posttransfusional intravascular 
haemolysis.27 Membrane permeable CPAs28 can result in extensive membrane 
damage (osmotic shock) if changes in osmotic pressure are sufficiently rapid and 
abrupt.11 The distinctive membrane composition of RBCs means its membrane 
permeability differs from most other cell types29 and varies extensively between 
different mammalian species.30,31 Therefore RBCs are possibly more susceptible 
to membrane lesions and as a consequence haemolysis, though haemolysis may 
also be dependant upon the thermoelasticity of the RBC membrane.32,33 Figure 
3.2.A demonstrates how the direct addition and mixing (vortex) of glycerol at 23 
°C to a final concentration of 5 % (v/v) glycerol (that is 3-fold lower than the 
minimum used in current cryopreservation protocols) leads to significant 
haemolysis of ovine RBCs. Even after the shortest time interval of 1 minute a 
clinically intolerable level of haemolysis (23.9 % ± 2.8 %) is observed and after a 
period of 15 minutes haemolysis has risen to near totality (93.9 % ± 3.8 %). The 
susceptibility of human RBCs to haemolysis with the addition of 5 % (v/v) glycerol 
was much lower even after a period of 60 minutes (12.1 % ± 1.9 %) but is still 
unacceptably high. However as shown in Figure 3.2.B haemolysis does not 
increase over this time period unlike observations with ovine RBCs that show an 
increase in haemolysis with time (Figure 3.2.A). The Plateauing of haemolysis is 
probably as a consequence of human RBCs attaining an equilibrium state faster 
than ovine RBCs due to their differences in membrane permeability with human 
RBCs having greater permeability (57-fold) than ovine RBCs. The robustness of 
human RBCs is contrary to literature findings that reveal that human RBCs were 
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more susceptible than ovine RBCs which were the second most robust from eight 
mammalian species tested where as human RBCs ranked seventh, however an 
essential difference is that such findings were determined using a lower glycerol 
concentration of 2.1 % (v/v) and at a temperature of 37 °C. Susceptibilities to 
haemolysis in this study correlated strongly with decreasing glycerol permeability 
though all species showed appreciable (> 50 %) haemolysis within 10 
minutes.34,35 Another determinant may be that the level of haemolysis might also 
vary with haematocrit, the rationale being that studies examining the impact of 
haematocrit on the postthaw recovery of human RBCs when cryopreserving with 
a fixed concentration of glycerol showed dramatic and significant discrepancies 
between the highest (83 %) and lowest (4 %) haematocrits examined. Once 
haematocrits exceeded 50 % substantial increases in haemolysis were 
observed,16,17 additionally differences in tonicity (osmolarity) have been proven to 
considerably influence postthaw recoveries,15 therefore various membrane 
permeable CPAs are likely to have dissimilar and hard to define cryoprotective 
properties between different cell types and species. 
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Figure 3.2. Cytotoxicity of the cryoprotectant glycerol to RBCs. (A) (%) 
Haemolysis of ovine RBCs (1 mL) incubated with glycerol (direct addition) over 
15 minutes at 23 °C. (B) (%) Haemolysis of human RBCs (200 µL) incubated with 
glycerol (direct addition) over 60 minutes at 23 °C.  Each data point was 
measured (mean) in quintuplicate with the error bars representing ± standard 
deviation. 
 
The susceptibility of ovine and human RBCs to another commonly used 
cryoprotectant DMSO, was also evaluated using a similar methodology (Figure 
3.3.). After a period of 60 minutes at 23 °C a dramatic level of haemolysis with 
ovine RBCs (40.3 % ± 20.7 %) was detected at concentrations as low as 1.5 % 
(v/v) with haemolysis at the highest concentration tested of 4 % (v/v) equaling 
77.1 % ± 17.9 %. Extending the incubation time further to 150 minutes significant 
(63.8 % ± 14.5 %) haemolysis at the lower concentration of 0.75 % (v/v) was 
detected. Analogous with glycerol a difference in the susceptibility of human 
RBCs to DMSO was observed. Only the highest concentration tested of 4 % (v/v) 
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elicited significant haemolysis in human RBCs (23.2 % ± 0.7 %) after a period of 
60 minutes at 23 °C, extending further at this concentration to 150 minutes 
resulted in greater haemolysis (68.3 % ± 18.6 %), similar to ovine RBCs with 0.75 
% (v/v) DMSO. Human RBCs exposed to concentrations lower than 4 % (v/v) 
demonstrated no significant haemolysis even after a period of 300 minutes 
(Figure 3.3.C). Though it has been reported that DMSO can cryoprotect human 
and bovine RBCs it is not routinely used.36 This cryoprotective effect is 
understood to be due to its high membrane permeability37 which is enhanced 
compared to glycerol especially with respect to bovine RBCs.38 In spite of the 
cryoprotective effect of DMSO it has been shown that DMSO can have 
detrimental effects at physiological temperatures in a range of biological systems 
in in vitro39,40 and ex vivo41,42 models as well as clinically with the transfusion or 
transplantation of cells (including platelets) cryopreserved with DMSO.43-45 
Compared to DMSO and glycerol, HES (membrane impermeable) incites minimal 
haemolysis in ovine RBCs by simple addition after 120 minutes (0.66 % ± 0.45 
%) at a concentration (17.7 wt% (low molar concentration)) that has a proven 
cryoprotective effect.46-48 Therefore going forward HES was the established 
cryoprotectant used in future experimentation. The HES preparation selected in 
this instance was isolated from the previously clinically utilized plasma expander, 
Volulyte® (Fresenius Kabi Ltd, Cheshire, UK) which was used to combat 
hypovolemia which is the reduction in blood volume often as a consequence of 
severe trauma.49 Volulyte® is provided as a 6 wt% isotonic solution (composition 
and structure in Figure 3.4.A and Figure 3.4.B) hence necessitating its 
purification and concentration (Section 3.5.1.). HES is prepared as a 
polydispersed compound and frequently characterized by its average MW (130 
kDa), degree of substitution (0.4) and C2/C6 substitution ratio (≈9:1). Numerous 
preparations ranging from 70 kDa and 670 kDa with degrees of substitution from 
0.4 to 0.75 are available. These different preparations have assorted efficacies 
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and varied pharmacodynamic and pharmacokinetic profiles with the latest 
generation of HES products have tended to focus on lower MWs.50 HES is a non-
IRI active and non-membrane permeable compound at reasonably low 
concentrations with a % MLGS of 87.9 % ± 6.0 % at 10 mg/mL (0.157 [OH]\L) 
(Figure 3.4.C). At the concentrations used in cryopreservation (> 30 mg/mL), 
HES alters viscosity51 and at higher concentrations limits ice crystal formation 
forming gel like particles (Figure 3.4.D),52 though these changes in solubility are 
likely to be influenced by MW.53,54 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Cytotoxicity of the cryoprotectant DMSO to human and ovine 
RBCs. (%) Cell recovery of cells (human (200 µL) and ovine (1mL)) incubated 
with varying concentrations of DMSO for 60 minutes (A), 150 minutes (B) and 
300 minutes (human only) (C) at 23 °C. Each data point was measured (mean) in 
quintuplicate with the error bars representing ± standard deviation. 
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Figure 3.4.  Ice recrystallization inhibition activity and composition of HES. 
A) Composition of Volulyte® solution. B) Structure of HES derived from Volulyte®. 
C) Quantitative assessment of IRI activity of HES, relative to PBS solution alone. 
D) Cryomicroscopic images showing influence of HES on ice crystal growth, 
following 30 minutes at – 6 °C, highlighting at high concentrations the inhibition of 
ice crystal formation from top left clockwise 10 mg/mL, 30 mg/mL, 100 mg/mL 
and 215 mg/mL HES. Data presented as (N=3) % mean largest grain size 
relative to PBS. Error bars represent ± SD.  
 
3.3.3. Cryopreservation of Ovine RBCs with HES. 
 
To reiterate literature statements and to form a basis upon which improvements 
in cell recovery could be established, HES was utilized in its capacity as a 
cryoprotectant of RBCs.54,55 Several studies have examined the use of HES 
 	  	   145	  
(albeit with different HES preparations) in the cryopreservation of human and 
canine RBCs at concentrations ranging from 2.5 wt% to 22.5 wt% with notable 
success even with large volumes of clinical relevance (470 mL).47,48,56 
Furthermore it has been demonstrated in a small clinical trial that HES 
cryopreserved human RBCs can be successfully transfused autologously.46 
Small (100 µL) suspensions of RBCs diluted two-fold with HES at final 
concentrations between 46 mg/mL – 215 mg/mL (4.4 wt% - 17.7 wt%) were 
frozen rapidly (N2(l) (-196 °C) for 180 seconds) from 23 °C. The use of a high 
freezing rate promoted the rapid nucleation of many small yet tolerable 
extracellular ice crystals, which were uninfluenced by the presence of HES (i.e. 
not vitrified). RBCs were then thawed rapidly (45 °C water, 600 seconds) limiting 
ice recrystallization and cryodamage. Cell recovery was measured against 
untreated RBCs (100 % cell recovery) and RBCs frozen without HES in (inciting 
osmotic shock) H2O(l) (0 % cell recovery). A concentration dependant relationship 
was observed with ovine cell recovery highest (51.4 % ± 13.2 %) at 215 mg/mL 
decreasing with concentration to effectively no recovery at 46 mg/mL (1.8 % ± 
5.1 %) the lowest concentration examined (Figure 3.5.A). The cryopreservation of 
human RBCs was performed using an identical cryopreservation strategy albeit 
with a different range of HES concentrations ranging from 70 – 215 mg/mL (6.5 
wt % - 17.7 wt%) and larger volumes (200 µL). A similar concentration 
dependency is observed but the maximal level of cell recovery is even higher 
than with ovine RBCs when using 215 mg/mL HES (81.8 % ± 5.7 %) (Figure 
3.5.B). Microscopy studies of the ultrastructure of human RBCs from literature 
suggests the absence of intracellular ice with cryopreservation again more 
effective at higher concentrations (14 wt%).57 However for the prolonged storage 
(5 days) of human RBCs using HES (12 wt%) a strong and significant factor 
determining cell recovery was storage temperature with the lowest storage 
temperature of -16 °C inciting a near complete loss of cell recovery after 120 
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hours where as with storage at -75 °C cell recovery was approximately 80%, 
which is only slightly lower than the short term recoveries (85%) observed under 
similar conditions. Intermediate storage temperatures were shown to have cell 
recoveries between these values.58 The effect of storage temperature on cell 
recovery provides further evidence that HES does not limit ice crystal growth and 
prevent the associated damage it causes. Demonstrating that HES does not limit 
ice crystal growth is key as there is a continual importance in reducing 
cryopreservation storage temperatures. Reducing storage temperature is 
important, as the demand for and volumes of clinically relevant blood products is 
significantly higher than other biological materials especially in environments with 
logistical difficulties. The scale of which can be emphasized by the transfusion of 
over 140,000 units of fresh RBCs in both Afghanistan and Iraq between 
November 2001 and December 2010 by the US military necessitating twice 
weekly flights of fresh blood products sourced and collected from the continental 
US.23 Currently only the Netherlands Armed Forces routinely cryopreserves 
RBCs and other blood products in such scenarios but using glycerol and DMSO 
(platelets) as opposed to HES.24 The recent withdrawal of HES59 as a plasma 
expander and controversy60 regarding several studies investigating the safety of 
HES means it is unlikely to be developed further as a clinically utilized 
cryoprotectant in the near future, thus alternatives that reduce or eliminate the 
dependency of organic solvents remains a difficult task but would yield far spread 
benefits. 
 	  	   147	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Figure 3.5. Cryopreservation of RBCs using HES. (A) (%) Cell recovery of 
ovine RBCs (100 µL) supplemented with various concentrations (46 – 215 
mg/mL) of HES. (B) (%) Cell recovery of human RBCs (200 µL) supplemented 
with various concentrations (70 mg/mL – 215 mg/mL) of HES. Cells were frozen 
(-196 °C N2(l), 180 seconds) and thawed rapidly (45 °C water, 600 seconds). Each 
data point was measured (mean) in quintuplicate with the (whiskers) error bars 
representing ± standard deviation and the upper and lower box limits the upper 
and lower quartiles. 
 
As aforementioned a rapid thawing strategy was used in order to minimize the 
damage arising from ice recrystallization. However cryodamage derived from ice 
recrystallization can be illustrated by cryopreserving ovine RBCs in the presence 
of 215 mg/mL and 130 mg/mL HES and thawing at various rates including those 
that encourage ice recrystallization. During this process a rapid (but different) 
freezing rate (IPA(l)/CO2(s) (-78 °C)) was again utilized in order attenuate ice 
crystal growth during freezing enabling rapid nucleation and the presence of only 
small but tolerable extracellular ice crystals, thus minimizing damage during 
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freezing and focusing principally on damage arising during thawing. The 
relationship of ice crystal size and freezing rate has been previously discussed 
and illustrated in Figure 2.21. The highest thawing rate (45 °C water) yielded 
substantially higher levels of cell recovery (77.6 % ± 6.2 % and 42.8 % ± 9.5 % at 
215 mg/mL and 130 mg/mL respectively) than either of the significantly slower 
(23 °C air and 4 °C air) thawing rates that promote ice recrystallization61 as seen 
in Figure 3.6. Thawing at a modest 23 °C elicited significant ice recrystallization 
derived cryodamage, depressing cell recovery nearly 4-fold in a 130 mg/mL HES 
solution from 42.8 % ± 9.5 % to 11.7 % ± 10.1 %. Thawing cells at an even 
slower rate (4 °C) did not further alter cell recovery significantly (16.2 % ± 8.6 %) 
highlighting that extensive ice recrystallization damage can arise from even 
moderate thawing rates. At the higher concentration tested (215 mg/mL HES) the 
damaging effect of slow thawing was still significant with comparable losses 
equating to approximately 30 % of the total cell population due to ice 
recrystallization. It is worth highlighting (as previously noted) that greater volumes 
(1 unit = 470 mL) more relevant to clinical scenarios62,63 would have a larger 
extent of heterogeneous thawing and thus may be expected to be even more 
susceptible to ice recrystallization derived cryodamage. Limiting the impact of ice 
recrystallisation is especially important when samples are thawed incorrectly or in 
environments where rapid controlled thawing is not easily available. 
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Figure 3.6. Impact of thawing temperature (°C) on ovine RBC 
cryopreservation. (%) Cell recovery of ovine RBCs (100 µL) supplemented with 
either 0, 130 or 215 mg/mL HES in PBS after cryopreservation (-78 °C 
CO2(s)/IPA(l), 60 seconds/ -78 °C CO2(s), 20 minutes) with an either a rapid (45 °C 
water, 600 seconds), slow (23 °C air, 45 minutes) or very slow (4 °C air, 150 
minutes) thawing rate. Each data point was measured (mean) in quintuplicate 
with the (whiskers) error bars representing ± standard deviation and the upper 
and lower box limits the upper and lower quartiles. Statistical difference (*) (p < 
0.05) as determined by the Students t-test. 
 
3.3.4. Cryopreservation of Ovine RBCs with HES supplemented 
with PVA. 
 
Cryodamage from ice recrystallization significantly reduces the recovery of ovine 
RBCs (Figure 3.6). Therefore the addition of IRI active compounds attenuating 
ice recrystallization in vitro may improve cell recovery during cryopreservation by 
eliminating or dampening this mechanism of cryodamage. However as previously 
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reported with the use of recombinant AFPs I, II and III and a synthetic AF(G)P 
mimic in conjunction with HES in the cryopreservation of human RBCs a balance 
must be sort between IRI and DIS.64-66 DIS can greatly increase mechanical 
damage outweighing the benefits that IRI provides. Further work using site-
directed mutagenesis67 to influence the IRI and DIS activity of a recombinant 
(Macrozoarces americanus) AFP III appeared to agree with this hypothesis.65  
 
To examine the effect of PVA addition, RBCs were cryopreserved with 130 
mg/mL HES. 130 mg/mL HES had the most significant fold reduction in cell 
recovery due to ice recrystallization and thus was examined with and without a 
comparatively low concentration (10 mg/mL) of 9 kDa PVA. 10 mg/mL 9 kDa 
PVA has a very strong IRI activity (Figure 2.14.) suppressing ice recrystallization 
(Chapter 2). Furthermore 9 kDa PVA is not cytotoxic with ovine RBCs stored with 
15 mg/mL 9 kDa PVA at 4 °C for 6 days eliciting a haemolytic value of 2.3 % ± 
1.6 % which is not significantly different to ovine RBCs stored under the same 
conditions for a comparable length of time (7 days and a haemolytic value of 3.4 
% ± 0.7 %) in the absence of 9 kDa PVA (Figure 3.7.). No notably elevated levels 
of haemolysis are detected with the addition of 15 mg/mL 9 kDa PVA to human 
RBCs either over a comparable time frame but it must be noted that the storage 
of human RBCs (as with ovine RBCs (Figure 3.1.)) in simple isotonic solutions 
tends to a greater rate of haemolysis. Furthermore 9 kDa PVA (membrane 
impermeable) functions purely as an extracellular CPA meaning its removal 
would be inline with HES if indeed at all necessary68 and therefore far more trivial 
than glycerol and other intracellular CPAs.69 
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Figure 3.7. Cytotoxicity of 15 mg/mL 9 kDa PVA to ovine RBCs. Cytotoxicity 
of 15 mg/mL 9 kDa PVA to ovine RBCs after 6 days in a simple isotonic solution 
stored at 4 °C. Each data point was measured (mean) in triplicate with the error 
bars representing ± standard deviation. 
 
The addition of 10 mg/mL 9 kDa PVA did improve cell recovery when ovine 
RBCs were cryopreserved with 130 mg/mL HES but perhaps even more 
remarkably is that the presence of 9 kDa PVA alone in the absence of HES 
elicited a comparable amount of cell recovery as illustrated in Figure 3.8. 
Nevertheless the overall level of cell recovery is reasonably low (19.9 % ± 6.1 %) 
and not to clinical standards the comparatively small amounts of 9 kDa PVA 
needed to attain this effect compared to traditional CPAs does create much 
intrigue and promise. Further refinements in terms of PVA concentration, 
haematocrit and the freezing and thawing strategy in addition to changes in MW 
and hydrolysis could allow additional improvements. The investigation of 
branched and star polymer derivatives and PVA (block) copolymers may also 
yield even more potent IRI compounds. Further development could emphasize 
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the importance of PVA as a supplement to traditional cryoprotectants and with 
the possibility of substituting significant amounts of intracellular CPAs for small 
quantities of PVA. However under these conditions the presence of both 130 
mg/mL HES and 10 mg/mL 9 kDa PVA does not lead to a cumulative level of cell 
recovery (14.7 % ± 10.5 %) indicative of non-complimentary mechanisms. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Cryopreservation of ovine RBCs supplemented with 130 mg/mL 
HES and/or 10 mg/mL 9 kDa PVA. Rapid (-78 °C CO2(s)/IPA(l), 60 seconds/ -78 
°C CO2(s), 20 minutes) freezing with a slow (23 °C air, 45 minutes) thawing rate. 
Each data point was measured (mean) in quintuplicate with the (whiskers) error 
bars representing ± standard deviation and the upper and lower box limits the 
upper and lower quartiles. Statistical difference (*) (p < 0.01) as determined by 
the Students t-test. 
 
The previous work of Carpenter et al that as aforementioned used AFP I in 
conjunction with HES highlighted that high concentrations of AFP I (1.54 mg/mL) 
actually decreased cell recovery and that a moderate concentration of AFP I that 
still retained significant IRI activity had the greatest benefit.64 Therefore it was 
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hypothesized that reducing the concentration of 9 kDa PVA whilst lowering IRI 
marginally but still retaining significant activity may have a similar effect and thus 
the optimal concentration of 9 kDa PVA may actually be lower than 10 mg/mL. 
Reducing 9 kDa PVA concentration has the obvious benefit of requiring even less 
cryoprotectant. This rationale is further strengthened by previous observations 
that have suggested that PVA can incite DIS in a concentration dependant 
manner.70,71 DIS has been attributed to the reduction in cryoprotection by 
promoting an increase in mechanical damage offsetting the benefits attained 
from IRI.64,72 This property has even been exploited by using AFP I 
(Pseudopleuronectes americanus) as a cryoadjuvant (4 mg/mL) in cryosurgery, 
significantly increasing ablation in subcutaneous tumors but only after a double 
freeze treatment.73 Therefore ranges of 9 kDa PVA concentrations from 0.5 
mg/mL to 10 mg/mL were investigated as illustrated in Figure 3.9. Concentrations 
greater than 10 mg/mL were not considered as at concentrations higher than this 
difficulties in solubility without heating beyond 37 °C would be encountered 
without an appreciable increase in IRI activity, highlighting the importance of 
other physiochemical properties in developing novel IRI active compounds.61 A 
similar rationale was responsible for choosing 9 kDa PVA as opposed to 31 kDa 
PVA or 85 kDa PVA, which are other commercially available preparations of 
comparable cost. It must be noted that decreasing the MW of PVA does have a 
consequential effect on IRI but that this effect is only significant with PVA at a 
MW lower than 6.5 kDa. The extent of PVA hydrolysis is also important as 
acetylation greater than 20 % also results in a reduction in IRI activity.74 
Reducing the concentration of 9 kDa PVA did result in improved cell recoveries 
as illustrated in Figure 3.9. 1 mg/mL 9 kDa PVA conferred the greatest cell 
recovery (40.2 % ± 5.1 %) under the same conditions examined with a 
progressive reduction in cell recovery at concentrations higher than this. At 0.5 
mg/mL 9 kDa PVA whereby a significant reduction in IRI activity begins (Figure 
 	  	   154	  
2.17.) cell recovery begins to decrease (36.7 % ± 11.6 %). Furthermore RBCs 
cryopreserved with 8 kDa PEG (non-IRI active (Figure 2.14.)) had minimal 
cryoprotective effect at comparable concentrations furthering strengthening that 
the IRI activity of 9 kDa PVA contributes to improved cryoprotection and 
enhanced cell recovery. 
 
Figure 3.9. Cryopreservation of ovine RBCs with either 9 kDa PVA or 8 kDa 
PEG.  (%) Cell recovery of ovine (1 mL) supplemented with either (A) 9 kDa PVA 
(0.5 – 10 mg/mL) or 8 kDa PEG (1 – 5 mg/mL) after cryopreservation (-78 °C 
CO2(s)/IPA(l), 60 seconds/ -78 °C CO2(s), 20 minutes) with a slow (23 °C air, 30 
minutes) thawing rate. Each data point was measured (mean) in quintuplicate 
with the (whiskers) error bars representing ± standard deviation and the upper 
and lower box limits the upper and lower quartiles. Statistical difference (*) (p < 
0.01) as determined by the Students t-test. 
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3.3.5. Cryopreservation of Human RBCs with HES 
supplemented with PVA. 
Though ovine RBCs provide an easily accessible and affordable model for 
human RBCs, notable differences are present in the RBCs of these two 
species.35 Differences between species are as aforementioned include 
membrane permeability and cell size, which for instance affect the toxicity of 
glycerol and DMSO (Figure 3.2. and Figure 3.3.). Fundamentally though such 
difference are not apparent with the extracellular CPAs HES or PVA that have no 
detrimental effect under similar conditions. Therefore it was critical to assess 
whether or not similar supplementation of 9 kDa PVA could attain improvements 
in the recovery of human RBCs. It has already been demonstrated that the 
cryopreservation of human RBCs using HES is dependant upon HES 
concentration (Figure 3.5.B). The similar susceptibility of human RBCs to ice 
recrystallization damage during slow thawing is also apparent (Figure 3.10.). The 
addition of 1 mg/mL 9 kDa PVA to 215 mg/mL HES did result critically, in an 
elevated level of cell recovery (60.2 % ± 14.9 %) compared to 215 mg/mL HES 
alone (26.0 % ± 12.5 %), though the improvement was still below the cell 
recovery attained when cells were thawed rapidly minimizing IR (81.8 % ± 5.7 %) 
as demonstrated in Figure 3.11. The use of both HES and 9 kDa PVA represents 
a remarkable level of recovery and closely reflects the results of others with a 
similar haematocrit and HES concentration but with the substitution of AFPs or a 
synthetic AF(G)P mimic for 9 kDa PVA.64-66 AFPs as already noted are hard to 
isolate or produce recombinantly on a large scale and synthetic AF(G)P mimics 
have only been produced in small quantities where as PVA is routinely 
synthesised on a tonne scale, with a proven biodegradability and biocompatibility 
as a foodstuff.75,76 PVA therefore has great potential as an extracellular CPA with 
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possible application to a wide variety of biological materials and is explored in 
this context in the following chapters (Chapter 4 and 5). 
 
 
 
 
 
 
 
 
 
Figure 3.10. Impact of thawing temperature (°C) on human RBC 
cryopreservation. (%) Cell recovery of human RBCs (200 µL) supplemented 
with either 70 mg/mL, 170 mg/mL or 215 mg/mL HES after cryopreservation (-
196 °C N2(l), 180 seconds) with an either a rapid (45 °C water, 600 seconds) or 
slow (23 °C air, 45 minutes) thawing rate. Each data point was measured (mean) 
in quintuplicate with the error bars representing ± standard deviation. 
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Figure 3.11. Cryopreservation of human RBCs supplemented with 215 
mg/mL HES and/or 1 mg/mL 9 kDa PVA. (%) Cell recovery of human RBCs 
(200 µL) supplemented with 215 mg/mL HES with or without 1 mg/mL 9 kDa PVA 
after cryopreservation (freeze (N2l) / 180 seconds)) with either a rapid (45 °C, 
water bath / 600 seconds) or slow (23 °C, air / 900 seconds) thawing rate. Each 
data point was measured (mean) in quintuplicate with the error bars representing 
± standard deviation. Statistical difference (*) (p < 0.01) as determined by the 
Students t-test. 
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3.4. CONCLUSIONS. 
 
9 kDa PVA has been successfully demonstrated to have no significant 
cytotoxicity at concentrations that have a proven IRI activity (Chapter 2) to ovine 
and human RBCs. Conversely both the organic solvents DMSO and glycerol 
which are popular cryoprotectants (with a range of biological materials) showed 
substantial cytotoxicity at concentrations far lower than that necessary for 
reported cryoprotection when added and mixed directly. The polysaccharide HES 
that has a demonstrable cryoprotective effect showed no cytotoxicity but has 
been shown to possess substantial clinical side effects in vivo in its primary role 
as a plasma expander, which has resulted in its withdrawal in the EU and USA 
signifying the need for novel cryoprotectants. The impact of slow thawing was 
also confirmed to be highly detrimental even at moderate thawing rates to both 
ovine and human RBCs emphasizing the impact of ice recrystallization derived 
cryodamage. 9 kDa PVA alone was able to cryopreserve a significant proportion 
of ovine RBCs subjected to slow thawing with an optimum concentration of 1 
mg/mL. Concentrations higher than this resulted in reduced cell recoveries that 
were attributed to a potential DIS activity of 9 kDa PVA mirroring findings in 
literature that use AFPs. Furthermore HES (215 mg/mL) supplemented with 9 
kDa PVA (1 mg/mL) was able to substantially improve the cell recovery of human 
RBCs subjected to a harmful slow thawing rate. These results prove the ability of 
small concentrations of the extracellular polymer 9 kDa PVA to attenuate ice 
crystal growth promoted by the use of slow thawing in vitro and limit this 
mechanism of cryodamage to enhance overall cell recovery. 
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3.5. MATERIALS AND METHODS. 
 
3.5.1. Purification of HES, PVA and PEG. 
 
HES, 9 kDa PVA and 8 kDa PEG were prepared using the methodology listed in 
Section 2.5.2. 
 
3.5.2. Preparation of Ovine RBCs. 
 
A suitably sized aliquot of (haematocrit 32 % - 52 %) ovine (Ovis aries) RBCs 
(defibrinated) as supplied (TCS Biosciences Ltd, Oxfordshire, UK) and shipped 
overnight was centrifuged (23 °C, 10 minutes, 1950 x g) and the top layer 
(containing any residual plasma with all its constituents) removed. The top layer 
was immediately replaced with an equivalent volume of PBS. Ovine RBCs were 
then used immediately or stored at 4 °C for a maximum of 1 week (haemolysis 
3.7 % ± 0.7 %). Immediately prior to use ovine RBCs were mixed by inversion to 
ensure a homogenous suspension of cells. 
 
3.5.3. Preparation of Human RBCs. 
 
Human RBCs were sourced from healthy male volunteers with informed consent 
on demand and collected in polypropylene 6mL EDTA vacutainers® (BD Ltd, 
Oxford, UK) to prevent coagulation. Aliquots were then centrifuged (23 °C, 10 
minutes, 1950 x g) and the top layer containing plasma and other constituents 
removed and replaced with an equivalent volume of PBS. Human RBCs were 
then used immediately or stored at 4 °C for a maximum of 3 days on a SRT2 
roller mixer (Bibby Scientific Limited, Stone, UK) to ensure a homogenous 
suspension of cells. 
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3.5.4. Haemolysis measurement of Ovine RBCs stored at 4 °C 
and 23 °C. 
 
Upon delivery 50 mL aliquots of ovine RBCs were prepared as described 
previously and stored statically at the appropriate temperature. For each data 
point 50 µL aliquots in triplicate were diluted in 50 µL PBS and vortexed 
rigorously. A 20 µL aliquot was then diluted in 200 µL PBS and vortexed 
meticulously before centrifugation (23 °C, 5 minutes, 1950 x g). 50 µL of 
supernatant was then transferred to 150 µL PBS in duplicate in a clear flat bottom 
96-well polystyrene plate and absorbance measured at 450 nm using a Multiskan 
ascent plate reader (Thermo-scientific Ltd, Hampshire, UK). A background value 
of 200 µL PBS was recorded and subtracted to give a final absorbance value with 
the mean and standard deviation reported (Figure 3.1.). This generated data that 
enabled the calculation of both (%) cell recovery and (%) haemolysis. (Equations 
3.1.A and 3.1.B.). The absorbance value attained on day 1 was taken as 0% 
haemolysis. A mean value for 100% haemolysis was calculated in parallel by 
preparing samples in triplicate with H2O(l) instead of PBS to induce osmotic shock 
and therefore total haemolysis. Samples were taken a regular intervals over 
either a 35 or 42 day period to monitor the extent of haemolysis when stored 
unagitated at 4 °C and 23 °C. 
A     (%) Haemolysis = 
  
€ 
Abs ( 450nm) (Sample) −Abs ( 450nm) (0%)[ ]
Abs ( 450nm) (100%)−Abs ( 450nm) (0%)[ ]
 
B     (%) Cell Recovery = 100 % - (%) Haemolysis 
 
Equation 3.1. Equations used to calculate (A) (%) Haemolysis and (B) (%) 
Cell Recovery of ovine and human RBCs. 	  
 	  	   161	  
3.5.5. Measurement of Glycerol, DMSO, HES and PVA 
cytotoxicity in Ovine and Human RBCs. 
 
Freshly prepared aliquots of ovine and human RBCs were diluted in quintuplicate 
in an equal volume of analyte prepared at an appropriate concentration in PBS to 
give a total volume ranging between 100 µL and 1000 µL (as indicated in the 
main text). Samples were then vortexed to ensure homogeneity and gently 
agitated (200 rpm) for 120 minutes (or longer where specified) at 23 °C with 
haemolysis measured as described previously. Samples that were deemed 
cytotoxic (10 % haemolysis or above) were repeated at a lower concentration 
over a shorter duration such that a range of concentrations and durations are 
reported to highlight any significant cytotoxicity. 
 
3.5.6. Cryopreservation of Ovine and Human RBCs with HES. 
 
Freshly prepared ovine and human RBCs were diluted in quintuplicate in an 
equal volume of HES in PBS to a desired final concentration ranging between 46 
mg/mL – 215 mg/mL to a volume of 100 µL (ovine) or 200 µL (human) prior to 
vortexing. Samples were then rapidly cooled as desired either in N2(l) for 180 
seconds prior to thawing or an IPA(l)/CO2(s) slurry (-78 °C) for 60 seconds and 
then CO2(s)  for 20 minutes prior to thawing. Samples were either thawed at 45 °C 
(water), 23 °C (air) or 4 °C (air) as described in the main text before (%) cell 
recovery was measured as described previously and compared with 
(unprotected) treated (0 % cell recovery) and untreated (100 % cell recovery) 
H2O and PBS controls respectively with the mean and standard deviation 
reported (Equation 3.1.). 
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3.5.7. Cryopreservation of Ovine and Human RBCs with HES 
and/or 9 kDa PVA. 
 
Freshly prepared ovine and human RBCs were diluted in quintuplicate in an 
equal volume of HES and/or 9 kDa PVA in PBS to a desired final concentration 
(as indicated in Figure 3.8. and 3.11.) to a volume of 100 µL (ovine) or 200 µL 
(human) prior to vortexing. Samples were then rapidly cooled in an IPA(l)/CO2(s) 
slurry (-78 °C) for 60 seconds and then CO2(s)  for 20 minutes (ovine and human) 
or in N2(l) (-196 °C) for 180 seconds (human) prior to thawing at 45 °C (water, 600 
seconds), or 23 °C (air, 45 minutes) to modulate either rapid and slow thawing. 
(%) Cell recovery was then calculated using aforementioned methodologies 
(Equation 3.1.). 
 
3.5.8. Cryopreservation of Ovine RBCs with 9 kDa PVA or 8 
kDa PEG. 
 
Freshly prepared ovine RBCs were diluted in quintuplicate in an equal volume of 
9 kDa PVA  (ovine and human) or 8 kDa PEG (ovine) in PBS to a desired final 
concentration ranging between 0.5 mg/mL – 10 mg/mL (as indicated in Figure 
3.9.) to a volume of 1 mL (ovine) or 200 µL (human) prior to vortexing. Samples 
were then rapidly cooled in an IPA(l)/CO2(s) slurry (-78 °C) for 60 seconds and then 
CO2(s)  for 20 minutes prior to thawing at 23 °C (air / 45 minutes). (%) Cell 
recovery was then calculated using aforementioned methodologies (Equation 
3.1.). 
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CHAPTER 4.  
 
4. ICE RECRYSTALLIZATION INHIBITORS 
IMPROVE THE CRYOPRESERVATION OF 
IMMORTALIZED CELL LINES. 
 
4.1. CHAPTER SUMMARY.   
 
The application of poly(vinyl alcohol) (PVA) that has been previously identified 
(Chapter 2) as a potent ice recrystallization inhibition (IRI) active compound is 
explored as a cryoprotectant for immortalized mammalian cell lines namely A549, 
BeWo and FAO cells. Mammalian cell lines are frequently used as models for a 
multitude of diseases where primary material is scarcely available, as they can 
be grown quickly with reproducible and defined phenotypic characteristics and 
can also undergo extensive genetic manipulation. The supplementation of low 
concentrations (≤ 2 mg/mL) of 9 kDa PVA to high concentrations of DMSO (≥ 4 
% (v/v)) aids the cryopreservation of each cell type. Each cell variety was 
examined under several experimental conditions and where tested were able to 
undergo complex modifications that invoke changes in gene expression amongst 
standard several measures of viability. Higher concentrations (10 mg/mL) of 9 
kDa PVA in addition to 1 mg/mL 31 kDa PVA were detrimental to the 
cryopreservation process and cause a significant reduction in cell recovery 
compared to cryopreservation in the complete absence of any additives. This is 
due to their tendency to promote DIS at these concentrations despite not being 
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cytotoxic at concentrations far greater than this at physiological (37 °C) 
temperatures. 
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4.2. INTRODUCTION. 
 
The importance of mammalian cell culture in research and development is highly 
significant, with attempts to culture mammalian tissue explants dating back one 
hundred years.1,2 However not until the routine availability of complex cell 
mediums was the establishment of a variety of (immortalized) mammalian cell 
lines possible.3 In the present day, the European collection of cell cultures 
(ECACC) for example contains over 40,000 cell lines from 45 species and 50 
tissue types representative of 800 genetic disorders.4 Many cell lines have been 
developed as in vitro models for a multitude of diseases due to their reproducible 
genotypes and phenotypes, especially in the fields of oncology and 
neurobiology.5-7 Furthermore cell lines can be cultured to produce cells in vast 
quantities quickly and numerous techniques exist that enable extensive genetic 
manipulation.8,9 As a result of their versatility there is a sustained interest to use 
mammalian cell lines recombinantly to produce therapeutics that cannot be 
produced in simpler bacterial and yeast species due to their inability to perform 
complex posttranslational modifications.10-13 Additionally an extensive array of 
high throughput assays have been developed that measure the viability, 
proliferation and functionality of cultured cells by a range of analytical endpoints 
that investigate both apoptotic and necrotic cell death pathways.14-20  
 
The importance of cryopreservation can be accentuated by the high cost of 
continuous propagation, the likelihood of microbial and cross contamination in 
addition to genetic drift that occurs with ceaseless passaging causing non-
representative phenotypic changes.21,22 Techniques and protocols to 
cryopreserve cultured mammalian cells have however remained relatively 
unchanged with a continued reliance on the organic solvent, DMSO. Compared 
to advances in their application, the overall yields of cells recovered post 
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cryopreservation tends to have had relatively little improvement. Though a great 
clinical need for red blood cells (Chapter 3) is immediately apparent their relative 
availability from source as well as their comparative robustness to physical 
stimuli and simplicity due to their non-nucleated nature separates them from 
mammalian cell cultures. Differences that can be highlighted fundamentally by 
the preference for DMSO (mammalian cell culture) as opposed to glycerol 
(RBCs) as the membrane CPAs of choice reflected somewhat by their 
distinctively different membrane compositions and permeabilities.23 Mammalian 
cell lines contain nucleic material and thus undergo mitosis, which is a highly 
regulated and intricate process. The majority of mammalian cell lines are derived 
from oncogenic tissues, which by their very nature tend to arise from errors in cell 
division. As a consequence the majority of immortalized cell lines are aneuploid 
(containing an abnormal karotype). For instance the popular HEK 293 cell line 
has an average of 64 chromosomes per cell including 4 copies of chromosomes 
17 and 22 with the equally prevalent Caco-2 and MCF7 cell lines possessing 
chromosomal counts of 96 and 82 respectively and therefore their complexity is 
far greater than red blood cells.24-27 This complexity may be reflected in their 
sensitivity to cryopreservation treatments. 
 
A vital principle to clarify is the differences between the two main mechanisms of 
cell death, necrosis and apoptosis. Necrosis can be defined as the physical 
destruction or loss of cell integrity due to extremes in the prevailing cell 
environment such as pH, temperature and osmotic pressure.28 In contrast 
apoptosis is a controlled system of programmed cell death activated in senescent 
cells as a consequence of damage spontaneously accumulated from their native 
surroundings.29,30 The initiation of apoptosis is triggered biochemically by a 
variety of signaling cascades. Apoptosis can also be inadvertently activated by 
environmental stresses and the presence of other damaged or destroyed cells 
that perturb cellular homeostasis, which is of particular importance in 
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cryopreservation.31,32 However apoptotic pathways in mammalian cell lines have 
a propensity to be adversely effected due to their oncogenic nature. As a 
consequence of this and other previously aforementioned factors immortalized 
cell lines cannot substitute the use of primary cells entirely but have greater 
reproducibility and a wealth of literature to draw upon historically. Mammalian cell 
culture therefore remains a powerful investigative tool. 
 
Few studies have investigated the use of cryopreservatives other than 
extracellular CPAs such as a DMSO with immortalised mammalian cells, fewer 
still with properties akin to AF(G)Ps and AFPs. A few exceptions include a study 
by Liu et al. who demonstrated the cytotoxicity of AF(G)P8 to HEK 293 (human) 
cells but AF(G)P8 was well tolerated by Rtgill-W1 (fish (non-mammalian)) and 
WRL-68 (human) cells.33 Chaytor et al. later showed the impact of moderate IRI 
active monosaccharides and disaccharides on the cryopreservation of WRL-68 
cells and were able to eliminate DMSO and attain comparable levels of cell 
recovery. However these protocols still necessitated high concentrations of 
cryoprotectant, though inherently impermeable these compounds can be readily 
internalised by a variety of transmembrane transporters.34 Critically though the 
work of Leclère et al. showed the effect of two C-linked AF(G)P analogues, which 
had a more pronounced IRI activity were able to cryopreserve WRL-68 cells. As 
seen with the use of PVA with RBCs (Chapter 2) increasing the concentration of 
each analogue corresponded with a decrease in recovery. These results give 
promise that the attenuation of ice recrystallization with PVA may allow 
improvements in cell recovery but in a concentration dependant manner.35,36 
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4.3. RESULTS AND DISCUSSION. 
 
4.3.1. Cytotoxicity of DMSO to lung adenocarcinoma (A549) 
cells. 
 
For the cryopreservation of mammalian cells the cryoprotective agent (CPA) of 
choice is DMSO but it is often required at concentrations as high as 10 % (v/v).37 
However it is well documented that high concentrations of DMSO can have 
adverse effects on cell integrity at physiological temperatures.38,39 Therefore it is 
important to assess the ability of DMSO to cause lysis at physiological (37 °C) 
temperatures. The reasoning being that when cells have been thawed and plated 
a notable amount of DMSO will persist especially if the cells cannot be 
centrifuged and washed prior. Only when sufficient time has allowed cells to 
adhere can the medium containing DMSO be removed and exchanged. As a 
consequence cells will be exposed to significant amounts of DMSO at 
physiological (37 °C) temperatures. A549 cells (Figure 4.1.A) are a frequently 
utilized cell line derived from a lung adenocarcinoma patient 40 years ago and 
often used as a model for type II alveolar epithelial cells and is a typical and 
representative cell line to investigate initially.40,41 Figure 4.1.B highlights the 
relative amounts of (confluent) A549 cells recovered after a 4 hour incubation 
with 0 % (v/v) – 20 % (v/v) DMSO quantified by the MTT (metabolism) and 
neutral red (NR) (compartmentalization) assays (Section 4.5.7 and Section 
4.5.8). A strong correlation between DMSO (% (v/v)) concentration and recovery 
was attained. For example cell recoveries of 74.9 % ± 9.5 % (MTT) and 80.3 % ± 
1.8 % (NR) were obtained with 5 % (v/v) DMSO which is a significant reduction in 
cell number over a relatively short time period. To further emphasize the impact 
of DMSO a low density of A549 cells were incubated over a 3 day period to 
assess the relative population of cells as a consequence of the supplementation 
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of DMSO between 0 % (v/v) – 6 % (v/v) DMSO (Figure 4.1.C). A low density of 
cells was used in order to ensure that within this time frame A549 cells did not 
attain a confluent state and were still undergoing exponential growth where 
possible. A substantial reduction in cell number was attained even at the low 
concentration of 2 % (v/v) DMSO with recoveries of 59.3 % ± 2.1 % (MTT) and 
77.2 % ± 5.5 % (NR). The supplementation of PVA (IRI active) may aid 
cryopreservation and thus reduce the amount of DMSO necessary to attain 
significant cell recovery and could be highly beneficial with respect to cell 
recoveries and have additional benefits with sensitive downstream 
applications.42,43 
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Figure 4.1. (%) Cell recovery of A549 cells exposed to various levels of 
DMSO at 37 °C. (A) Phase contrast micrographs demonstrating confluent A549 
cells (40x magnification (left) and 100x magnification (right)). (B) Confluent cells 
incubated for 4 hours with various concentrations of DMSO in triplicate and (C) 
Seeded (low density) cells incubated in triplicate for 3 days (to allow proliferation) 
in the presence of various concentrations of DMSO. Each concentration was 
assessed by both the MTT and NR assays and referenced against untreated 
controls. Values represent the mean of 3 wells each measured in duplicate with 
the error bars representing ± standard deviation.  
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4.3.2. Cryopreservation of lung adenocarcinoma (A549) cells. 
 
Current protocols typically recommend 10 % (v/v) DMSO for mammalian cell 
culture cryopreservation.37 A549 cells are however sold commercially as frozen 
aliquots containing 5 % (v/v) DMSO.44 As a consequence defining the optimum 
concentration (% (v/v)) of DMSO for cryopreservation provides a starting point for 
optimization prior to the addition of IRI active additives. Testing the cryoprotective 
effects of DMSO also serves to define the upper and lower limits at which point 
DMSO ceases to give feasible cell recoveries and provide target areas whereby 
the addition of IRI active compounds may be of benefit.45 Figure 4.2 shows the 
effect of A549 cells cryopreserved in an absence of medium as several studies 
have indicated a desire to remove or limit the presence of FBS46,47 with 
concentrations of DMSO up to 20 % (v/v) using a rapid freezing and slow thawing 
strategy (Section 4.5.5). A concentration of 4 % (v/v) DMSO was defined as the 
optimum concentration of DMSO for the (%) cell recovery of A549 cells (referred 
to as 100 %). The commonly cited concentration of 10 % (v/v) DMSO by contrast 
elicited lower cell recoveries of 65.1 % ± 24.8 % (MTT) and 34.3 % ± 21.8 % 
(NR) by comparison using these freezing and thawing parameters. DMSO is 
known to alter membrane plasticity and thus as a result perturb membrane 
integrity and therefore can cause cells to be more susceptible to lysis. This effect 
is especially apparent at physiologically relevant temperatures (Figure 4.1.). 
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Figure 4.2. Cryopreservation of A549 cells with various concentrations of 
DMSO. (%) Cell recovery of A549 cells cryopreserved with various 
concentrations of DMSO in PBS measured by both MTT and NR assays and 
referenced against the most effective concentration (4 % (v/v) DMSO). Values 
represent the mean of 2 cryovials each plated in 2 wells and measured in 
duplicate with the error bars representing ± standard deviation. 
 
Concentrations of 2 % (v/v) DMSO and lower and 15 % (v/v) DMSO and higher 
gave unacceptably low levels of recovered cells thus necessitating the presence 
of at least 3 % (v/v) DMSO.  In addition to the low levels of cells recovered the 
presence of non-viable cells or lysed but adherent cell debris may negatively 
affect proliferation and have detrimental effects on the remaining cell population 
in terms of the presence of apoptotic inducers and necrotic factors.48 As a result 
of the findings presented (Figure 4.2) all ongoing cryopreservation studies with 
A549 cells were conducted with 4 % (v/v) DMSO supplemented with or without 
various concentrations of IRI active additives in PBS. The cryopreservation of 
A549 cells supplemented with between 0 mg/mL and 10 mg/mL 9 kDa PVA was 
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examined (Figure 4.3.A). Thawing cells rapidly (37 °C, water) and thus limiting 
ice recrystallization gave the highest recoveries whereas identical components 
and conditions with the exception of a slow thawing rate (23 °C, air) caused a 
reduction in cell number.  A rapid thawing temperature of 37 °C is the 
temperature used in typical protocols and thus used here as opposed to 45 °C 
utilized in parts of chapter 2. A slow thawing rate emphasizes the impact of ice 
recrystallization in a similar manner to that illustrated with both ovine and human 
RBCs (Figure 3.6 and Figure 3.10). The addition of 1 mg/mL 9 kDa PVA however 
did appear to promote a greater level of cell recovery if only marginal in this 
scenario (113.8 % ± 16.0 % (MTT) and 106.7 % ± 21.0 % (NR)). Though even a 
marginal increase could be beneficial. Interestingly the addition of higher 
amounts of 9 kDa PVA that promotes a stronger IRI effect (Figure 2.17.) but at 
concentrations that are not cytotoxic (Figure 4.3.B) at physiologically relevant 
temperatures, results in a reduction in cell recovery. The extent of this reduction 
is concentration dependant with the addition of 10 mg/mL 9 kDa PVA proving to 
be exceptionally detrimental with cell recoveries of 44.1 % ± 3.3 % (MTT) and 
22.2 % ± 0.8 % (NR). This effect was observed in a similar fashion with ovine 
RBCs (Figure 3.9.A) and in several publications with AFPs49,50 and a synthetic 
AF(G)P mimic.51 A reduction in cell recovery has been attributed to an increase in 
mechanical damage due to the onset of dynamic ice shaping (DIS), with PVA 
shown to induce DIS activity at high concentrations but concentrations that are 
far higher than those required for an IRI effect.52 
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Figure 4.3. Cytotoxicity and cryopreservation impact of 9 kDa PVA on A549 
cells. (A) (%) Cell recovery of A549 cells cryopreserved with 4 % (v/v) DMSO 
supplemented with various concentrations of 9 kDa PVA in PBS measured by 
both MTT and NR assays. (B) Cytotoxicity of 25 mg/mL 9 kDa PVA on confluent 
cells incubated for 4 hours. Values represent the mean of 3 wells each measured 
in duplicate with the error bars representing ± standard deviation. Values 
represent the mean of 2 cryovials each plated in 2 wells and measured in 
duplicate with the error bars representing ± standard deviation. 
 
Having shown the effect of increasing 9 kDa PVA concentration on reducing cell 
recovery, it was important to assess if the addition of a PVA with a greater IRI 
(and DIS) activity at a similar concentration still provoked a reduction in cell 
recovery. Examining the effect of a more potent PVA at an equivalent mass 
concentrations is to ensure that the reduction in activity is not a direct 
consequence of simply introducing more PVA that could be limiting cell recovery 
by an otherwise unidentified effect, though at physiologically relevant 
temperatures 9 kDa PVA has been shown to be well tolerated (Figure 4.3.A). For 
that reason a cryopreservation experiment was undertaken with the more IRI 
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potent (Figure 2.17.) compound 31 kDa PVA at 1 mg/mL, which with 9 kDa PVA 
was beneficial. In addition to assessing the effect of the similar sized non-IRI 
isomer 8 kDa PEG. Figure 4.4.A shows crucially that the presence of 1 mg/mL 31 
kDa PVA is detrimental (27.7 % ± 2.2 %) whereas the presence of 1 mg/mL 9 
kDa PVA still retained a beneficial effect (124.6 % ± 3.3 %) in an independently 
conducted experiment separate from the data presented in Figure 4.3. In contrast 
1 mg/mL 8 kDa PEG had neither a beneficial nor detrimental effect (92.1 % ± 
20.6 %).  
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Cryopreservation of A549 cells with 9 kDa PVA, 31 kDa PVA, 8 
kDa PEG and lower DMSO (% (v/v)) concentrations. (A) 4 % (v/v) DMSO 
supplemented with or without 1 mg/mL of either 9 kDa PVA, 31 kDa PVA or 8 
kDa PEG in PBS or (B) A549 cells cryopreserved with one of 4 % (v/v) DMSO, 3 
% (v/v) DMSO or 3 % (v/v) DMSO with 1 mg/mL 9 kDa PVA in PBS. Each 
experiment was measured by the MTT assay. Values represent the mean of 2 
cryovials each plated in 2 wells and measured in duplicate with the error bars 
representing ± standard deviation. 
 
Figure 4.4. rationalises the need to further investigate the use of PVA as an IRI 
active cryoprotectant, especially as IRI activity has been shown to be heavily 
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influenced by both MW and hydrolysis.53 As the presence of DMSO was shown 
to promote lysis and slow proliferation rates an experiment was undertaken to 
assess whether reducing the concentration of DMSO which lowers cell recovery 
could be offset by the beneficial effects of adding 1 mg/mL 9 kDa PVA (Figure 
4.4.B). The effect of lowering DMSO content from 4 % (v/v) to 3 % (v/v) did yield 
a reduction in cell recovery (63.6 % ± 10.3 %), which was not significantly 
improved by the addition of 1 mg/mL 9 kDa PVA (67.0 % ± 3.2 %). Figure 4.4B 
shows the importance of DMSO in maintaining membrane plasticity (Chapter 
1).54,55 A 25 % reduction in DMSO concentration is likely to significantly alter 
membrane plasticity and cause cell loss during freezing there by lowering the 
number of (viable) cells that can be protected by IRI activity during thawing. The 
effect of PVA is independent of plasticity (and freezing) and thus it is unsurprising 
that IRI activity is unable to rescue cell recovery to the level observed when using 
4 % (v/v) DMSO. The localisation of PVA during the cryopreservation process in 
terms of whether or not PVA is membrane penetrative is of critical importance, as 
this will determine the ability of PVA to influence intracellular ice crystal 
growth.56,57 PVA localisation will influence the ease with which PVA can be 
removed post thaw. The presence of intracellular ice is highly destructive so to 
limit its growth would be highly desirable but this is offset by the ease and speed 
with which thawed cells need to be processed. This requires the removal of 
cryoprotectants which is intrinsically harder with membrane permeable CPAs58, 
but if PVA is membrane permeable its low concentration, biocompatibility and 
biodegradability may negate this issue.59,60 
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4.3.3. Uptake of FITC conjugated 9 kDa PVA in lung 
adenocarcinoma (A549) cells. 	  
It is important to assess whether or not PVA is able to penetrate (either actively 
or passively) immortalized cells and thus act as an intracellular CPA and impact 
the growth of intracellular ice, the presence of which is highly dependant on the 
cryopreservation protocol utilized.61 Fluorescein isothiocyanate (FITC) is a highly 
fluorescent non-toxic compound with an excitation maximum of 494 nm and 
emission maximum of 521 nm. FITC can be easily conjugated to many molecules 
including proteins such as streptavidin and more complex structures, in particular 
antibodies and therefore has widespread biotechnological applications including 
enzyme linked immunosorbent assays (ELISA).62 As a result 9 kDa PVA was 
conjugated with FITC with the extent of conjugation quantified to ensure a 
sufficient proportion of molecules were conjugated to enable detection (Section 
4.5.10.). Approximately 6 % of the 9 kDa PVA population was conjugated 
(Section 4.5.11.) and though a relatively low proportion the high molar extinction 
co-efficient (68,000 M-1cm-1) of FITC ensures that the fluorescent intensity of a 5 
mg/mL 9 kDa PVA (non-toxic) solution was far above detection limits. A549 cells 
were incubated over a 3-day period with 5 mg/mL FITC conjugated 9 kDa PVA 
(Figure 4.5.) in complete medium (Section 4.5.12.). FITC is known to not alter the 
membrane permeability dramatically of conjugated products and the uptake of 
large FITC-conjugated molecules such as chitosan and bovine serum albumin 
(BSA) with A549 cells has been previously demonstrated.63,64 Furthermore FITC 
has been successfully conjugated to numerous polymeric assemblies and 
nanoparticles that aim to improve drug delivery.65,66 It has also found versatility 
coupled to polypeptides helping to identify peptide sequences that enhance 
membrane permeability.67 After incubation the effluent containing FITC - 9 kDa 
PVA was removed and the cells twice washed with PBS in order to remove any 
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residual fluorescence that may generate a false positive before the cells were 
lysed to liberate any internalized FITC - 9 kDa PVA, with each solution analyzed 
for FITC - 9 kDa PVA content. Figure 4.5. highlights that no significant amounts 
of 9 kDa PVA is internalized, especially not an amount that would have a 
significant IRI effect. The absence of PVA internalization is critical as it simplifies 
the removal of 9 kDa PVA post cryopreservation. The extracellular localization of 
PVA also shows that PVA acts as an IRI active compound exclusively in an 
extracellular context, which highlights further the necessity to avoid the formation 
of intracellular ice by using a slow cooling rate allowing the controlled efflux of 
water from cells.68 The removal of cryoprotectants from cryopreserved cells and 
tissues is highly desirable in order to limit the potential impact on downstream 
research efforts and clinical applications.42,43 
  
 
 
 
 
 
 
 
 
 
Figure 4.5. Relative uptake of 5 mg/mL 9 kDa PVA conjugated with FITC in 
A549 cells. Uptake of 5 mg/mL PVA-FITC (average conjugation rate 6.3 % ± 0.4 
%) incubated with A549 cells for 3 days prior to analysis. Values represent the 
mean relative fluorescence intensity of 3 wells each measured in triplicate with 
the error bars representing ± standard deviation. 
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4.3.4. Cryopreservation of human choriocarcinoma (BeWo) 
cells. 
 
A549 cells are an excellent and popular cell line that can be easily propagated 
and are widely used as a model for type II alveolar epithelial cells.41 The MTT 
and NR assays used to quantify their viability are standardized high throughput 
assays used extensively in industry and academia for toxicological studies.69 
However these assays are only indicative of a single property being either the 
reduction of MTT due to mitochondrial activity (by the actions of several 
dehydrogenases) or the pH driven lysosomal (pH 4-5) specific uptake and 
retention of neutral red dye.14,15,70,71 Ideally an ability to measure the functionality 
of cells on a more complex scale (i.e. modifications that invoke changes in gene 
expression) would be of further benefit and a more robust assessment of 
normality. BeWo cells which were derived from a human choriocarcinoma are a 
cell line of interest to those who study placental development.72 BeWo cells 
possess an ability to undergo a gross and inducible change, syncytialization.73 
Syncytialization in vivo is the generation of a villous epithelium tissue on the 
placenta as a result of cell fusion and is as a consequence the only villous tissue 
to have direct contact with maternal blood.74 Syncytialization can be induced in 
vitro in BeWo cells by the addition of forskolin75 giving a characteristic 
morphological change. A direct consequence of syncytialization is the production 
of the hormone β-human chorionic gonadotropin (β-hCG).76-78 However JEG-3 
cells have also been shown to produce β-hCG in response to forskolin but not 
undergo the characteristic morphological changes, dissociating biochemical and 
morphological differentiation from one another.79 β-hCG has a similar structure to 
many other reproductive hormones including follicle stimulating hormone (FSH) 
and luteinizing hormone (LH). However β-hCG has a different expression profile 
in that it is exclusively produced in significant quantities by syncytiotrophoblasts 
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during the formation of placental tissue in pregnancy.80,81 For that reason the 
presence of β-hCG is commonly used as an indicator of pregnancy with a range 
of immunochromatographic assays commercially available.82  
 
Figures 4.6.A shows the lack of 9 kDa PVA cytotoxicity even at 50 mg/mL with 
figure 4.6.B showing the cryopreservation of BeWo cells using an identical 
methodology to that adopted with the previously tested A549 cells (Section 
4.3.1.). Figure 4.6. highlights the benefits of using 4 % (v/v) DMSO over 10 % 
(v/v) DMSO (74.7 % ± 7.2 %) the beneficial effects of adding 1 mg/mL or 2 
mg/mL 9 kDa PVA (157.9 % ± 4.1 % and 177.5 % ± 0.7 % respectively). 
Furthermore the harm that strong IRI (and DIS) activities can induce with 10 
mg/mL 9 kDa PVA and 1 mg/mL 31 kDa PVA reducing cell recovery to values of 
52.6 % ± 2.8 % and 4.7 % ± 4.5 % respectively. These observations are highly 
significant given the relatively low concentration of 9 kDa PVA added to attain 
such increases in cell recovery. Therefore the response of BeWo cells is similar 
to that of A549 cells with the addition 9 kDa PVA again proving advantageous at 
low concentrations using a rapid freezing strategy in the absence of complete 
medium. 
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Figure 4.6. Cytotoxicity and cryopreservation impact of 9 kDa PVA on 
BeWo cells. (A) Confluent BeWo cells incubated for 4 hours with 9 kDa PVA 
between 0 – 50 mg/mL and measured by the non-destructive resazurin reduction 
assay. Values represent the mean of 3 wells each measured in duplicate with the 
error bars representing ± standard deviation. (B) (%) Cell recovery of BeWo cells 
using 4 % (v/v) DMSO supplemented with either 9 kDa or 31 kDa PVA in PBS 
measured by the MTT assay. Values represent the mean of 2 cryovials each 
plated in 3 wells and measured in duplicate with the error bars representing ± 
standard deviation.  
 
However as shown in Section 4.3.2., 9 kDa PVA is non-penetrative and therefore 
has minimal impact on intracellular ice. As a consequence of this and in order to 
reduce the probability of intracellular ice formation that rises with increasing 
freezing rate a slow freezing rate was applied (Section 4.5.6.); with a slightly 
higher DMSO concentration (6 % (v/v)) and in complete medium that aids to 
accelerate water exchange by generating a larger osmotic gradient.83 A slow 
freezing rate was achieved using a Nalgene “Mr FrostyTM” freezing container that 
incites a freezing rate of approximately 1 °C/min. BeWo cells were frozen to -80 
°C overnight and then transferred to N2(l) (-196 °C) for 35 days. Previous 
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experiments focussed on short term freezing whereas this extended time frame is 
more akin to a research environment. After thawing, cells were then analysed 
using a non-destructive viability test that monitors the conversion (postulated to 
be due to mitochondrial enzymes84) of resazurin into the fluorophore resorufin 
(Section 4.5.9.) over 3 consecutive days with separate experiments to show that 
the cells are able to proliferate and remain viable even 72 hours later. The results 
of which are shown in Figure 4.7. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.7. Cryopreservation of BeWo cells with 6 % (v/v) DMSO and 9 kDa 
PVA. Prolonged cryopreservation (slow freezing) of BeWo cells with 6 % (v/v) 
DMSO with or without various concentrations of 9 kDa PVA in complete medium 
as measured by the resazurin reduction assay on consecutive days. Values 
represent the mean of 2 cryovials each plated overnight in 3 wells and measured 
in duplicate with the error bars representing ± standard deviation. 
 
Under these conditions the addition of 0.5 mg/mL 9 kDa PVA proved the most 
beneficial in terms of immediate (Day 1) cell recovery with recoveries of 67.5 % ± 
6.8 % (6 % (v/v) DMSO + 0.5 mg/mL 9 kDa PVA) compared to 52.5 % ± 10.5 % 
(6 % (v/v) DMSO (slow thaw)). Values that were referenced against a 6 % (v/v) 
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DMSO with a fast thawing rate (minimal ice recrystallization) with gradual 
escalations in 9 kDa PVA proving detrimental following trends seen previously 
and in literature (Section 4.3.1.). However as elaborated prior BeWo cells are 
able to undergo syncytialization upon the addition of forskolin and produce β-
hCG. It was reasoned therefore that the extent of β-hCG production would be 
proportional to cell number. Complete medium containing 50 µM forskolin was for 
that reason added for 48 hours to induce syncytialization with a medium change 
after 24 hours, aliquots were then taken to enable β-hCG detection. To 
qualitatively assess β-hCG production standard immunochromatographic assays 
(Section 4.5.14.) predominantly used to determine pregnancy were utilized 
(Figure 4.8.). In each instance β-hCG was successfully detected (sensitivity 25 
mIU/mL) indicating syncytialization. 
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Figure 4.8. Qualitative assessment of BeWo cell syncytialization 
subsequent to forskolin treatment (50 µM). (A) Phase contrasted micrograph 
(40x magnification) of BeWo cells pre-forskolin treatment. (B) Table highlighting 
the detection of β-hCG (48 hours after forskolin addition) using 
immunochromatographic assays principally used to detect pregnancy. (C) Image 
highlighting immunochromatographic assay outcomes outlined in the above 
table. 
 
From Figure 4.8.C it is immediately apparent that all cells recovered after 
cryopreservation produced a detectable level of β-hCG indicative of 
syncytialization with Figure 4.8.A showing BeWo cells prior to syncytialization 
using an inverted phase contrast microscope. However in an attempt to further 
quantify the amount of β-hCG produced a quantitative measure was used, 
namely an ELISA specific for β-hCG which allows the a range of samples to be 
quantified in parallel without further downstream processing as cell culture 
medium does not adversely effect the performance of the assay (Section 4.5.14). 
Figure 4.9 shows the outcome of this analysis with a standard curve (Figure 
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4.9.A) allowing the conversion of the raw absorbance data into concentration 
values (pg/mL). An appreciable amount of β-hCG was detected in each sample 
again indicative of β-hCG production however the values did not correlate with 
the recoveries determined by the resazurin assays prior (Figure 4.7.). The lack of 
correlation between cell number and β-hCG production may be due to the effect 
of cell density on the rate and onset of syncytialization meaning that β-hCG 
production does not necessarily scale linearly with cell density.85 A possible 
consequence being that the health of the cells recovered at higher 9 kDa PVA 
concentrations maybe superior and thus more responsive to forskolin treatment. 
 
 
 
 
Figure 4.9. Quantitative assessment of BeWo cell syncytialization 
subsequent to forskolin treatment (50 µM). (A) Standard curve quantifying β-
hCG concentration (pg/mL) fitted with a linear model with a strong positive 
correlation between concentration (pg/mL) and absorbance at 450 nm (Adj-R2 = 
0.9932). (B) β-hCG concentration (pg/mL) detected by ELISA from syncytialized 
BeWo cells cryopreserved under each of the tested conditions.  Values represent 
the mean of 2 cryovials each plated for 3 days and measured in duplicate with 
the error bars representing ± standard deviation. 
 
This data therefore suggests that BeWo cells can be cryopreserved under 
conditions that mimic current freezing protocols for a prolonged period of time (35 
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days) and thawed under harsh conditions that promote ice recrystallization, which 
has a harmful effect on cell recovery. The addition of low concentrations (0.5 
mg/mL) of 9 kDa PVA with an established IRI activity and biocompatibility at 
concentrations up to the highest concentration tested of 50 mg/mL (which nears 
the limit of solubility) is able to have a positive impact on cell recovery. An 
additional 25 % of cells are successfully recovered which is attributed to the 
presence of 0.5 mg/mL 9 kDa PVA compared to identical conditions that lack 9 
kDa PVA. However the addition of 9 kDa PVA is unable to fully eliminate the 
damage arising from slow thawing that no doubt has an effect of the rate of cell 
rehydration also. Furthermore the inducible process of syncytialization is 
unaffected with the presence of β-hCG indicative of syncytialization detected by 
two independent methods. Figures 4.8 and 4.9 emphasize that the use of 9 kDa 
PVA in cryopreservation does not adversely affect this biologically complex 
transformation. 
 
The attenuation of ice recrystallization and resulting impact on cell recovery is 
even more pronounced in a low DMSO (4 % (v/v)) serum free mixture 
supplemented with (1 mg/ml and 2 mg/mL) 9 kDa PVA. This methodology also 
uses a non-ideal rapid freezing technique but still elicits significant cell recovery. 
The addition of 1 mg/mL and 2 mg/mL 9 kDa PVA allows an additional 58 % and 
78 % of cells to be recovered successfully (4.6.B). In line with the findings 
attained with A549 cells (Figure 4.4.A) the addition of small amounts of 9 kDa 
PVA is beneficial but increasing the concentration of 9 kDa PVA to elicit a 
stronger IRI activity is detrimental which as aforementioned is postulated by an 
increased DIS effect caused by increasing concentrations of PVA.52 However the 
onset of DIS could not be ascertained by microscopy. Improving the 
cryopreservation of primary and clinically relevant cells, tissues and even organs 
that have scarce availability and short storage times is the ultimate goal. 
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Understanding how close mimics of primary cells86 behave and how PVA 
influences their recovery is vital. This leads to studies investigating the 
cryopreservation of FAO cells in the following section that are an excellent model 
for rat hepatocytes.87,88 
 
4.3.5. Cryopreservation of rat hepatoma (FAO) cells. 
 
FAO cells are epithelial cells derived from the chemical carcinogenesis of a rat 
(Rattus norvegicus) inciting a H-35 reuben hepatoma approximately 50 years 
ago.89,90 FAO cells also commonly referred to as H4IIE cells are a popular mimic 
for rat (liver) hepatocytes that are a frequently used primary tissue in 
pharmacokinetic and pharmacodynamic studies91,92 in particular they are used in  
monitoring the impact of xenobiotics on cytochrome p450s that metabolize the 
vast majority of pharmaceutical drugs.93 Though the expression of cytochrome 
p450s is reduced in hepatic cell lines including the often used human hepatoma 
cell line HepG294,95 they still retain importance in drug metabolism studies and in 
in vitro toxicity screening.96-98 FAO cells are also of particular interest due to a 
behaviour that they share with primary rat hepatocytes, the steroid driven 
induction of tyrosine aminotransferase (TAT) expression.99-102 TAT catalyses the 
conversion of L-tyrosine to p-hydroxyphenylpyruvate (pHPP) that is then further 
catalyzed by pHPP oxidase. Studies by Diamondstone allowed development of 
an assay that allows pHPP oxidase inhibition by Sodium diethyldithiocarbamide 
(DDC) and the base catalysis of pHPP to p-hydroxybenzaldehyde (pHBA) that 
has a strong absorbance at 331 nm allowing relative assessments of TAT 
expression.103 Therefore FAO cells are a suitable model for primary rat 
hepatocytes with a shared enzymatic endpoint. To begin with the cytotoxicity of 9 
kDa PVA, 31 kDa PVA and DMSO was assessed (Figure 4.10.) with neither 10 
mg/mL 9 kDa PVA or 4 mg/mL 31 kDa PVA proving detrimental. However as with 
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A549 cells increasing amounts of DMSO instigated a significant loss in cell 
recovery even at concentrations as low as 2 % (v/v) DMSO (85.2 % ± 4.6 % 
(resazurin) and 67.8 % ± 13.3 % (MTT)).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10. Cytotoxicity of 9 kDa PVA, 31 kDa PVA and DMSO on Confluent 
FAO cells. FAO cells incubated for 4 hours with either 9 kDa PVA, 31 kDa PVA 
or DMSO and measured by the MTT and Resazurin assays. Values represent 
the mean of 3 wells each measured in duplicate with the error bars representing 
± standard deviation. 
 
As with BeWo cells and using the same rationale the forthcoming experiments 
used a slow freezing rate in complete medium with the supplementation of 
different IRI additives. To begin with the FAO cells were cryopreserved with 
various concentrations of DMSO and thawed slowly to identify a concentration for 
optimal cell recovery. The recovery of cells was assessed over 3 consecutive 
days post thaw using the resazurin assay with 6 % (v/v) DMSO proving to be the 
best concentration giving values relative to 10 % (v/v) DMSO of 134.3 % ± 10.4 
% (Figure 4.11.). Going forward all cryopreservation studies using FAO cells 
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used 6 % (v/v) DMSO. The addition of 9 kDa PVA again proved beneficial at low 
concentrations with 0.5 mg/mL 9 kDa PVA, 1 mg/mL 9 kDa PVA and 2 mg/mL 9 
kDa PVA with values of 111.0 % ± 10.6 %, 114.1 % ± 4.7 % and 96.5 % ± 13.7 % 
respectively (Figure 4.12.). These values are referenced against 6 % (v/v) DMSO 
(rapid thaw) (100 %). Figure 4.12 implies that in this instance the 
supplementation of 9 kDa PVA is able to attenuate all ice recrystallization 
damage (6 % (v/v) DMSO (slow thaw), 68.5 % ± 4.6 % cell recovery) with 
comparable recoveries to that when a rapid thawing rate is used. Critically the 
addition of large amounts of 9 kDa PVA (10 mg/mL) as with every other model 
system tested proved detrimental to cell recovery (51.8 % ± 19.1 %). 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. Cryopreservation of FAO cells with various concentrations of 
DMSO. Cryopreservation (slow freezing) of FAO cells with various concentrations 
of DMSO (% (v/v)) in complete medium (slow thaw). Values represent the mean 
of 2 cryovials each plated in 3 wells and measured in duplicate with the error bars 
representing ± standard deviation and referenced against 10 % (v/v) DMSO on 
day 1. 
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Figure 4.12. Cryopreservation of FAO cells with 6 % (v/v) DMSO and 9 kDa 
PVA. Cryopreservation (slow freezing) of FAO cells with 6 % (v/v) DMSO with or 
without various concentrations of 9 kDa PVA in complete medium as measured 
by the resazurin assay after 1, 2 and 3 days post plating. Values represent the 
mean of 2 cryovials each plated in 3 wells and measured in duplicate with the 
error bars representing ± standard deviation and referenced against 6 % (v/v) 
DMSO (rapid thaw) on day 1. 
 
Figure 4.12. suggests a significant increase in cell recovery occurs upon the 
addition of 9 kDa PVA. As a result of the increase in cell recovery the 
aforementioned TAT assay was performed in order to quantify the production of 
pHBA without the steroid driven induction that elevates TAT expression (Section 
4.6.17.). Figure 4.13.A shows the absorbance spectrum of pHBA highlighting the 
absorbance maximum at 331 nm with Figure 4.13.B showing the kinetics of the 
base catalysis of pHPP to pHBA with near completion after a period of 1800 
seconds. Figure 4.13.C shows the linear relationship between pHBA 
concentration and absorbance at 331 nm with a strong positive correlation (Adj-
R2 = 0.9996) allowing the accurate quantification of pHBA concentration (µM). 
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Figure 4.13.D shows the concentration of pHBA attained from FAO cells 
cryopreserved with 6 % (v/v) DMSO supplemented with and without 9 kDa PVA. 
Samples supplemented with 0.5 mg/mL 9 kDa PVA and 1 mg/mL 9 kDa PVA 
elicited higher concentrations of pHBA compared to 6 % (v/v) DMSO alone with 
these values correlating with the improvements detected using the resazurin 
assay (Figure 4.12.). However the concentration of pHBA in samples 
supplemented with 2 mg/mL 9 kDa PVA was not significantly greater as shown 
by the division of (%) cell recovery by the concentration of pHBA (µM) (Figure 
4.13.E). 
 
To further probe the cryoprotective effect of 9 kDa PVA on FAO cells one final 
experiment was performed that utilized 9 kDa PVA at 0.5 mg/mL intervals 
between 0 mg/mL and 2.5 mg/mL (Figure 4.14.A) and is thus different to figure. 
4.12. In this experiment the presence of 0.5 mg/mL 9 kDa PVA proved the most 
beneficial (93.7 % ± 10.2 %) with gradual decreases in cell recovery with 
increasing concentration. The addition of 2.5 mg/mL 9 kDa PVA had no beneficial 
effect over the presence of 6 % (v/v) DMSO alone at 77.3 % ± 7.4 % and 79.1 % 
± 6.1 % respectively. Furthermore the addition of 9 kDa PVA had no significant 
impact on the proliferation rates as the relative improvements in cell recovery 
translated over a period of 72 hours (Figure 14.4.B). 
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Figure 4.13. TAT assay standards and measurements with FAO cells. (A) 
Absorbance spectrum of pHBA highlighting an absorbance maximum at 331 nm. 
(B) Kinetic plots of the base catalysis of pHPA into pHBA over a period of 45 
minutes. (C) Graph showing pHBA concentration (µM) vs. Abs (331 nm) 
highlighting the proportional increase in absorbance with increasing 
concentration (Adj R2 = 0.9996). (D) Levels of pHBA (µM) indicative of the relative 
levels of TAT expression and by virtue FAO population. Values represent mean 
values of 2 cryovials each plated overnight in triplicate prior to TAT liberation and 
enzymatic catalysis of L-tyrosine to pHPA and the base catalysis of pHPA to the 
chromophore pHBA. (E) % Cell recovery per µM of pHBA indicative of the 
quantity of cells required per µM of pHBA with lower values suggestive of greater 
vitality.   
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Figure 4.14. Cryopreservation of FAO cells with 6 % (v/v) DMSO and 9 kDa 
PVA at smaller concentration intervals. Cryopreservation (slow freezing) of 
FAO cells with (A) 6 % (v/v) DMSO with or without various concentrations of 9 
kDa PVA in complete medium as measured by the resazurin assay. (B) 
Cryopreservation of FAO cells with recovery assessed over 72 hours. Values 
represent the mean of 2 cryovials each plated overnight in 3 wells and measured 
in duplicate with the error bars representing ± standard deviation. 
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4.4. CONCLUSIONS. 
 
 
9 kDa PVA has been successfully used as an IRI active macromolecule to 
improve the cryopreservation of 3 distinctly different cell lines (A549, BeWo and 
FAO) significantly despite the addition of only a proportionately low concentration 
of PVA. The susceptibility of A549 cells to DMSO at concentrations used in 
current cryopreservation protocols at physiologically relevant temperatures was 
shown highlighting the need to limit its application. Using the optimal DMSO 
concentration of 4 % (v/v) DMSO and a rapid freezing protocol in the absence of 
medium the supplementation of a low (1 mg/mL) concentration of 9 kDa PVA 
enhanced cell recovery. At concentrations higher than this cell recovery was 
reduced and speculated to be due to increased DIS activity as a similar reduction 
was identified with a more potent IRI compound (31 kDa PVA) at an equivalent 
concentration. However 9 kDa PVA was not an effective substitute for DMSO and 
shown to be membrane impermeable and thus only influences extracellular ice 
growth.  
 
A similar relationship was shown with BeWo cells using a rapid freezing strategy. 
A slow freezing rate with a slightly higher DMSO concentration of 6 % (v/v) in 
complete medium to aid water exchange was used that has the effect of lowering 
the probability of intracellular ice formation which 9 kDa PVA is unable to 
influence. Under these conditions that are more akin to traditional methodologies 
the addition of 0.5 mg/mL 9 kDa PVA proved the most beneficial with higher 
concentrations having an analogous detrimental effect with cells stored in N2(l) for 
35 days. However all recovered cells were able to undergo some form of 
syncytialization a complex morphological and biochemical change evidenced by 
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the production of β-hCG quantified by two separate methods and thus the use of 
9 kDa PVA does not inhibit this complex biochemical process.  
 
Finally the addition of 0.5 mg/mL 9 kDa PVA provided a cryoprotective effect in 
the cryopreservation of FAO cells that are an excellent model system for primary 
rat hepatocytes using a slow freezing rate. The benefit of PVA addition was 
evidenced by two independent methodologies with beneficial effects shown even 
after a period of 72 hours. The consequence of 0.5 mg/mL stepwise increments 
in 9 kDa PVA highlighted further that simply increasing IRI activity does not led to 
greater cell recoveries. Although the beneficial effects seen in each cell variety 
justify the investigation of primary tissues that have the greatest clinical fragility 
and demand. 
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4.5. MATERIALS AND METHODS 
 
4.5.1. Cell culture reagents and conditions. 
 
All cell cultures reagents were sourced from either Life Technologies Ltd, Paisley, 
UK or Sigma-Aldrich Company Ltd, Dorset, UK and of the highest attainable 
quality and stored at 4 °C or -20 °C as instructed when not in use. Complete 
medium consisted of RPMI (with phenol red) containing 10 % (v/v) FBS plus 100 
U/mL Penicillin and 100 µg/mL Streptomycin (unless otherwise specified) and all 
cells were incubated at 37 °C in a 5 % CO2(g) humidified atmosphere. PBS was 
prepared in house and autoclaved prior to use. All cell culture plasticware was 
obtained from Greiner Bio-One Ltd, Gloucestershire, UK and all cell culture 
experiments were performed in a class II biosafety cabinet to ensure sterility with 
cells regularly assessed for bacterial, fungal and yeast contamination.  
 
4.5.2. Rejuvenation of cells from cryopreserved stocks. 
 
A single 1 mL cryopreserved aliquot (10 % (v/v) DMSO in complete medium) in a 
1.8 mL cryovials of cells was removed from cryostorage (N2(l)) and immediately 
thawed rapidly in a 37 °C water bath. Thawed cells were then immediately placed 
in a 75 cm2 flask containing 20 mL of pre-warmed medium and incubated 
overnight. Phase-contrast light microscopy (Nikon UK Limited, Surrey, UK) was 
used to confirm the presence of adherent cells and the medium aspirated and 
cells washed with 10 mL of PBS to remove any non-adherent cells, debris and 
residual DMSO. 20 mL of pre-warmed medium was added and cells incubated 
until confluency. 
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4.5.3. Passaging of cultured cells. 
 
The following details how to passage cells from one 175 cm2 flask into another 
175 cm2 flask. All quantities were scaled linearly according to any changes in the 
surface area(s) or number of flasks/plates required. Confluence was defined as 
70-80 % of the total surface area consisting of cultured cells as assessed by 
phase-contrasted light microscopy and all cells were incubated at 37 °C in a 5 % 
CO2(g) humidified atmosphere. 
 
Medium from confluent cells was removed and the cells washed with 25 mL pre-
warmed (37 °C) PBS and replaced with 3.5 mL (pre-warmed) 0.25 % (w/v) 
trypsin solution. The flask was incubated for a minimum of 2 minutes (5 minute 
maximum) to ensure all cells were detached but not allowed to aggregate. The 
trypsin solution was immediately neutralized by the addition of 3.5 mL of 
complete medium. A 1 mL aliquot was removed and transferred into a 175 cm2 
flask containing 25 mL of pre-warmed (37 °C) media. The flask was then 
replaced in the incubator and cells allowed to adhere and proliferate to (70 % - 80 
%) confluency. 
 
4.5.4. Cytotoxicity of DMSO, 9 kDa PVA and 31 kDa PVA. 
 
Cells (A54941, BeWo72 and FAO89) were grown to confluence in either 48-well or 
24-well plates as required and washed with an appropriate amount of pre-
warmed PBS before the addition of 400 µL complete medium supplemented with 
the desired concentration of the analyte under scrutiny. Cells were then 
incubated for 4 hours prior to analysis using one or more of the MTT, NR or 
resazurin assays. Additionally in the case of assessing the impact of DMSO on 
the proliferation of A549 cells a low density of A549 cells were plated in a 48-well 
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plate and incubated with 400 µL of complete medium supplemented with the 
desired concentration of DMSO and analyzed by the MTT, NR and resazurin 
assays. 
 
4.5.5. Cryopreservation of cells using a rapid freezing rate in 
the absence of complete medium. 
 
A549 cells and BeWo cells (where indicated prior) were subjected to a rapid 
freezing protocol as follows with the same procedure undertaken for each cell 
line. Cells were grown to confluency and trypsinised according to Section 4.5.3. 
prior to centrifugation at 23 °C and 1000 rpm and resuspended in pre-warmed 
PBS to amount equivalent to 750 µL per sample. 700 µL of the cell suspension 
was placed in 1.8 mL cryovials for each analyte mixture in duplicate and the 
desired amount of DMSO, PVA and PBS added to give a final volume of 1 mL. 
Cryovials were then mixed gently by inversion to ensure a homogenous cell 
suspension. Cells were then frozen as individual aliquots in a pre-cooled 
IPA(l)/CO2(s) slurry (-78 °C) for 60 seconds and then buried in CO2(s)  for 20 
minutes prior to thawing by either a rapid or slow thawing technique as required. 
Rapid thawing was defined as the immersion of the cryovial in a 37 °C water bath 
until no ice visibly remained. Slow thawing was achieved by thawing cells in air at 
room temperature (approximately 23 °C) until no ice visibly remained. 
Subsequent to thawing, cells were plated as desired in a 48 well or 24 well plate 
with 30 µL and 60 µL aliquots of each thawed aliquot added to 600 µL pre 
warmed complete medium and incubated overnight. Plates were then assessed 
by phase contrast microscopy and samples with the most suitable cell density 
(i.e. 30 µL or 60 µL supplements) assessed by the MTT and NR assays. 
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4.5.6. Cryopreservation of cells using a slow freezing rate in the 
presence of complete medium. 
 
FAO and BeWo cells (where indicated prior) were subjected to a slow freezing 
protocol as follows with the same procedure for each cell line. 1 mL aliquots of 
cells in 1.8 mL cryovials were prepared in an identical manner to Section 4.5.5. 
but substituting PBS for complete medium. Cells were then chilled at 4 °C for 120 
minutes and then mixed gently by inversion and positioned in a Nalgene “Mr 
FrostyTM” placed at -80 °C to achieve a cooling rate of 1 °C/min and kept at -80 
°C for between 24 and 72 hours and then either transferred to N2(l) as required or 
thawed (Section. 4.5.5.) and analyzed using the MTT and resazurin assays  
 
4.5.7. MTT reduction assay. 
 
The following details a MTT reduction assay14 for cells seeded in a 24-well (1.92 
cm2 surface area per well) plate format. All quantities were scaled linearly 
according to any changes in surface area(s) and the same protocol applied to 
each cell variety that have approximately equal sensitivity and responsiveness. 
Complete medium was removed and cells washed with 600 µL of pre-warmed 
(37 °C) PBS and replaced with 300 µL of pre-warmed (37 °C) complete medium 
and 50 µL of 5 mg/mL MTT in PBS and incubated for 4 hours. The cells were 
examined briefly using phase contrast light microscopy for the presence of the 
insoluble formazan product (Figure 4.15.). The medium and MTT mixture was 
aspirated and replaced with 300 µL of 90 % (v/v) IPA / 10 % (v/v) DMSO, 0.1 % 
HCl(aq) and incubated for 20 minutes at 23 °C and 200 rpm to enable lysis and 
solubilisation giving a uniform purple colouration. 100 µL aliquots were then in 
duplicate transferred to a 96-well plate and absorbance measured at 595 nm 
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(Multiskan Ascent, Fisher Scientific UK Ltd, Leicestershire, UK). The values 
attained were then contrasted against untreated controls. A percentage 
estimation of cell recovery could then be calculated (Equation 4.1.). 
 
 
 
 
 
 
 
 
Figure 4.15. Phase contrasted micrograph of A549 cells after MTT assay. 
Exemplifying the presence of the insoluble and crystalline formazan product after 
a 4 hour incubation period (100x magnification) . 
 
Equation 4.1. Calculation of (%) relative metabolic activity using the MTT 
assay. 
 
(%) Relative metabolic activity = 
  
€ 
Abs ( 595nm) (Sample) −Abs ( 595nm) (0%)[ ]
Abs ( 595nm) (100%)−Abs ( 595nm) (0%)[ ]
 
 
4.5.8. Neutral red uptake assay. 
 
The following details a neutral red (NR) uptake assay15 for A549 cells seeded in a 
24-well (1.92 cm2 surface area per well) plate format. All quantities were scaled 
linearly according to any changes in the surface area(s) cultured and the same 
protocol applied to each cell variety that have approximately equal sensitivity and 
responsiveness. Complete medium was removed and cells washed with 600 µL 
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of pre-warmed (37 °C) PBS and replaced with complete medium with 120 µL pre-
warmed neutral red solution that was diluted 10-fold in PBS from the originally 
provided 0.33’ %(w/v) stock solution. The cells were then incubated for 2 hours. 
The neutral red solution was then discarded and the cells examined briefly using 
phase contrast light microscopy for the presence of stained cells (Figure 4.16.) 
prior to two washes with 600 µL PBS. 600 µL of 1 % (v/v) acetic acid, 50 % (v/v) 
ethanol solution was added and the cells left for 10 minutes at 23 °C and 200 rpm 
to enable lysis and solubilisation giving a uniform pink colouration. 150 µL 
aliquots were then in duplicate transferred to a 96-well plate and absorbance 
measured at 540 nm (Multiskan Ascent, Fisher Scientific UK Ltd, Leicestershire, 
UK). The values attained were then contrasted against untreated controls. A 
percentage estimation of cell recovery could then be calculated (Equation 4.2.). 
 
 
 
 
 
 
 
 
Figure 4.16. Phase contrasted micrograph of A549 cells after NR assay. 
Exemplifying the presence of the neutral red stained cells after a 2-hour 
incubation period (100x magnification). 
 
Equation 4.2. Calculation of (%) relative dye uptake using the NR assay. 
 
(%) Relative dye uptake = 
  
€ 
Abs ( 540nm) (Sample) −Abs ( 540nm) (0%)[ ]
Abs ( 540nm) (100%)−Abs ( 540nm) (0%)[ ]
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4.5.9. Resazurin reduction assay. 
 
The following details a resazurin reduction assay104,105 for cells seeded in a 48-
well (0.95 cm2 surface area per well) plate format. Complete medium was 
removed and cells washed with 400 µL of pre-warmed PBS and replaced with 
200 µL of pre-warmed complete medium and supplemented with 10 µL 0.33’ 
mg/mL resazurin in triplicate. The cells were then incubated for 3 hours (unless 
stated otherwise) allowing the conversion of resazurin to the highly fluorescent 
chromophore resorufin prior to subsequent conversion to the non-fluorescent 
compound hydroresorufin (Figure 4.17.). 50 µL aliquots were taken in duplicate 
and added to 50 µL PBS in a 96 well plate and fluorescence measured using 
excitation and emission wavelengths of 530/25 nm and 590/30 nm respectively 
using a BioTek Synergy HT plate reader (BioTek UK, Bedfordshire, UK).  
 
 
 
 
 
 
 
 
 
Figure 4.17. Assessment of resorufin and hydroresorufin production in 
FAO cells. Confluent FAO cells incubated with 0.0833’ mg/mL resazurin to 
assess the reduction of non-fluorescent resazurin to the highly fluorescent 
resorufin at frequent intervals (increase in fluorescence) prior to further reduction 
to non-fluorescent hydroresorufin (decrease in fluorescence). 
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The values attained were then contrasted against untreated controls. A 
percentage estimation of cell recovery could then be calculated (Equation 4.3.). If 
required for subsequent time points, cells were washed with 400 µL of pre-
warmed PBS and 400 µL of complete medium added and incubated for 
experimentation the following day.  
 
Equation 4.3. Calculation of (%) relative fluorescence using the resazurin 
assay. 
 
(%) Relative fluorescence =  
  
€ 
Fluorescence( 590 / 30nm) (Sample) −Fluorescence( 590 / 30nm) (0%)[ ]
Fluorescence( 590 / 30nm) (100%)−Fluorescence( 590 / 30nm) (0%)[ ]
 
  
4.5.10. Conjugation and purification of FITC-labeled PVA. 
 
100 mg of purified PVA was dissolved with 1 mg/mL FITC in DMSO to a final 
concentration of 10 mg/mL PVA and 0.1 mg/mL FITC and kept at 23 °C whilst 
gently agitated for 48 hours in an absence of light. This solution was then 
dialysed (MWCO:1000, Spectrum Laboratories Inc, CA, USA)) repeatedly with 4 
L of ultrahigh purity (18.2 mΩ cm (resistivity) at 23 °C) H2O(l) with a minimum of 5 
H2O(l) changes at regular intervals to remove any unbound dye. The sample was 
then freeze-dried overnight giving a compound with a characteristically pale lime 
green colouration. Conjugated PVA could then be store at 23 °C in an absence of 
light indefinitely until required.  
 
4.5.11. Determination of FITC conjugation. 
 
The extent of FITC conjugation could be calculated spectrophotometrically using 
a BioTek Synergy HT plate reader (BioTek UK, Bedfordshire, UK). The 
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absorbance at 494 nm (adsorption maximum) of 200 µL aliquots of 1, 0.5, 0.25 
and 0.125 mg/mL conjugated polymer in H2O(l) was measured in a clear flat 
bottomed 96-well plate. The background absorbance of unconjugated polymer at 
equivalent concentrations was also measured and these values subtracted. The 
concentration of FITC could then be approximated using the Beer-Lambert law 
(Equation 4.4.) given that the molar extinction coefficient (ε) of FITC (68,000 M-
1cm-1) and path length (l) (0.48 cm). The ratio of FITC:Compound could then be 
calculated and an estimation of the percentage of molecules labeled with FITC 
(assuming only 1 conjugation event per molecule). 
 
Equation 4.4. Beer-Lambert law 
Concentration (M) = 
  
€ 
Abs( 494 nm)
ε(M −1 ⋅ cm −1) ⋅ l(cm)
 
 
4.5.12. Assessment of conjugated FITC-9 kDa PVA uptake in 
A549 cells. 
 
A549 cells were plated at a low density in a 48-well plate with 400 µL of medium 
supplemented with 5 mg/mL of FITC-conjugated polymer and incubated. After 3 
days the FITC containing effluent was removed and cells washed twice with 400 
µL PBS prior to lysis with 400 µL 100 mg/mL SDS. The FITC content of each 
solution was then measured in triplicate (100 µL) by fluorescence in a 96 well 
plate using a BioTek Synergy HT plate reader (BioTek UK, Bedfordshire, UK) 
with excitation and emission wavelengths of 485/20 nm and 520/20 nm 
respectively at sensitivity 35. The FITC content of each solution was then 
referenced against the FITC supplemented medium of each compound allowing 
FITC uptake to be calculated (Equation 4.5.). 
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Equation 4.5. Calculation of 9 kDa PVA – FITC uptake. 
(%) 9 kDa PVA uptake =  
  
€ 
Fluorescence( 520 / 20nm) (Sample)[ ]
Fluorescence( 520 / 20nm) (Effluent)[ ]
 
	  
4.5.13. Forskolin treatment of BeWo cells to incite 
syncytialization and β-HCG expression. 
 
The following details the syncytialization of BeWo cells incited by the addition of 
Forskolin. Forskolin was prepared in DMSO at a final concentration of 10 mM 
and stored a 4 °C until required. A 30 µL aliquot of BeWo cells post-
cryopreservation with 600 µL of complete medium were seeded in triplicate in 48-
well plates and incubated for 3 days. The medium was then replaced with 400 µL 
of complete medium supplemented with Forskolin at a final concentration of 50 
µM and incubated for 72 hours. After 72 hours the cells were assessed using an 
inverted phase contrast light microscope to assess the morphology and integrity 
of the cells. A 300 µL aliquot of media was removed prior to β-HCG 
quantification. 
 
4.5.14. β-HCG detection via immunochromatographic and 
(ELISA) enzyme-linked immunosorbent assays. 
 
Detection of β-HCG was by two separate methods. A qualitative assessment for 
β-HCG used immunochromatographic assays supplied from SureScreen 
Diagnostics Ltd, Derbyshire, UK. Each assay had a sensitivity of 25 mIU/mL. In 
each instance 200 µL of cell culture medium (Section 4.5.13.) was applied as two 
separate 100 µL aliquots and kept a 23 °C for a minimum of 2 minutes prior to 
inspection with two solid bars indicative of β-HCG (Figure 4.8.). A quantitative 
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measure of β-HCG production was achieved using a β-HCG specific ELISA kit 
specific for detecting β-HCG present within cell culture medium purchased from 
Sigma-Aldrich Company Ltd, Dorset, UK and following the as supplied protocol. 
 
4.5.15. Tyrosine amino transferase (TAT) enzymatic assay. 
 
Cryopreserved FAO cells were washed twice with 300 µL PBS prior to the 
addition of 50 µL of 0.25 % (v/v) trypsin for 2 minutes before the addition of 150 
µL of complete medium. A 180 µL aliquot was then transferred into 500 µL 
eppendorf tubes and centrifuged for 5 minutes at 1000 rpm and 4 °C. The 
supernatant was removed and the cells resuspended in 180 µL of PBS prior to 
cell lysis. Cell lysis was achieved using a freeze-thaw method. FAO cells were 
frozen quickly in an IPA(l) / CO2(s) slurry (-78 °C) for 2 minutes and then thawed at 
room temperature for 10 minutes. This process was repeated 3 times in order to 
maximize lysis and therefore the amount of freely available TAT. The conversion 
of L-tyrosine into p-hydroxyphenylpyruvic acid (pHPP) and then the chromophore 
p-hydroxybenzaldehyde (pHBA) was attained as follows103,106. A 120 µL aliquot of 
32 µM (5.82x10-3 mg/mL) L-tyrosine (substrate), 0.5 mM (0.124 mg/mL) 
pyridoxal-5’-phosphate (co-factor) and 8 mM (1.802 mg/mL) sodium 
diethyldithiocarbamide (inhibits the action of pHPP oxidase) was added to a 40 
µL aliquot of cell lysate in duplicate in 500 µL eppendorf tubes and pre-warmed 
at 37 °C for 20 minutes. To initiate the reaction 40 µL 50 mM (7.306 mg/mL) α-
ketoglutaric acid (co-factor) was added and the samples incubated at 37 °C for 
20 minutes to enable the conversion of L-tyrosine to pHPP. To stop the reaction 
a 30 µL aliquot of 10 M NaOH(aq) was  added and the sample vortexed 
immediately and a 100 µL aliquot transferred to a 96 well plate. NaOH(aq) addition 
also served to catalyze the conversion of pHPP into pHBA. Measurement of 
pHBA was achieved by measuring the absorbance after 1800 seconds at which 
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point pHPP to pHBA conversion is near total (Figure 4.13.B). The absorbance 
maximum of pHBA is 331 nm (Figure 4.13.A). The derived data can then be used 
to comparatively estimate the amount of TAT in each sample and the amount of 
pHBA can be quantified against a pHBA standard curve (Figure 4.13.C).  
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CHAPTER 5. 
  
5. ICE RECRYSTALLIZATION INHIBITORS 
IMPROVE THE CRYOPRESERVATION OF 
PRIMARY CELLS. 
 
5.1. CHAPTER SUMMARY.   
 
The application of poly(vinyl alcohol) (PVA) that has been previously identified 
(Chapter 2) as a potent ice recrystallization inhibition (IRI) compound is explored 
as a cryoprotectant for improving the cryopreservation of primary cells, namely 
rat hepatocytes and mouse mesenchymal stem cells (MSCs). There is a great 
clinical and pharmacological demand for primary cells, tissues and organs in the 
fields of transplantation, pharmacology and regenerative medicine. Low 
concentrations of 9 kDa PVA are shown to improve the recovery of 
cryopreserved rat hepatocytes when a slow thawing strategy was used, though 
higher concentrations proved detrimental in agreement with observations noted 
prior with RBCs and immortalized cell lines (Chapter 3 and Chapter 4). In 
addition to improving the cryopreservation of rat hepatocytes, low concentrations 
of 9 kDa PVA may also be of benefit in the cryopreservation of mouse MSCs 
though further work is required to accurately confirm any beneficial effect. The 
presence of 9 kDa PVA during the cryopreservation process critically however 
did not affect the potential of mouse MSCs to undergo differentiation 
(adipogenesis) into adipocytes. This suggests the 9 kDa PVA may be a powerful 
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tool for modulating IR activity and limit cryodamage that arises as a 
consequence. 
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5.2. INTRODUCTION. 
 
Primary (nucleated) cells are biological materials with the greatest clinical value. 
Whether these are cells such as hepatocytes or islets sourced from living or 
deceased donors for use in transplantation1-4 or the isolation of pluripotent stem 
cells. Pluripotent stem cells of which are of increasing importance due to the 
growth of tissue engineering and regenerative medicine.5,6 Greater availability of 
primary cells undoubtedly has the potential to dramatically advance healthcare in 
the 21st century with their direct therapeutic application and in accelerating 
pharmaceutical development as more relevant pharmacological models.7-9 
However the cryopreservation of primary cells is poorly implemented except in 
the field of reproductive medicine in which samples tend to be successfully and 
routinely managed albeit on a small scale.10 This accomplishment has had a 
fundamental impact on embryology and in the selective breeding of livestock in 
agriculture.11,12 In contrast to the successful cryostorage of primary reproductive 
material few strategies for the long term cryostorage of large tissues and organs 
exist whereby the utilization of short term hypothermic perfusion techniques 
predominate.13 However such solutions may be more susceptible to bacterial 
contamination. This contamination has resulted in scenarios whereby such 
solutions have had to be withdrawn from clinical use14-16 and thus an alternative 
to prolong the storage of primary biological materials safely and effectively is a 
highly desired attribute. The need for improved cryopreservation strategies is 
critical more than ever with the emergence of stem cell therapies that may 
become more frequently utilized in the coming decades especially with an aging 
population and increasing drives towards personalized medicine.17-20 
 
Current strategies to cryopreserve primary cells, tissues and organs have 
focused on the use of organic solvents that have had effectiveness with less 
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sensitive and less valuable biological materials and with vitrification strategies 
that aim to eliminate ice formation.21-23 However the use of organic solvents and 
the high concentrations required in order for them to be effective cryoprotectants 
is undesirable as such solvents possess cytotoxic properties that cannot be 
neutralized easily.24 Plus the removal of these (membrane permeable) 
cryoprotectants is non-trivial. The vitrification of biological samples is also 
currently limited to small volumes. Additionally devitrification and then 
consequently ice formation during thawing would also need to be averted as 
rapidly thawing large volumes homogenously to overcome ice recrystallisation is 
not practically achievable.25-27    
 
A few studies have investigated the use of AFPs, AF(G)Ps and closely related 
derivatives but with varied success.28 In particular these proteins and compounds 
have failed to successfully cryopreserve cardiac tissues due to the tendencies of 
these molecules to actually heighten cryodamage as a consequence of DIS and 
intracellular ice formation.29,30 Success has been demonstrated though with both 
islets31 and hepatocytes32 whereby improvements in cell recovery were attained 
by the supplementation of comparatively low concentrations of IRI active 
molecules. In addition to studies that use AFPs and AF(G)Ps the 
supplementation of oligosaccharides including trehalose, raffinose and 
maltoheptose at (high) concentrations that have moderate IRI activity (Figure 
2.27 and Figure 2.28) to rat hepatocytes had a demonstrable cryoprotective 
effect, though their protective effect is more akin to their ability to incite 
vitrification as oppose to their actions as mildly active IRI compounds.33 To date 
though no known studies have been reported that investigates the use of 
naturally occurring antifreezes or closely related mimics thereof with 
haematopoietic, embryonic or mesenchymal stem cells (MSCs). The addition of 
PVA has been reported to be beneficial with MSCs using a DMSO free method in 
both a vitrifying and non-vitrifying context however.34 Cell recovery under these 
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conditions was greatest when using a vitrifying method with the addition of PVA 
allowing an additional 25% of cells to be recovered. PVA has been shown 
elsewhere to assist in the preventing nucleation under vitrifying conditions and 
also limit ice crystal growth in these solutions.35 Observations identified with 
RBCs (Chapter 3) and with immortalized mammalian cell lines (Chapter 4) in 
conjunction with literatures findings warranted the preliminary investigation of 
PVA with primary cells in order assess its cryoprotective potential as an IRI active 
compound and compatibility with downstream applications. 
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5.3. RESULTS AND DISCUSSION. 
 
5.3.1. Cryopreservation of Primary Rat Hepatocytes. 
 
The demand for hepatic tissue can be emphasized by the number of liver 
transplants undertaken per annum in addition to the length of current waiting lists 
that further stresses the desire to maintain the highest possible viabilities ex vivo 
in order to ensure that no material is wasted given the scarcity of clinically eligible 
donors. For example the number of liver transplant procedures undertaken in the 
US in 2011 and in 2012 was approximately 6,000 in each year yet the number of 
recipients awaiting transplantation exceeded 15,000.3,36 The shortage of human 
hepatic tissue means that rat hepatocytes are routinely used in in vitro studies 
especially with regards to assessing the toxicity and metabolism of xenobiotics.37-
40 Rat hepatocytes are therefore still of importance with many similarities to 
human hepatocytes and so a representative model. However rat hepatocytes 
were still only available in limited quantities (Figure 5.1.).  
 
 
 
 
 
 
 
 
Figure 5.1. Phase contrast light micrographs of primary rat hepatocytes. 24 
hours after isolation plated on collagen coated plates at (A) 100x magnification 
and (B) 200x magnification. 
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Due to the lack of available material a full investigation into the cytotoxic effects 
of DMSO on rat hepatocytes was not undertaken as with immortalized 
mammalian cells (Section 4.3.1.). DMSO is known to be cytotoxic to rat 
hepatocytes and have a minor effect on hepatocyte gene expression, though 
these changes in expression were considered to have minimal toxicological 
impact. At high concentrations of DMSO however such alterations may become 
significant.41 Differences in the cell culture conditions can also influence gene 
expression profiles.42 Furthermore some studies have however actively 
investigated how the supplementation of low concentrations of DMSO (up to 2 % 
(v/v)) which can be reasonably well tolerated with beneficial effects in vitro that 
enable prolonged maintenance.43-47  
 
However it is important to investigate the potential influence that 9 kDa PVA may 
have, though the biocompatibility of 9 kDa PVA has proven exemplary with 
previously tested cells (Figures 3.2., 4.1. and 4.10.). The impact of 20 mg/mL 9 
kDa PVA incubated with freshly isolated hepatocytes over a 4-hour period was 
assessed by the resazurin reduction assay.48 Figure 5.2. shows the relative 
fluorescence both before and after the addition of 20 mg/mL 9 kDa PVA, which 
as established prior is far greater than the amount required to have a IRI effect 
(Figure 2.17.) with a cell viability equivalent to 85.0 % ± 11.2 % attained. 
Therefore a slight cytotoxic effect at this concentration and at physiological 
temperatures for a prolonged period may be apparent. However several studies 
have shown that the concentration of numerous (liver specific) cytochrome p450 
isoforms declines rapidly after isolation.49 Cytochrome p450s are known to 
metabolize (phase I) a vast majority of commercially available pharmaceutical 
xenobiotics by catalyzing their oxidation. This decline is significant in terms of the 
desire to minimize any post-thaw processing to maintain their usefulness as a 
valid drug metabolism model,50 with rat hepatocytes (relative catalytic activity 
after 24 hours of 53 % ± 5 %) having a greater susceptibility than human 
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hepatocytes (relative catalytic activity after 24 hours of 81 % ± 10 %).51 Though 
the exact catalytic mechanism for the reduction of resazurin to resorufin is 
unknown at present52 they may be a similar effect that results in a decline in the 
rate of resazurin conversion that accounts at least partially for the perceived 
lower cell viability. The presence of adherent but non-viable material (Figure 5.1.) 
in which the isolated rat hepatocytes contained a notable proportion of non-viable 
cells (21.7 % ± 5.7 %) deemed by a trypan blue exclusion assay might also affect 
the longevity of maintaining rat hepatocytes ex vivo. 
 
 
 
 
 
 
 
 
Figure 5.2. Cytotoxicity of 9 kDa PVA to rat hepatocytes. Resorufin 
fluorescence over a 2-hour incubation period showing the rate of resazurin to 
resorufin conversion prior to and after addition of 20 mg/mL 9 kDa PVA incubated 
for 4 hours. 
 
Cryopreservation of rat hepatocytes53 (1x106 cells) was undertaken using slow-
freezing (Section 5.5.3.) with 10 % (v/v) DMSO supplemented with or without 
various concentrations of 9 kDa PVA (Figure 5.3.) inline with current protocols. 
The addition of low concentrations of 9 kDa PVA (1 mg/mL) improved recovery 
levels (49.1 % ± 5.4 %) compared to DMSO alone (35.4 % ± 3.0 %) when using a 
slow thawing strategy that promotes ice recrystallization but these values were 
still far lower than when using a rapid thawing strategy (100 %). High 
concentrations of 9 kDa PVA (10 mg/mL) however proved dramatically 
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detrimental with cell recovery equal to just 11.6 % ± 7.4 % following trends 
observed with all other cell types tested and thus should not be surprising 
(Figures 3.9., 4.3., 4.4., 4.6., 4.7., 4.12. and 4.14.). Going forward therefore with 
an ample supply of cells, investigating whether or not larger (or smaller) PVA 
molecules that have varied IRI (and DIS) activities also display a concentration 
dependant benefit as cryoprotectants in order to identify the optimum 
concentration of PVA for a variety of MWs and whether or not this correlates with 
a single IRI value. 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. Impact of 9 kDa PVA on the cryopreservation of rat hepatocytes. 
Cryopreservation of rat hepatocytes with 10 % (v/v) DMSO supplemented with 
and without various concentrations of 9 kDa PVA. (A) Resazurin assay 
undertaken on cryopreserved rat hepatocytes with fluorescence values measured 
at 60-minute intervals. (B) (%) Cell recovery of rat hepatocytes cryopreserved 
with and without 9 kDa PVA referenced against rapidly thawed 10 % (v/v) DMSO 
samples (minimal ice recrystallization damage). Values represent the mean of 2 
cryovials measured individually with the error bars representing ± standard 
deviation. 
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5.3.2. Cryopreservation of Mouse Mesenchymal Stem Cells. 
 
Mesenchymal stem cells (MSCs) (Figure 5.4.) can be derived from either 
umbilical cord blood (UCB)54 or from bone marrow tissue.55 MSCs are of interest 
in that they are able to proliferate significantly in vitro yet still retain a multipotent 
capacity. MSCs are typically able to differentiate into adipocytes, chondrocytes or 
oesteocytes each with specific phenotypes.56 MSCs have also been forcibly 
differentiated into non-typical MSC derived endpoints such as neuronal57 and 
myogenic cells.58 Therefore there is abundant interest in the cryopreservation of 
MSCs due to their therapeutic potential.59 However there must be caution 
concurrently as for example undifferentiated MSCs applied to damaged cardiac 
tissues resulted in a subset of the population differentiating into fibroblastic scar 
tissue which could prove problematic in the recovery process after a myocardial 
infarction.60,61 However MSCs are largely considered to be safe for therapeutic 
use according to a review of recently conducted clinical trials.62 
 
 
Figure 5.4. Phase contrast light micrographs of mouse mesenchymal stem 
cells. Mouse MSCs prior to cryopreservation and adipogenesis. (A) 100x 
magnification and (B) 200x magnification. 
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The cryopreservation of MSCs is therefore complicated in that any 
cryopreservation process needs to not interfere with their proliferative capacity 
and differentiation potential. This means neither reducing the number of inducible 
fates nor triggering spontaneous differentiation. The cryopreservation of MSCs is 
of particular importance therefore as continuously propagated MSCs will begin to 
loose their multipotency even after a few passages.63,64 The cost of reagents (due 
to their purity and complex composition) is also another factor that supports the 
long term cryostorage of MSCs. Therefore any potential improvements to the 
cryopreservation of MSCs that also lessens the concentration of DMSO required 
for cryopreservation would be advantageous. Figure 5.5. shows how the 
supplementation of 9 kDa PVA to 10 % (v/v) DMSO which is the concentration 
used in the majority of cryopreservation (slow freezing) protocols at present 
affects cell recovery (100 % cell recovery refers to the number of cells recovered 
after cryopreservation using a rapid thawing strategy) of mouse MSCs (Section 
5.5.4.). A clear difference between thawing MSCs slowly (66.5 % ± 2.2 %) and 
rapidly (100 % ± 3.2 %) is apparent indicative of IR damage with the addition of 
small concentrations of (1 mg/mL) 9 kDa PVA having a possible cryoprotective 
effect (72.3 % ± 19.8 %) but more data would be necessary to corroborate this, 
though as with all other cell types the presence of greater amounts of 9 kDa PVA 
proved injurious with 3 mg/mL 9 kDa PVA eliciting cell recovery equivalent to 
43.2 % ± 3.7 %. 
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Figure 5.5. Impact of 9 kDa PVA on the cryopreservation of Mouse MSCs. 
Resazurin assay of mouse MSCs cryopreserved with 10 % (v/v) DMSO 
supplemented with and without 9 kDa PVA. Values represent the mean of 2 
cryovials plated in triplicate measured in duplicate with the error bars 
representing ± standard deviation. 
 
Though the resazurin reduction assay is a good indicator of overall cell viability 
the ability of recovered MSCs to undergo differentiation that is a complex 
transformation reliant on the correct signalling of numerous biochemical 
pathways is a more stringent examination of the effects of 9 kDa PVA 
supplementation in the cryopreservation process. Three fates (adipocytes, 
chondrocytes, oesteocytes) are inducible using commercially available cocktails 
allowing detectable phenotypic changes over a 7-14 day period. Therefore MSCs 
assessed using the resazurin assay prior were evaluated for their potential to 
differentiate (adipogenesis) into adipocytes (Section 5.5.5.).65 Figure 5.6. shows 
a representative phase contrast micrograph 9 days after the application of 
adipocyte differentiation medium (critically differentiation inhibits any sizable 
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proliferation) that successfully shows the presence of visible lipid droplets (black 
arrows) that are a phenotypic characteristic of adipocytes.66  
 
 
 
 
 
 
 
 
 
Figure 5.6. Visual assessment of mouse MSC adipogenesis. Phase contrast 
light micrograph of mouse MSCs subsequent to cryopreservation and 9 days 
post adipogenesis induced differentiation (200x magnification). Arrows highlight 
the presence of lipid droplets indicative of adipocytes. 
 
To further clarify the existence of adipocytes, the cells were fixed 11 days after 
the application of adipocyte differentiation medium using a 2 % (v/v) glutaldehyde 
solution and stained using two non-competitive fluorescent dyes. The first dye 
utilised was Hoechst 33258 that is a fluorescent dye with a high affinity for DNA 
(chromatin) with excitation and emission maximums of 352 nm and 461 nm 
respectively.67,68 Hoechst 33258 will therefore bind any cells present regardless 
of whether or not they have undergone differentiation. As a result of the non-cell 
specificity of Hoechst 33258 a second dye specific for adipocytes was used. 
LipidTOXTM Red is a fluorophore that binds specifically to neutral lipids and thus 
an excellent indicator of adipogenesis and has excitation and emission 
maximums of 577 nm and 609 nm respectively. The ratio of each dye (Figure 
5.7.) therefore shows the effect that 9 kDa PVA has had on the ability of the cell 
population to undergo adipogenesis. 
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Figure 5.7. Fluorescence intensities of Hoechst 33258 and LipidTOXTM Red 
as indicators of adipogenesis. (A) Relative fluorescence intensities of Hoechst 
33258 (460/40 nm) and LipidTOXTM Red (640/40 nm) consequent to fluorophore 
staining of cells cryopreserved using a variety of solutions. (B) Ratio of 
LipidTOXTM Red:Hoechst 33258 highlighting relatively consistent levels of 
adipogenesis. 
 
Figure 5.7.A. shows that the relative fluorescence intensities of both dyes are 
roughly equal across each of the cryopreservation solutions (but not to each 
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other given the different sensitivities employed) emphasizing that adipogenesis is 
approximately uniform (Figure 5.7.B.). 9 kDa PVA is perceived to act only in an 
extracellular context due to its membrane impermeability with A549 cells (Section 
4.3.3.) and there is no reason to assume otherwise here and thus 9 kDa PVA is 
removed prior to the initiation of adipogenesis. This shows that the presence of 9 
kDa PVA during cryopreservation does not affect the ability of cells to 
differentiate into adipocytes with the presence of lipid droplets (Figure 5.6.) and 
resulting LipidTOXTM Red staining. Further work would ideally investigate the 
ability of (9 kDa PVA) cryopreserved MSCs to differentiate into both 
chondrocytes and oesteocytes that both have well defined endpoints and further 
refine the concentrations of both DMSO and 9 kDa PVA to identify the optimum 
composition for cryopreservation. Plus the rate at which differentiation occurs to 
ensure no significant changes in behavior are observed due to the presence of 9 
kDa PVA in the cryopreservation process would be a valid measure of normality. 
In addition, application to human MSCs to assess whether these behave in a 
similar fashion would be an attractive avenue of interest from a clinical point of 
view. Plus the ability to improve the cryopreservation of other stem cell types 
(embryonic and haematopoietic) that would potentially yield the greatest clinical 
benefit.69-71   
 
The application of 9 kDa PVA has from these early observations arguably not 
had as profound a benefit with primary cells as noted elsewhere in Chapter 3 and 
Chapter 4 with other cell types. A possible rationale for a reduction in the benefit 
of 9 kDa PVA is that the use of a higher concentration of DMSO (10 % (v/v)) will 
alter the thawing process meaning the onset of thawing will differ, beginning at a 
lower temperature (Figure 2.24.).72 Furthermore the presence of greater amounts 
of DMSO will affect extracellular ice crystal growth in part due to the alteration in 
the melting point. Suppression of the melting point in these system will reduce IR 
partially and henceforth decrease the amount of IR damage that can be 
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subsequently attenuated. However this reduction in IR damage does not justify 
the concentration of DMSO because as noted elsewhere DMSO is significantly 
cytotoxic. Therefore lowering the concentration of DMSO (that may prove 
beneficial to recovery regardless) applied is likely to give an advantageous effect 
superior to those observed here (Figure 5.3. and Figure 5.5). For the reason that 
extracellular ice formation drives the efflux of H2O and hence aids to avoid 
intracellular ice formation that is highly damaging. There is no doubt that a higher 
concentration of DMSO will also cause an increase in H2O efflux but as the 
system approaches equilibrium (by the passive diffusion of DMSO) the greater 
amount of DMSO will only account for a small difference proportionately in 
osmotic pressure. Extracellular ice formation lowers the extracellular liquid H2O 
content increasing solute concentration concurrently as solutes are not 
incorporated into ice (solute rejection).73 Solute rejection also serves to change 
the viscosity that further influences ice formation, differences in temperature will 
also cause changes in thermodynamics that will influence the rate of H2O 
exchange and ice crystal growth.23,74 Extracellular ice formation is therefore an 
important part of the cryopreservation process in promoting cellular dehydration, 
though subsequent growth is not desirable as iterated previously. A lower 
concentration (i.e. lower than 10 % (v/v)) of DMSO may therefore in this instance 
prove beneficial and thus improve the overall rates of cell recovery upon the 
addition of 9 kDa PVA (Chapter 3 and Chapter 4) and thus remains a tantalizing 
area of future investigation. 
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5.4. CONCLUSIONS. 
 
The application of IRI active 9 kDa PVA to two distinctive primary cell varieties 
has been investigated in order to improve their cryopreservation with an eventual 
aim of reducing the currently high concentrations of cytotoxic organic solvents 
such as DMSO required in existing cryopreservation strategies. Freshly isolated 
primary hepatocytes were shown to be tolerant of 20 mg/mL 9 kDa PVA that is a 
concentration far than necessary for IRI activity. The addition of low 
concentrations (1 mg/mL) of 9 kDa PVA proved beneficial when utilizing a slow 
thawing strategy at improving the number of cells recovered post thaw. However 
the addition of higher concentrations of 9 kDa PVA (10 mg/mL) that have a 
superior activity and thus greater potential at attenuating IR cryodamage were 
detrimental and this is speculated to be due to a secondary DIS effect that 
enhances mechanical damage offsetting to the benefits attained from IRI, similar 
to findings observed and reported elsewhere. Secondly the potential of 9 kDa 
PVA to improve the cryopreservation of mouse MSCs was undertaken showing a 
mild beneficial effect at low concentrations though further work is needed to 
clarify this. Nevertheless higher concentrations of 9 kDa PVA appeared to again 
be detrimental to total cell recovery as with rat hepatocytes no doubt due to a 
similar increase in the level of DIS induced mechanical damage. However the 
presence of 9 kDa PVA during cryopreservation at all concentrations tested 
appeared to have minimal influence on the downstream ability of mouse MSCs to 
undergo adipogenesis with an approximately proportional number of adipocytes 
detected in each instance. Therefore the presence of 9 kDa PVA at low 
concentrations (1 mg/mL) that influences extracellular ice crystal growth during 
thawing can be a powerful tool for attenuating IR without intolerable levels of DIS 
that elevate mechanical damage and thus improve the recovery of primary cells 
as a supplement to traditional cryopreservation strategies.  
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5.5. MATERIALS AND METHODS 
 
5.5.1. Isolation and preparation of Rat Hepatocytes. 	  
Approximately 1.5 x 107 of freshly isolated rat (sprague dawley) hepatocytes 
were provided by the Marrion Bessin Liver Centre at The Albert Einstein College 
of Medicine, Bronx, NY, USA prepared according standard (percoll) protocols.75 
A small aliquot was taken and diluted 6.66’-fold in complete medium (DMEM, 
High Glucose + 10 % (v/v) FCS and supplemented with Penicillin (100 U/mL) and 
Streptomycin (100 µg/mL) all of which were sourced from Sigma Aldrich Corp., 
MO, USA) to estimate viability using a standard trypan blue exclusion assay with 
the proportion of viable cells equal to 78.3 % ± 5.7 % of the observable 
population. Cells were then processed immediately according to the following 
procedures for use in cytotoxicity or cryopreservation assays. 
 
5.5.2. Cytotoxicity assessment of 9 kDa PVA with Rat 
Hepatocytes. 
 
Fresh rat hepatocytes were isolated as above with 8 x 105 cells plated in triplicate 
with 5 mL of pre-warmed (37 °C) complete medium on to 60 mm ∅ collagen 
(type I) coated plates (BD Biosciences, CA, USA) and incubated (37 °C / CO2(g)) 
for 3 hours. After 3 hours cells were washed twice with 5 mL of pre-warmed PBS 
to remove any non-adherent extracellular debris and replaced with 5 mL of pre-
warmed complete medium and incubated overnight. Approximately 36 hours later 
cells were imaged by phase contrast microscopy (Figure 5.1.) to visualize and 
clarify the presence of adherent cells. The inherent metabolic activity of untreated 
cells was then assessed using the resazurin assay. Measuring the inherent 
metabolic activity involved the addition of 5 mL of complete medium plus 250 µL 
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of 0.33’ mg/mL resazurin in PBS. Cells were then incubated for a period of 2 
hours with 50 µL aliquots taken at 15-minute intervals and the relative 
fluorescence measured (excitation and emission wavelengths of 530 nm / 25 nm 
and 590 nm / 30 nm) using a BioTek Synergy HT plate reader (BioTek UK, 
Bedfordshire, UK). After the 2-hour incubation period the cells were washed twice 
with 5 mL of pre-warmed PBS and replaced with 5 mL complete medium 
containing 20 mg/mL 9 kDa PVA and incubated for 4 hours. Finally cells were 
washed twice with 5 mL of pre-warmed PBS and an identical resazurin assay 
performed. (%) Cell viability was quantified according to Equation 5.1. with values 
for each time point used to define the mean (%) cell viability ± standard deviation. 
 
Equation 5.1. Calculation of (%) Cell viability at specific time points using 
the resazurin assay. 
(%) Cell Viability = 
  
€ 
Fluorescence( 590 / 30nm) (Pre − treatment ( x−min) ) −Fluorescence( 590 / 30nm) (0min)[ ]
Fluorescence( 590 / 30nm) (Post − treatment ( x−min) ) −Fluorescence( 590 / 30nm) (0min)[ ]
 
 
5.5.3. Cryopreservation assessment of 9 kDa PVA with Rat 
Hepatocytes. 
 
Approximately 3 mL of 4.2 x 106 cells/mL of freshly isolated rat hepatocytes were 
diluted in 10 mL of pre-warmed complete medium and centrifuged at 500 rpm at 
23 °C for 5 minutes. The supernatant containing any small extracellular material 
was discarded and the cells resuspended in 5.5 mL of complete medium to a 
final concentration approximating 2.29 x 106 cells/mL. 440 µL aliquots were then 
transferred into 1.8 mL cryovials (as used previously with immortalized 
mammalian cell lines) and 560 µL of the desired cryopreservation solution that 
comprised a final concentration of DMSO equal to 10 % (v/v) and various amount 
of 9 kDa PVA as indicated in Figure 5.3. Samples were prepared in duplicate and 
 	  	   239	  
gently mixed by inversion to ensure a homogenous suspension of cells. Cells 
were then frozen using standard protocols. This involved transferring each vial 
into a Nalgene “Mr. FrostyTM” freezing container that has a fixed cooling rate 
approximating 1 °C/min and were kept at 4 °C for 60 minutes. Cells were then 
mixed by inversion and then transferred to a -80 °C freezer for 90 minutes and 
then finally transferred to N2(l) (-196 °C) overnight. The following day cells were 
either thawed rapidly (37 °C, water) or slowly (23 °C, air) as required (Figure 5.3.) 
and plated with 5 mL of pre-warmed complete medium on a 60 mm ∅ collagen 
(type I) coated plate. Cells were then incubated for 3 hours. After 3 hours cells 
were washed twice with 5 mL of pre-warmed PBS to remove any non-adherent 
cells and debris and replaced with 5 mL of pre-warmed complete medium and 
incubated overnight prior to assessing viability using the aforementioned 
resazurin assay described in Section 5.5.2. except that the assay was performed 
for an 8-hour duration with samples taken at 60-minute intervals for analysis with 
(%) cell recovery calculated using Equation 4.3. with 10 % (v/v) DMSO (rapid 
thaw) referenced as 100 % cell recovery. 
 
5.5.4. Preparation and cryopreservation of Mouse 
Mesenchymal Stem Cells. 
 
A frozen 1 mL aliquot (60 % (v/v) DMEM/F12 medium with GlutaMAXTM-I plus 30 
% (v/v) FBS (MSC-qualified) and 10 % (v/v) DMSO) of mouse (C57BL/6) 
mesenchymal stem cells (approximately 1x106 cells) and all reagents required for 
their subsequent propagation and differentiation were purchased from Life 
Technologies Ltd, Renfrewshire, UK. Complete MSC medium is defined as 
DMEM/F12 medium with GlutaMAXTM-I plus 10 % (v/v) FBS (MSC-qualified) 
supplemented with gentamicin, penicillin and streptomycin at final concentrations 
of 5 µg/mL, 100 U/mL and 100 µg/mL. To revive the as supplied mouse MSCs 
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stored in N2(l) MSCs were thawed rapidly for 2 minutes in a 37 °C water bath. 
Cells were then transferred into a 50 mL Falcon tube and 10 mL of pre-warmed 
(37 °C) complete MSC medium added slowly. Cells were then centrifuged at 300 
x g and 23 °C for 5 minutes and the resultant supernatant discarded with cells 
resuspended in 5 mL of complete MSC medium. Cells were divided evenly 
between 2 separate 75 cm2 flasks containing 15 mL of complete MSC medium 
and incubated (5 % CO2(g) / 37 °C) overnight. The presence of adherent cells 
were assessed by phase contrast microscopy (Figure 5.4.) and allowed to reach 
70 % - 80 % confluence. The passaging of mouse MSCs was undertaken by 
washing cells with 15 mL of pre-warmed PBS before the addition of 2 mL of 
TrypLE™ express dissociation reagent and incubated for two minutes to promote 
cell detachment prior to neutralization with 5 mL of complete MSC medium. Cells 
were then centrifuged as previous and transferred evenly between 3 separate 
175 cm2 flasks containing 25 mL of complete MSC medium and incubated until 
confluent to attain a suitable quantity of cells relevant for cryopreservation, with 
medium changes every 2-3 days. The doubling time under these conditions was 
just under 24 hours. Prior to cryopreservation MSC cells were subjected to a 
trypan blue exclusion assay with cell viability in excess of 99 %. Cryopreservation 
was achieved by trypsinising cells as described prior and prepared as 1 mL 
aliquots in duplicate in 1.8 mL cryovials supplemented with 10 % (v/v) DMSO and 
the relevant concentration of 9 kDa PVA as shown in Figure 5.5. Cells were 
frozen slowly in a “Mr. FrostyTM” freezing container by being transferred to 4 °C 
for 60 minutes prior to gentle mixing by inversion and placed in a -80 °C  freezer 
overnight and then N2(l) for 2 days. Cells were then thawed either rapidly (37 °C 
(water bath)) or slowly (23 °C (air)) as required and 30 µL and 60 µL aliquots 
each added in triplicate to separate 48 well plates containing 600 µL of pre-
warmed complete MSC medium overnight. The following day cells were washed 
with pre-warmed PBS and 600 µL of fresh medium added. After a further 24 
hours the confluency of each 48 well plated was estimated by phase contrast 
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microscopy and a resazurin assay as described in Section 4.5.9. performed on 
the most relevant plate (i.e. less than 70 % confluent) with cell recovery 
calculated according to Equation 4.3. 
 
5.5.5. Adipogenesis of Mouse Mesenchymal Stem Cells. 
 
Cryopreserved mouse MSCs that were subjected to a resazurin assay as 
described in Section 5.5.4. were washed twice with 600 µL of pre-warmed PBS 
and 400 µL of StemPro® adipocyte differentiation medium added and cells 
incubated for 10 days with (400 µL) differentiation medium changed every 3 
days. Cells were visualized every 2/3 days by phase contrast microscopy to 
identify changes in morphology and the presence of lipid droplets indicative of 
adipocytes (Figure 5.6.). To further clarify differentiation cells were fixed using a 2 
% (v/v) glutaldehyde solution and stained with an adipocyte specific fluorophore 
(LipidTOXTM red) that has a high affinity for neutral lipid droplets and a non-
competing nuclear specific fluorophore (Hoechst 33258). Subsequent to staining 
cells were washed twice with PBS and solubilized with 150 µL DMSO and 
incubated at 23 °C and shaken at 200 rpm for 60 minutes in the absence of light 
to ensure solubilization. Samples were then pooled and 200 µL aliquots 
measured using a BioTek Synergy HT plate reader (BioTek UK, Bedfordshire, 
UK) to detect the presence of LipidTOXTM red (excitation 590 nm / 20 nm, 
emission 640 nm / 40 nm) and Hoechst 33258 (excitation 360 nm / 40 nm, 
emission 460 nm / 40 nm) as shown in Figure 5.7. 
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CONCLUSIONS 	  
Poly(vinyl alcohol) (PVA) has been investigated as an ice recrystallization 
inhibitor (IRI) in order to improve the cryopreservation of biological materials. 
Despite investigating a wide range of saccharides (mono-, di- and oligo-), low 
molecule weight polyols and synthetic and natural polymers only PVA retains a 
high IRI activity. This activity is comparable to naturally occurring antifreeze 
proteins (AFPs) and antifreeze (glyco)proteins (AF(G)Ps) yet retains greater 
availability, affordability and a proven biocompatibility (Chapter 2). PVA is applied 
as a cryopreservative improving the cryopreservation of a variety of biological 
materials by attenuating ice recrystallisation during thawing in conjunction with 
traditional cryoprotectative agents. It has been demonstrated that PVA can be 
successfully applied to red blood cells (Chapter 3), immortalized mammalian cell 
lines (Chapter 4) and primary cells (Chapter 5). In each instance PVA has no 
detrimental effects on each cell type in terms of functionality post thaw. 
Furthermore as PVA acts exclusively in an extracellular context PVA can be 
removed easily unlike traditional membrane permeable additives that are also 
required at significantly higher concentrations. However increasing PVA 
concentration that heightens IRI activity is disadvantageous due to the secondary 
property of dynamic ice shaping that intensifies mechanical damage outweighing 
its advantageous effect. Future work would continue to explore PVA as a 
cryoprotectant with an even wider range of cell varieties in order to perfect its 
application in cryopreservation protocols. In addition to this investigating a wide 
variety of PVA molecules with different configurations, extent of hydrolysis and 
molecule weights could elucidate a more detailed understanding of the IRI 
process leading to even more potent IRI cryopreservatives with widespread 
clinical applications that unobtainable at present. 
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